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Abstract 
 
Natural products have been a great benefit to mankind, especially in modern times. With 
approximately half of all drugs used today being derived from small molecules observed in nature, 
the impact of these compounds is immeasurable. In the mid-twentieth century, a period known as 
the Golden Age of Antibacterials, the natural product field experienced a wave of discovery that 
has yet to be replicated. Even with the increased focus on using synthetic chemistry to discover 
potential pharmaceuticals, there has been a steady decline in discovery rates over the past decades. 
While traditional natural product discovery methods are limited to what is detectable in nature, 
advances in DNA sequencing technology, bioinformatics, and molecular biology have given 
researchers the ability to mine genomes for new compounds. By combing the abundant wealth of 
available genomic data, biosynthetic gene clusters can be readily identified for exploitation. 
 
However, two bottlenecks impede the transition from identified gene cluster to useful drug. The 
first hurdle is identifying the molecule linked to a set of biosynthetic genes. This step is well 
beyond any computational approach and must rely on empirical substantiation.  The second hurdle 
is to produce enough of the compound in an economically feasible manner. In this work we 
implement pathway engineering strategies to further lower these barriers, with a focus on the class 
of natural products called phosphonic acids. These compounds have a stable carbon-phosphorus 
bond, which allow them to mimic phosphate esters and carboxylic acids, making them potential 
enzyme inhibitors. For the antimalarial phosphonate FR900098, a novel pathway engineering 
strategy, called enriched library screening, was developed that allows one to home in on top 
pathways in combinatorial libraries. When applied to the FR900098 pathway, a strain with a 
significant increase in production was found. This method can also be applied to other natural 
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product pathways to rapidly find expression configurations that give higher yields. Additional 
strain engineering was also undertaken on the FR900098 strain; however, improvements were not 
seen despite a number of gene knockouts and knockdowns tested. 
 
To discover new phosphonic acids, biosynthetic pathways from two actinobacteria, Streptomyces 
species NRRL F-525 and Kibdelosporangium aridum largum NRRL B-24462, were fully 
engineered for production in the expression host Streptomyces lividans. This was done by placing 
the individual biosynthetic genes downstream of promoters characterized in S. lividans. 
Phosphonate production was seen in both hosts, with a novel phosphonate being identified in the 
Streptomyces species NRRL F-525 cluster. This approach can also be extended to discover other 
natural product gene clusters. 
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1Chapter 1: Introduction 
1.1 A new era of natural product discovery 
For millennia, human beings have used biologically produced small molecules, often from plants, 
for medicinal and other purposes. In ancient times, for instance, Hippocrates used powder made 
of willow bark to relieve pain, with its analgesic properties now attributed to compounds with 
similar molecular structures as aspirin. The discovery of penicillin in 1928 by Sir Alexander 
Fleming in 1928 [1] opened the doors to an era of antibioitic discovery that has contributed to 
saving millions of lives. Today, natural products and natural product derivatives make up about 
one-half of all drugs and are used to treat a range of illnesses, including viral and bacterial 
infections, cancer, and neurological disorders [2].   
 
Recently there has been a considerable rise in antibiotic resistant infections. In the United States, 
each year there are over 2 million infections for which our antibiotic arsenal has little effect, 
leading to more than 23,000 deaths [3]. This alarming predicament has led to renewed efforts in 
identifying new antibiotics. Despite the success of natural products as drug leads, pharmaceutical 
companies over the past 25 years have reduced their natural product research. One problem with 
the traditional discovery method of bioassay-guided fractionation is that it has become impractical 
as positive hits increasingly are identified as already known compounds [4].  Instead, there has 
been increased efforts in industry to use high-throughput screening of synthetic libraries against 
single targets for drug discovery. As success rates and drug approvals have fallen with such 
prevalent strategies, there has been renewed interest to explore natural products for new drug leads 
[5]. 
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Recent developments in DNA sequencing and bioinformatics has ushered in a new era of discovery 
that allows for the identification of strains harboring natural product biosynthetic machinery 
without a production screening [6, 7]. In 2014, over 14,000 bacteria and archaea genomes were 
sequenced, a result of the significant drop in genome sequencing costs, with one estimate being 
less than $1 for a bacterial draft genome [8].  This genomic sequence data can be combed for 
signature genes, such as polyketide synthases (PKS) and non-ribosomal peptide synthases (NRPS), 
to identify new gene clusters.  Bioinformatic algorithms, such as anitbiotics and Secondary 
Metabolite Analysis Shell (antiSMASH), have been developed to recognize such biosynthetic gene 
clusters when given a genome sequence [7]. Once identified, clusters can then be grouped into 
families depending upon their similarities, which can aid in determining which clusters may lead 
to new compounds [9].  
 
Although bioinformatics tools have been useful in discovering thousands of new cluster families, 
two bottlenecks exist for producing natural products in amounts that can treat infections and 
diseases. The first bottleneck is going from an identified biosynthetic gene cluster to a 
characterized product. Isolating the compound from the natural producer is one option, but the 
work can be laborious in finding the right conditions to elicit production, and there is no certainty 
that it will be successful [10].  Advances in molecular biology and microbiology have introduced 
methods that accelerate discovery both in the native host and in heterologous hosts, and some of 
these strategies are detailed below in Section 1.3. The second bottleneck is optimizing a strain to 
produce enough compound to be economically available for human treatments. Because of the 
complex structure of many natural products, biosynthesis may be the preferred method of 
production. However, grams per liter titers are often necessary for commercial production, which 
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will likely require extensive modification or engineering of the host strain.  This work focuses on 
the implementation of pathway engineering strategies to overcome these two bottlenecks in the 
discovery and production of a class of natural products called phosphonic acids. 
 
1.2 Phosphonic acid natural products 
Phosphonic acids are molecules that carry a phosphorous bonded to a non-oxygen atom, which in 
nature is most often a phosphorous-carbon bond. The configuration of phosphonate head groups 
shares similarities to phosphate esters and carboxylic acids. This has led to some phosphonates to 
have remarkable bioactivity by mimicking substrates and inhibiting essential enzymatic reactions. 
Compounds with beneficial bioactivities include FR900098 (antimalarial), glyphosate (herbicide), 
phosphothricin tripeptide (antibiotic, herbicide), and fosfomycin (antibiotic) (Figure 1).   
 
Although many small molecule phosphonic acids have been a source of great interest due to their 
bioactivities, other types of phosphonates have curious or unknown roles in biology. The first 
natural phosphonic acid discovered was 2-aminoethylphosphonic acid (2-AEP), which was 
initially reported in 1959 [11]. 2-AEP has been found to be associated with lipid head groups in a 
range of organisms [12] as well as on glycans [13] and glycoproteins [14].  Such macromolecules 
can be a great source of phosphorous for some organisms. For example, eggs of the freshwater 
snail Helisoma contain 95% of their phosphorous as phosphoglycans, which is metabolized during 
embryonic development [15]. Methylphosphonate has also been found to be a significant source 
of methane in aerobic ocean environments as marine microorganisms breakdown the molecule 
when using it as a phosphorous source [16]. 
4 
 
In nature, the entry point to most known phosphonates is via phosphonopyruvate, which is formed 
by a rearrangement of phosphoenolpyruvate (PEP) by a phosphoenolpyruvate mutase (PepM) [17, 
18]. Although the mechanism is not fully understood, it appears that the phosphate group of PEP 
disassociates and is stabilized by the enzyme as metaphosphate while the pyruvate enolate rotates 
allowing attack by C3 to form the phosphonate bond [19, 20]. The thermodynamics of this reaction 
favor PEP 500:1, requiring a subsequent reaction to drive further phosphonate production, which 
is often done by a decarboxylation to form phosphonoacetaldehyde or an acetylation making 2-
phosphonomethylmalate. There are two phosphonates in nature, K-26 [21] and I5B2 [22] which 
are not catalyzed by PepM , but their biosynthesis is poorly understood. A number of unnatural 
phosphonic acids have also been synthesized, including the herbicide glyphosate (better known 
under its trade name Roundup), which has 200 million pounds applied to plants in the United States 
alone each year [23]. The drug alendronate, which is used to treat osteoporosis, is another example 
of a useful unnatural phosphonic acid [24]. Synthesized analogs of naturally occurring 
phosphonates have also been developed for increased biological activities [25, 26]. 
 
The pepM gene has been successfully used as a genetic handle to identify strains containing 
phosphonic acid biosynthetic machinery. Ju et al. tested 10,000 bacteria strains for phosphonic 
acid clusters using a PCR screen on the pepM gene, identifying 278 strains positive for the gene 
[27]. Fortunately, an analytic nuclear magnetic resonance (NMR) handle also exists for 
phosphonic acid screening. Phosphonates often give 31P-NMR signals above 10 ppm, which are 
easily distinguished from phosphate esters that give much lower ppm shifts. Although such a 
method reveals little about the structure, it can be used in a medium-throughput manner to gauge 
phosphonic acid abundance. 
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1.3 Strategies for natural product discovery 
 General methods for natural product discovery 
For decades natural product discovery has been limited to the isolation of compounds from culture 
extracts using bioassay guided fractionation. In such a manner were many of the bioactive 
phosphonates identified [28-30]. Two problems with such methods are first, only a fraction of 
strains are culturable in the lab [31], and second, the same molecules are often rediscovered [32]. 
With increasing access to genomic sequences, it has also become apparent that a number of 
pathways are also inactive with common culturing methods. A range of strategies have been 
developed to help elicit production of natural products from their respective biosynthetic gene 
clusters, some of which can be used in their native hosts and others that involve heterologous 
expression. Table 1.1 outlines each of these strategies that are described in greater detail. 
 
Several methods exist to assist in pathway activation in native hosts. Perhaps the most 
straightforward option is to test a range of media and culturing conditions, which has been shown 
to activate synthesis of compounds previously not detected [33, 34]. Another culturing strategy 
that does not rely on genetic manipulation is the co-culturing of strains, which simulates a more 
natural environment of competition to activate gene clusters [35]. A general method called 
“ribosome engineering” can also be used for secondary metabolite elicitation. It relies on the 
addition of certain antibiotics that target RNA polymerases and ribosomes, such as streptomycin, 
rifampicin, and gentamicin, which can alter transcriptional and translational machinery and lead 
to the activation of otherwise silent genes [36]. 
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 Genetic strategies for natural product discovery 
 
When general strategies are unable to elicit new metabolites, the use of genetic tools can be helpful 
to drive pathway expression in native producers. However, such genetic methods often rely on the 
target strain being genetically tractable and requires genomic sequence information. For instance, 
in Aspergilus nidulans a PKS-NRPS molecule was discovered by expressing an activator gene 
from a gene cluster of interest [37]. The ribosome engineering strategy mentioned above can be 
coupled with reporter-guided mutant selection to express specific pathways.  By placing the key 
promoter from an anthraquinone aminoglycoside cluster upstream of two reporter genes and 
screening for the desired output in a high-throughput manner, two novel molecules from 
Streptomyces sp. PGA64 were found [38].  
 
If the native host is not amenable to genetic engineering, a natural product gene cluster of interest 
can be expressed in a more tractable strain. The use of fosmid libraries has been used for the study 
of many pathways, including a number of phosphonic acid gene clusters [39-41]. These libraries 
are often made by inserting random segments of genomic DNA into a fosmid backbone and then 
screening the library either by PCR, as was the case for the phosphonate clusters mentioned above, 
or by a biological activity assay [42]. Because such libraries can require extensive screening, 
methods have been developed to pull out targeted gene clusters with much more ease. However, 
these newer methods rely on having genomic sequences available to pull out the gene cluster of 
interest, but with the reduction in cost of DNA sequencing this is becoming less of an obstacle. 
Recombination methods have been developed both in vitro and in vivo to isolate and express 
biosynthetic gene clusters of interest.  Target-assisted recombination (TAR) is one such method 
that uses homologous recombination in yeast with an efficiency rate of about 1% to 5% [43, 44] 
7 
 
and up to 30% when coupled with CRISPR technology [45]. Another CRISPR method used in 
conjunction with Gibson Assembly, called Cas9-Assisted Targeting of CHromosome segments, or 
CATCH, can clone out stretches of genomic DNA of 100 kb with over 20% efficiency [46]. The 
proteins RecET from Rac prophage and Redγ from lambda phage have been used together to clone 
large clusters from genomic DNA.  Fu et al. developed this method and tested it on ten PKS-NRPS 
gene clusters from Photorhabdus luminescens, cloning nine of the clusters with 30% efficiency 
and discovering new products from two of the clusters [47]. Although biosynthetic gene clusters 
are usually cloned from genomic DNA purified from cultured strains, environmental DNA 
(eDNA) collected from soil or other environments can also been used to express genes that are 
otherwise inaccessible with traditional culturing [48]. 
 
 Pathway refactoring for natural product discovery 
 
Sometimes pathways must be engineered to decouple native regulatory constraints and enhance 
expression in a heterologous host. Such pathway refactoring has been done for secondary 
metabolites from Streptomyces species, such as spectinabilin [49] and a novel tetramate 
macrolactam [50], as well as the nitrogen fixation system from Klebsiella oxytoca which was 
refactored into Escherichia coli [51].  A complimentary method has also been applied to a gene 
cluster derived from eDNA. When native promoters in a cryptic biosynthetic cluster were replaced 
with synthetic promoters engineered for Streptomyces expression, a series of new molecules were 
discovered called lazarimides [52]. 
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1.4 Pathway engineering for optimized production of natural products 
Engineering pathways for heterologous expression can be helpful in discovering new natural 
products, but it can also be critical for optimizing production of the target compound. Although a 
non-native compound can be produced in a certain host, the initial expression of the biosynthetic 
genes often lead to imbalances in the metabolic flux. It is well documented that overexpression of 
pathway genes often leads to decreases in production. Part of this is due to metabolic burden, for 
as the cell invests more material and energy into biosynthetic machinery, less is available for 
growth and product output [53, 54]. Improper expression of enzymes can lead to other problems, 
such as metabolic flux imbalances, which can lead to the buildup of intermediates that are toxic or 
shunted to other byproducts thus decreasing desired output [55]. 
 
Many strategies have been developed to optimize production by engineering pathways so that the 
expression of the individual genes are balanced. Rational approaches rely on identifying 
accumulating intermediates and altering expression of key enzymes to alleviate the bottleneck 
[56]. This can allow for straightforward engineering procedures, but can be limited to well 
characterized pathways. Another approach is to generate a random library of strains with different 
combinations of expression assignments for the pathway enzymes [57]. The size of the library is 
usually restricted to the method of quantification, so products reliant on low-throughput screens 
may be limited in library size.  Such combinatorial libraries have also been coupled with metabolic 
models to further optimize pathways [58].  
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1.5 Project overview 
The work presented in this dissertation focuses on applying tools of pathway engineering on 
phosphonic acid gene clusters for both discovery and optimized production. Chapter 2 will focus 
on using combinatorial pathway libraries to optimize the production of the antimalarial 
phosphonate FR900098. In these efforts, a novel screening strategy was developed, called enriched 
library screening, which only required screening 3% of a library consisting of over 250,000 
possible pathway combinations. Using this method, a top performing pathway configuration was 
found that produced 300% more FR900098 than the non-optimized pathway. With the addition of 
culturing optimization, a 16-fold total increase of production was seen. Chapter 3 will highlight 
strain optimization efforts, including gene knockout, knockdown, and overexpression, to increase 
FR900098 output. Despite a number of genomic alterations made, all attempts on strain 
engineering failed to increase production significantly. 
 
Chapters 4 and 5 will cover the use of the pathway engineering strategy of refactoring to express 
two Actinobacteria phosphonate pathways in Streptomyces lividans. The process of selecting 
candidate clusters for refactoring is given in Chapter 4 as well as the cluster refactoring and 
isolation of a phosphonic acid from Streptomyces species NRRL F-525, which harbors a gene 
cluster that appears to be completely unique from any known phosphonate.  Chapter 5 will focus 
on efforts to produce and purify a new phosphonic acid from a biosynthetic gene cluster of the 
strain Kibdelosporangium aridum largum NRRL B-24462. This cluster is of interest because it 
shares the first seven genes of the dehydrophos pathway, which produces a broad-spectrum 
antibiotic, yet differs in all the downstream genes from the common intermediate 
acetylphosphonate. 
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1.6 Figure and table 
 
 
Figure 1.1  Examples of phosphonic acids and their bioactivities. 
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Table 1.1   Strategies for activation of biosynthetic gene clusters. 
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s 
Media and 
culturing 
conditions 
Easy to test multiple 
configurations 
May not activate cluster of 
interest 
30, 31 
Co-culturing 
Creates environment that 
may elicit production 
May not activate cluster of 
interest 
32 
Ribosome 
engineering 
Easily scalable 
Fast screening method 
needed; limited activation 
33 
G
en
et
ic
 m
et
h
o
d
s 
Reporter-guided 
mutant selection 
Allows for high-
throughput screening 
Requires strain to be 
genetically tractable; 
limited activation 
35 
Activator gene 
expression 
Minimal engineering 
needed for activation; 
specific activation 
Activator gene may not 
always be present 
34 
H
et
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o
lo
g
o
u
s 
ex
p
re
ss
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n
 
Fosmid library 
Complete cluster 
sequencing not necessary 
Screening can be 
cumbersome; genes may 
not be active in host 
36-38 
RecE targeting/ 
TAR/CATCH 
High efficiency of cloning 
entire cluster 
Genes may not be active 
in heterologous host 
39-44 
Refactoring 
Gene expression 
decoupled from native 
regulatory elements 
Higher degree of design 
and assembly required 
45-48 
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2Chapter 2: Combinatorial pathway engineering for optimized production of the 
antimalarial phosphonate FR9000981 
2
 
2.1 Introduction 
 
 The current state of malaria 
 
Over 200 million people are living with malaria. Symptoms of this infectious disease range from 
mild (fever, headache) to severe (immune deficiency, brain damage). Children are often more 
susceptible to the devastating effects of the disease, with cerebral malaria impairing learning, 
making malaria a leading cause of neurological disabilities in African children. Perhaps the most 
startling statistic is that a disease that is virtually non-existent in developed countries continues to 
kill, by some estimates, over half a million people annually [1]. 
 
Malaria is caused by protozoan parasites of the Plasmodium genus that are transmitted into the 
human blood stream via mosquito bites. The parasite is in a motile form (sporozoite) upon 
introduction to the human host, where it takes residence in liver cells and multiplies asexually, 
where sporozoites form merozoites [2]. These parasitic progenies then rupture liver cells and are 
released into the blood stream, where they can infect red blood cells, replicate, and lyse their cell 
hosts. Cycles of replication in the blood cells lead to waves of fever that are associated with 
malaria. 
 
A number of methods are used to prevent and treat malaria. Many prevention methods rely on the 
control of mosquito populations and their contact with humans, such as indoor residual spraying 
 
1Portions of this chapter are adapted from the following publication as pertaining to the publisher’s 
guidelines: Freestone, T.S. and Zhao, H. (2016) Combinatorial pathway engineering for optimized 
production of the anti-malarial FR900098. Biotechnology and Bioengineering, 113,384-392. 
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of insecticides and the use of insecticide-treated mosquito nets [3]. Drug treatments are available 
for both the prevention and treatment of malaria. The most popular drug over the past century is 
chloroquine, which prevents biocrystallization of heme in red blood cells carrying the parasite [4]. 
The eventual buildup of heme can disrupt the cellular membrane and leads to cell lysis and 
autodigestion of the malarial parasite. Artemisinin is another drug with a long history in treating 
malaria in China, but has only relatively recently been used globally [5]. Its unique peroxide bridge 
is believed to disrupt redox homeostasis in malarial parasites [6]. One problem with both widely 
used insecticides and drugs is that the parasites and their vectors can acquire resistance to these 
methods of prevention and treatment [7, 8]. Within a decade of their wide use, resistance was seen 
for both chloroquine and artemisinin [8, 9]. Thus new compounds are always of interest in fighting 
the spread of malaria.  
 
For decades a malaria vaccine has also been sought after, but most vaccines have a less than ideal 
protection rate. Until recently, the RTS,S/AS01 vaccine was the most advanced malaria vaccine 
[10, 11]. It is composed of the circumsporozoite protein fused with hepatitis B surface antigen for 
increased immunogenicity [11]. However, in phase 3 clinical trials it was only effective in about 
one-third of children subjects who received the vaccine [12].  A newer vaccine was able to protect 
six of six volunteers who received five doses and six of nine volunteers who received four doses 
of attenuated sporozoites, but five of six of those who were not vaccinated developed malaria under 
controlled infection [13]. Although the effectiveness of this vaccine is much higher than any of its 
predecessors, it relies on multiple intravenous administrations, which cannot be easily adapted in 
the impoverished areas where the disease hits hardest. The production of the vaccine is another 
barrier to widespread use as it requires the irradiation of mosquitoes carrying the malaria parasite, 
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manual removal of salivary glands, and purification of sporozoites [14]. The difficulties of creating 
a vaccine that is effective, easily administered, and economical make the possibility of extensive 
immunization years and likely decades away. Thus molecular therapeutics will continue to be a 
major source of malaria treatments in the foreseeable future. 
 
 The antimalarial FR900098 
 
The phosphonate FR900098 was first reported in 1980 and was extracted from a fermentation of 
Streptomyces rubellomurinus, which was isolated from a soil sample [15]. Upon its discovery, the 
compound was shown to be a strong antibiotic against gram-negative bacteria, and has since been 
discovered to be a potent antimalarial [16]. Its activity against P. falciparum and other Plasmodium 
species comes from its inhibition of 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase 
(DXR) of the non-melavonate pathway. This pathway produces the precursors isopentenyl 
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) for isoprenoid synthesis [17]. 
Isoprenoids are essential for all plants and animals as well as many microorganisms. The 
Plasmodium parasites rely on organelles called apicoplasts for isoprenoid production [18]. These 
organelles resemble non-photosynthetic plastids and carry their own genome. The apicoplast 
utilizes the non-mevalonate pathway for isoprenoid synthesis where as humans have the 
mevalonate pathway which uses an entirely different route for IPP and DMAPP production and 
lacks DXR. FR900098 takes advantage of this difference to prevent isoprenoid synthesis in malaria 
causing parasites while having little or no effects on humans. 
 
DOXP is formed at the beginning of the non-mevalonate pathway as pyruvate is condensed with 
glyceraldehyde 3-phosphate. FR900098 is similar in structure to DOXP except for three key 
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differences: 1) the phosphonate group in place of the phosphate group, making a C-P bond instead 
of a phosphoester bond; 2) carbon 3 of DOXP is substituted with a nitrogen in FR900098; and 3) 
the lack of a hydroxyl group off of carbon 3 of FR900098 (Figure 2.1). The phosphonate group of 
FR900098 is necessary for binding to DXR; its replacement with a phosphate group actually 
increases inhibition, but when swapped with a carboxylate or sulfonate group the inhibition is 
severely diminished [19]. The amine in FR900098 allows for a coplanar configuration of the six 
atoms from the hydroxyl group on the amine to the acetyl end group, allowing for binding to the 
magnesium ion in the DXR active site [19].  The lack of the hydroxyl group on carbon 3 in 
FR900098 is essential for inhibition. DXR performs a fragmentation-reassembly via 
retroaldolization/aldoization on DOXP, where the bond between carbons 3 and 4 is broken and a 
new bond is formed with carbon 2 of the resulting enediol [20]. With no hydroxyl group on carbon 
3 of FR900098 to donate electrons for the fragmentation, the reaction is prevented from 
proceeding.  
 
 FR900098 biosynthesis 
 
The phosphoenolpyruvate mutase (PepM) gene in Streptomyces rubellomurinus was identified by 
performing PCR on the genomic DNA with degenerate primers designed to anneal to conserved 
sequences of known PEP mutases [21]. Once the PepM gene was found, specific primers were 
used to screen a S. rubellomurinus fosmid library for the gene, and a fosmid found carrying PepM 
was then conjugated into Streptomyces lividans. From this strain the production of FR900098 was 
verified by enzymatic assay, bioassay, nuclear magnetic resonance (NMR), and mass spectrometry 
(MS). The positive fosmid was then sequenced, and deletion studies were carried out to determine 
the minimal set of genes for FR900098 production. Eight genes were identified and designated as 
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frbA-H for FR900098 biosynthesis [21] (Figure 2.2). Additional genes were found in the operon 
(frbI and frbJ) that were not necessary as well as a DXR homologue named dxrB, all of which are 
detailed below.  
 
FrbD was identified as the PepM gene and the entry point for FR900098 production. The 
phosphonate rearrangement by FrbD is followed by an acetylation by FrbC to thermodynamically 
drive phosphonate biosynthesis, leading to the formation of 2-phosphonomethylmalate. The 
following steps have yet to be fully elucidated but have been proposed to be similar to those 
performed by enzymes in the citric acid cycle, to which FrbA, FrbB, and FrbE are homologues. 
Like aconitase, FrbA may perform an isomerization of 2-phosphonomethylmalate to 3-
phosphonomethylmalate [21]. The next reaction is carried out by FrbB or FrbE; although the 
deletion of either gene leads to some production of 2-oxo-4-phosphonobutyrate, an analog of α-
ketoglutarate, both proteins are required for high levels of product [22]. The next intermediate, 2-
amino-4-phosphonobutyrate (2-APn), is then likely catalyzed by an aminotransferase that is not 
associated with the cluster. The bifunctional FrbH, with its nucleotide transferase domain, then 
performs a CTP condensation with 2-APn followed by a decarboxylation to form CMP-5’-3-
aminopropylphosphonate (CMP-5’-3APn). Hydroxylation of the amino group is catalyzed by 
FrbG to make CMP-5’-N-hydroxy-3-aminopropylphosphonate (CMP-5’-H3APn) followed by an 
acetylation on the same amino group by FrbF forming CMP-5’-FR900098 [23]. The final step of 
FR900098 biosynthesis requires the cleavage of the CMP moiety, which can be catalyzed by FrbI, 
but has also been shown to be done in cellular extract lacking FrbI. FR33289 is a derivative that 
can be further formed when FR900098 is hydroxylated by FrbJ, another enzyme in the cluster. 
Because S. rubellomurinus itself utilizes the mevalonate pathway for isoprenoid synthesis, the 
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FR9000098 gene cluster contains an immunity gene, dxrB. The protein DxrB is a homolog of 1-
deoxy-D-xylulose 5-phosphate reductoisomerase, the target for FR900098 [23].  
 
It should be noted that the in the latter half of the pathway several dead-end byproducts can be 
formed that complicate the pathway’s efficiency [23]. Although FrbF acetylates CMP-5’-3HAPn, 
it actually has higher acetylation activity towards CMP-5’-3APn and forms CMP-5’-Ac3APn, 
which cannot be processed further towards FR900098. FrbF’s promiscuity leads to an additional 
problem of adding additional acetyl groups to CMP-5’-FR900098. FrbI also has promiscuous 
activity that leads to premature cleaving of the CMP moiety, leading to additional dead-end 
compounds. 
 
Current production in both the native producer and engineered Escherichia coli has yet to reach 
the scale for industrial application. The titer of FR900098 from its native producer, Streptomyces 
rubellomurinus, was 22.5 mg/L over three days in a 20 L fermentation [15]. This is a considerably 
larger titer than that of expressing the eight biosynthetic genes frbABCDEFGH and the immunity 
gene dxrB heterologously in E. coli BL21(DE3) [23]. The gene frbI is actually detrimental to 
production since it released CMP on earlier intermediates, and was thus left out. With the nine 
genes cloned into three DUET vectors (pACYC-, pET-, and pRSF-DUET) under strong, inducible 
T7 promoters, a final titer of 6 mg/L was formed when cultured in 50 mL Lysis Broth (LB) using 
shake flasks in 48 hours. However, when electron, carbon, and energetic balances are considered, 
one mole of glucose could produce 5/9 (0.556) moles of FR900098. Thus, if biomass production 
is not considered, a media containing only 0.4% glucose has a theoretical titer of 2420 mg/L of the 
target product.  Several methods of chemical synthesis of FR900098 have been developed, but 
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despite the compound’s simple structure, these synthetic routes either require harsh conditions [24, 
25] or multiple steps [26]. Thus biosynthesis of FR900098 remains an attractive option for large-
scale production if high enough titers can be achieved. 
 
 Combinatorial pathway engineering for optimized FR900098 production 
 
Because the initial titers of FR900098 in both the native producer and the engineered E. coli strain 
are underperforming for mass production, it is necessary to engineer the pathway for increased 
production and efficiency.  However, several obstacles prevent rational metabolic engineering of 
the FR900098 pathway. For example, as detailed in the previous section, multiple steps have yet 
to be conclusively demonstrated, and promiscuous activity of the enzyme FrbF leads to dead-end 
byproducts [23].  However, high expression of FrbF may be necessary to prevent the fast over-
oxidation of its substrate CMP-5’-N-hydroxy-3-aminopropylphophonate [27].  A toxic final 
product and a less toxic intermediate (2-amino-4-phophonobutyrate) also complicate 
straightforward rational design. 
 
Because the FR900098 pathway contains multiple enzymatic steps with unknown thermodynamic 
and kinetic parameters, a combinatorial pathway engineering strategy was pursued. Combinatorial 
pathway engineering consists of modulating the activity of each enzymatic step either intensively 
(changing enzyme activity, e.g. by substituting homologues [28]) or extensively (changing enzyme 
expression, e.g. by altering promoter strength [29]). By assembling and screening different 
combinations of enzymes with varying activities, the parameter space of the pathway is explored 
with the expectation that a certain arrangement of assigned activities will optimize the desired 
metabolic flux.   
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This strategy has been implemented in the engineering of several metabolic pathways, including 
the production of isoprenoids [30-32], (2S)-pinocembrin [33], and resveratrol [34], the utilization 
of xylose [28, 29, 35], and the fixation of nitrogen [36]. Examples of combinatorial engineering 
where phenotypes have been enhanced either have pathways that consist of a small number of 
genes [28, 29, 32], utilize high-throughput screening assays [28, 29, 35], or have genes grouped 
together in expression modules or operons [30, 31, 33, 34]. These conditions allow for workable 
library sizes that are critical for combinatorial pathway engineering to be effective, for it is 
important that the screening throughput accommodates the library size. For example, very large 
libraries (>104 samples) require growth-based assays to find optimal strains [29, 35] whereas 
products requiring low-throughput analytical quantification need their library sizes reduced, which 
may lead to overlooked optimal combinations [31, 33].  
 
This limitation of feasible library size and screening is a problem for large pathways that produce 
small molecules, including FR900098.  Modulating each step of the FR900098 nine-gene pathway 
with just four different activity levels per enzyme creates 262,144 possible combinations, a library 
size that cannot be reasonably screened by mass spectrometry, the fastest method to quantify 
FR900098. In this chapter, two strategies are introduced to overcome the limitations of this system 
to find engineered strains of E. coli with optimized production of FR900098. First, a qualitative 
screening assay was incorporated to determine if FR900098 was present above a certain threshold. 
Second, an iterative library construction and screening strategy was developed that significantly 
reduced the number of samples that needed screening before an optimal pathway could be 
identified. This latter strategy, called enriched library screening, can be used on other large 
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libraries to speed up screening for top performing pathways. By implementing these methods, a 
strain was identified where the biosynthesis of FR900098 was significantly increased. 
 
2.2 Results and Discussion 
 
 Preliminary screening for FR900098 production 
 
To increase the throughput of the screening, a qualitative screening method was developed that 
could determine if FR900098 levels were above a certain threshold. By exploiting FR900098’s 
antibiotic capability, a growth-inhibition assay was developed. Culture supernatant from 
producing strains was added to a target strain culture, and the growth of the target strain could be 
correlated with FR900098 concentration. Phosphonates are usually not readily taken up by cells, 
but E. coli strain WM6242 is sensitive to FR900098 when induced with isopropyl-β-D-1-
thiogalactopyranoside (IPTG), because it carries phosphonate transporter genes phnCDE under a 
Ptac promoter [37, 38]. It was found that a 400-fold dilution of spent media from the FR900098 
production strain HZ960 was capable of completely inhibiting growth of WM6242 whereas a 
1200-fold dilution did not (Figure 2.3). Although the bioassay’s small dynamic range could not 
give reliable quantification of FR900098 in test samples, it did allow for a qualitative evaluation 
of whether FR900098 concentrations were above a certain threshold. By using a growth-inhibition 
assay of diluted supernatants added to WM6242 cultures, thousands of samples could be relatively 
compared in a matter of hours.  
 
 Enriched library screening strategy  
 
A biased library screening strategy was developed that significantly decreased the necessary 
number of samples screened to find an optimal production strain (Figure 2.4). For the FR900098 
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pathway and in the example below, promoter strength as an activity modulator was used, but 
ribosome binding site strength, enzyme homologues, or mutants could also be used to alter enzyme 
activity. First, a random combinatorial library is constructed by a multi-fragment assembly method 
(Figure 2.4, step I) such as Golden Gate [39], Gibson Assembly [40], or DNA Assembler [41]. For 
the initial random library, an equimolar mixture of fragments is used for each gene under a 
different promoter. A fraction of possible combinations is screened as determined by the screening 
throughput (step II). The pathway from the first round’s top producing strain is designated as the 
parent pathway for the subsequent round, and the promoter assignment for each enzyme in this 
parent pathway is determined by either a PCR assay or DNA sequencing (step III). Unlike the first 
round library, subsequent libraries are not generated from an equimolar mixture of fragments. 
Rather, the new assembly library is enriched in fragments found in the parent pathway allowing 
for a more localized search around the first round’s top hit (step IV). Although all combinations 
are possible in an enriched library, the average distance is shorter between the parent pathway and 
an enriched library than the parent pathway and a random library (step V). The new library is 
screened for a top producer and the process is repeated until improvements in production are no 
longer seen (step VI). 
 
Simulations were performed using a basic model to understand how well the biased library strategy 
searches for an optimal strain (see section 2.4.9, Enriched Library Simulations for details). A nine-
gene mock pathway was modeled in silico that had similarities to the FR900098 pathway (eight 
biosynthetic genes, an immunity gene, toxic intermediate, and toxic product) yet does not represent 
the FR900098 pathway itself. Because many of the interactions have yet to be quantified (such as 
metabolic load or the effect of the toxic intermediate) and many parameters are unknown (such as 
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enzyme kinetics), a simplified dimensionless model was used. It is important to note that the 
purpose of the simulations is to explore how well the enriched library screening algorithm searches 
the flux space and not to understand the flux space of the FR900098 pathway specifically. The 
model developed uses the promoter assignments as input to calculate a cellular production term 
(PC), which is dependent on the rate-limiting step of the pathway, and a total cell mass term (m), 
which considers metabolic load, intermediate toxicity, and final product toxicity in its calculation. 
The total output is then a product of the cellular production and total cell mass terms.  
 
This model and simulations were used to investigate how the degree of fragment enrichment 
affects the search for an optimal pathway. The enrichment ratio is defined as the molar ratio of the 
biased fragment to a non-biased fragment, and enrichment ratios of 2-fold (low enrichment), 5-
fold (moderate enrichment) and 17-fold (high enrichment) were used.  For example, with the four 
different promoter strengths used, an enrichment ratio of 5-fold would give molar ratios of 5:1:1:1 
for each of the promoter-gene fragments. In other words, 62.5% of the fragments will contain the 
biased promoter assignment, while the non-biased fragments each comprise 12.5% of the total 
fragment pool. The percentages for the other enrichment ratios are 40% biased and 20% non-biased 
for 2-fold enrichment, and 85% biased and 5% non-biased for 17-fold enrichment (Figure 2.5). 
 
For the first round of each simulation, 1800 pathways with random promoter assignments were 
modeled. The product output for each pathway was calculated with the mock pathway model, and 
the top pathway was used as the parent pathway for the next library. This was done by using the 
best pathway’s promoter assignments for each gene and increasing the probability that these 
assignments will be incorporated into the new library based on the enrichment ratio being tested 
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(either no enrichment, 2-fold, 5-fold, or 17-fold). All 1800 pathways of the enriched library had 
their outputs calculated using the developed model, and the top performing pathway was used as 
the parent pathway for the next round. For each simulation this process was repeated for a total of 
nine rounds of enriched library screening, and each enrichment ratio was tested with 100 
simulations. By examining how many rounds it takes before a simulation finds the optimal strain, 
it was found that the moderate enrichment ratio (5-fold) performed best with 95% of the 
simulations finding the best pathway in just three rounds of enrichment and all 100 simulations 
reaching the optimal in eight rounds of enrichment (Figure 2.6A). The highly enriched (17-fold) 
simulations performed well, but plateaued after six rounds of enrichment. This was because the 
more biased library gave a narrower search, leaving a few of the simulations to persist on a local 
maximum. The low enrichment library (2-fold) gave a much broader search, but the simulations 
had a tendency to overlook the global optimum (Figure 2.6B). They had no traction in progressing 
towards the maximum because the new pathways were too different from the parent pathway used 
to bias each new library. However, the low enrichment simulations still considerably outperformed 
the random libraries alone in finding an optimum.   
 
 Creation and screening of the FR900098 pathway library 
 
Assembly of the FR900098 pathway library required the construction of thousands of plasmids 
with high efficiency. To modulate each gene separately in a library of this size without sacrificing 
efficiency, two rounds of Golden Gate assembly were required (Figure 2.7). A total of nine silent 
mutations were made in six of the pathway genes in order for the pathway to be compatible with 
the type IIs restriction enzymes used in the Golden Gate assemblies. 
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Each gene was placed into the plasmid pET28a from which the promoter-gene-terminator 
fragment would be amplified for assembly.  In the first round, three plasmids were made, each 
containing three genes. These three plasmids were then combined to build a single plasmid with 
all nine genes. Also to assist with assembly efficiency, the set of four-base-pair overhangs used 
for annealing between each fragment were optimized (see Table 2.7 in Section 2.4.8). For each 
first round assembly, hundreds of plasmids were assembled, covering the possible library of 64 
combinations several times over with a correct assembly efficiency of 95%. For the second round 
assembly, enough cells were plated for thousands of colonies and a final correct assembly 
efficiency of 80% was reached. About 2250 colonies were used per screening, giving an effective 
library size of 1800. To modulate each gene in the FR900098 library with a wide range of 
expression levels, the wild-type T7 promoter was used and three weaker promoters found by 
screening a T7 mutant library. These new promoters had expression levels of 3%, 15%, and 45% 
compared to that of the wild-type promoter (Figure 2.8).  
 
To start the enriched library screening strategy, an initial random library was constructed, and 
library strains were grown in 96-well plates for 24 hours after induction with 0.5 mM IPTG. The 
culture supernatants were then diluted and fed to freshly inoculated cultures of WM6242 in 
shallow-well 96-well plates. After 8 hours, OD600 was measured, and the top growth-inhibiting 
supernatants were then directly quantified by LC-MS. The strains producing the most FR900098 
as quantified by LC-MS of the 96-well plate samples were streaked out onto LB+Amp plates, and 
single colonies were re-inoculated to 5 mL cultures in duplicates for more reliable production 
quantification, with these supernatants also being analyzed by LC-MS. The best strain from the 
random library, 4pT, produced about 10 mg/L of FR900098 (Figure 2.9). A PCR assay was used 
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with the purified pathway plasmid as template to determine the promoter assignments for each 
gene, and any ambiguities of promoter assignment were resolved by DNA sequencing. These 
assignments were used as the parent pathway for the second library, which had a 5-fold enrichment 
ratio. Similar screening steps were used to find this library’s highest producer, 4pTR, which had a 
40% increase in production. A third round of enrichment based on 4pTR’s promoter assignments 
was carried out, and the top pathway, 4pTRA, produced similar titers as 4pTR.  
 
The promoter assignments for the best strain from each round are given in Table I. Notably, the 
wild-type T7 promoter was not found in any of the top strains. This strong promoter likely exerts 
a metabolic load on the cells, reducing total output. The promoter assignments from three 
additional top producing strains from the second enriched library (4pTRB, 4pTRN, and 4pTRQ) 
were also determined and the consensus assignments among these top strains and 4pTR are also 
shown in Table I.  Theoretically, the average number of different promoter changes between a 
parent pathway and all members in the 5-fold enrichment ratio library is 3.375. Because every top 
strain has lower than the average assignment changes with its parent, it can be seen that the search 
is converging on an optimum. Near the optimum, though, there can be several genotypes that share 
common production output, as can be seen by comparing 4pTR and 4pTRA’s similar production 
with differing promoter assignments. 
 
One aspect of the pathway profile that supports what is known about the pathway is the promoter 
assignments for frbD and frbC. Thermodynamics favor phosphoenolpyruvate (PEP) over 3-
phosphonopyruvate (PnPy) more than 500-fold [42, 43], making FrbC’s acetylation of PnPy the 
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driving force of the substrate into the pathway. It thus makes sense to not waste resources on FrbD 
if PEP and PnPy equilibrate quickly and instead to focus resources on FrbC production. 
 
By experimenting with different culturing conditions, it was found that by supplementing the 
media with acetate and inducing at higher cell density, the titer could further be increased to 96 
mg/L (Figure 2.10). It appears that the increase in production is due to higher cell mass, because 
experiments showed that production normalized by cell growth was about equal with or without 
acetate.  
 
2.3 Conclusions 
 
By implementing the enriched library screening strategy, the number of necessary samples to 
screen was significantly reduced from hundreds of thousands to less than 7,000. This strategy can 
be used with any pathway, but will be most useful for large ones and in cases where products must 
be quantified using low-throughput methods. The simulations reported here show the effect 
enrichment ratios have on biased libraries used to find optimal pathways. Although the flux space 
topology will be different for each metabolic pathway screened, optimal pathways may be 
overlooked if too low of an enrichment ratio is used or searches may converge on local maxima 
under too high of an enrichment ratio.    
 
Recently developed strategies have also aimed at reducing the search space of combinatorially 
constructed pathways, relying on the characterization of a fraction of the library to model the entire 
space [32, 44]. These approaches are very promising, yet they were demonstrated with smaller 
pathways and with modeling that may be too simple for complex pathways [44] or do not 
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incorporate certain factors that may impact output, such as metabolic load, toxicity, and 
promiscuous enzyme activity [32]. If such effects significantly influence final production, using 
an enriched library screening may be a beneficial option in discovering high producing strains. It 
may also be possible to couple biased searching libraries with computational modeling tools to 
better understand how the expression of each pathway enzyme affects final production. 
 
Although a significant increase in FR900098 production was achieved, further improvement 
would be required to develop a commercially relevant bioprocess. With the best strain producing 
FR900098 near 100 mg/L, the production cost of FR900098 was roughly estimated in the hundreds 
of dollars per gram range, a small fraction of the $17,000/g for the commercially available product 
from Sigma-Aldrich. However, currently used antimalarials cost $1 or less per treatment, against 
which FR900098 cannot currently compete. Further strain and pathway engineering, testing with 
different hosts, and culturing optimization could continue to improve the FR900098 titers. 
 
2.4 Materials and methods 
 
 Strains, media, and reagents 
 
All plasmid cloning was performed in E. coli DH5α, and all FR900098 production was done in E. 
coli BL21(DE3). All cloning cultures and starter cultures were grown in LB broth (Fisher 
Scientific, Pittsburgh, PA) at 37 °C with 250 rpm shaking. Screening and production culturing 
conditions are described in their respective sections below. Antibiotics were used at the following 
concentrations: ampicillin (Amp), 100 mg/L; chloramphenicol (Cm), 34 mg/L; kanamycin (Kan), 
50 mg/L, and streptomycin (Sm), 100 mg/L. Antibiotics and isopropyl-β-D-thiogalactoside (IPTG) 
were purchased from Gold Biotechnology (St. Louis, MO). Sodium acetate was from Fisher 
35 
 
Scientific. All other reagents were from Sigma-Aldrich (St. Louis, MO). PCR primers were 
synthesized by Integrated DNA Technologies (Coralville, IA) and are listed in Table 2.2. PCR 
reactions were performed in FailSafe PCR PreMix G (Epicentre Biotechnologies, Madison, WI) 
with either Phusion or Q5 DNA polymerase (New England Biolabs, Ipswich, MA). PlasmidSafe 
ATP-Dependent DNase was from Epicentre, restriction enzyme Esp3I was from Thermo-
Scientific (Pittsburgh, PA), and other restriction enzymes and T4 ligase were from New England 
Biolabs. Plasmids pET26b, pETDuet-1, and pACYCDuet-1 were from EMD Millipore (Billerica, 
MA), and plasmids containing FR900098 genes that were used as templates were previously 
constructed in the Zhao laboratory [23, 45]. Plasmids were purified using QIAprep Spin Miniprep 
Kit (QIAGEN, Valencia, CA) and DNA from agarose gels were purified using QIAquick Gel 
Extraction Kit (QIAGEN). 
 
 Promoter library construction and screening 
 
Degenerate forward primers T7-mut-3N and T7-mut-6N were used to introduce mutations within 
the strength region of the T7 promoter [46] when amplifying a GFP promoter-gene cassette with 
reverse primer XhoI-GFP-rev. Amplified fragments were ligated into pET26b with cutsites NdeI 
and XhoI, electroporated into E. coli BL21(DE3), and plated on LB+Kan+0.5 mM IPTG agar 
plates. The next day, colonies were analyzed under ultraviolet light and 164 colonies which 
exhibited a range of fluorescence were inoculated into 300 µL of LB+Kan in 96-well plates and 
grown overnight at 37 °C. The next day, 5 µL of each culture was inoculated into 300 µL of 
M9+Kan+0.5 mM IPTG and grown for 3 hours at 37 °C then another 3 hours at 30 °C. Plates were 
then analyzed for GFP fluorescence (395 nm excitation/509 nm emission) by a Synergy H4 
fluorescent plate reader (BioTek, Winooski, VT) and 15 cultures that exhibited a range of 
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fluorescence strengths were streaked out onto LB+Kan agar plates. Two colonies from each plate 
were then inoculated into LB+Kan, grown overnight, washed twice in M9, and inoculated into 5 
mL M9 in a culture tube and grown at 37 °C. After 3 hours, cultures were induced with 0.5 mM 
IPTG and then moved to a 30 °C shaker. A sample of culture was diluted 2-fold in water for a final 
volume of 120 µL and analyzed by fluorescent plate reader, and larger cultures were diluted into 
phosphate buffer and analyzed by a BD LSR II Flow Cytometry Analyser (BD Biosciences, San 
Jose, CA). Three strains exhibiting a nearly logarithmic range of expression (3%, 15%, and 45% 
of wild-type) had their plasmids purified and their promoters sequenced by ACGT, Inc (Wheeling, 
IL) using their in-house T7 terminator reverse primer. To ensure that strength of fluorescence was 
due to the promoter sequence and not any other mutation on the plasmid, each of these plasmids 
were reconstructed using primers T7-low-for, T7-med-for, or T7-hi-for. The promoter strengths of 
the recreated plasmids were similar to those found in the original plasmids (Figure 2.8).  
 
 Construction of Golden Gate compatible FR900098 genes 
 
Nine mutations were made in six of the FR900098 genes as given in Table 2.3. These mutations 
were made by PCR and overlap extension PCR (OE-PCR) as outlined in Table 2.4.  The final 
fragments (A7, C4, D4, E1, G1, and H2) were then ligated into pET26b at cutsites NdeI and 
HindIII. 
 
 FR900098 pathway assembly 
 
Primers and setup of PCR reactions for all 36 promoter-gene fragments are listed in Table 2.5. In 
the first round of Golden Gate assembly (three plasmids with three genes each) for the random 
library, three 20 µL reactions were set up, each with 20 U restriction enzyme (BbsI or BsaI), 400 
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U T4 ligase, 1x T4 ligation buffer, 100 ng of PCR-amplified backbone (BB-I for pFRGG1 and 
BB-II/III for pFRGG2), and 1:1 molar ratio of each gene fragment mixture to the backbone. The 
following thermocycler program was used for the assembly: Step 1, 37 °C for 20 minutes; step 2, 
37 °C for 10 minutes; step 3, 16 °C for 10 minutes; step 4, go to step 2 10 times; step 5, 16 °C for 
20 minutes; step 6, 37 °C for 30 minutes; step 7, 80 °C for 20 minutes. After assembly, 5 µL of 
the reaction was run on a gel to confirm assembly, and the remaining reaction was treated with 
Plasmid-Safe DNase (1x buffer, 5 U enzyme) at 37 °C for 10 minutes then 80 °C for 20 minutes. 
5 µL of the reaction was then heat shocked into E. coli DH5α and plated onto LB+Cm agar plates. 
The next day, colonies were scraped from the plates and their plasmids were purified. The 
concentration of each plasmid batch (pFRGG1, pFRGG2, and pFRGG3) was measured, and 
another 20 µL Golden Gate reaction was set up as described for the first-round assemblies, but 
with 100 ng of the final plasmid backbone (pFRGG-BB) and equimolar ratios of and the three 
newly purified pFRGG1, pFRGG2, and pFRGG3 plasmids. For this second round of DNA 
assembly, the same thermocycler assembly program, gel confirmation, Plasmid-Safe DNase 
treatment, E. coli DH5α transformation, and plasmid collection as stated above were carried out, 
except that LB+Amp agar plates were used after transformation. The final plasmid library was 
then electroporated into E. coli BL21(DE3) and plated on LB+Amp agar plates. For the 
construction of pFRGG-BB, fragments were amplified by PCR as outlined in Table 2.6, and 
Golden Gate assembly was used as stated above to build the plasmid. 
 
 Library screening 
 
About 2250 individual colonies were inoculated in 150 µL LB+Amp in 96-well plates that were 
then covered with a rayon breathable membrane (VWR, Radnor, PA) and grown overnight at 37 
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°C with 250 rpm shaking. Cultures diluted 50-fold into 500 µL of M9GF (M9 with 0.4% glycerol 
as carbon source and 10 µM FeSO4) in deep-well 96-well plates and grown at 37 °C. After 4 hours, 
500 µL of M9GF+1 mM IPTG was added for induction, the incubation temperature was reduced 
to 30 °C, and the cultures were grown for another 24 hours. 5 µL of culture was diluted 20-fold in 
H2O+Sm, and 5 µL of this solution was added to 150 µL of WM6242+pCDFDuet-1 in LB+Sm+0.5 
mM IPTG. After 8 hours, the OD600 of each well was measured. The supernatant from 30 to 40 
wells with the least cell growth had the corresponding supplemented supernatant collected for LC-
MS analysis, which is detailed below. After quantification, the top 10 to 20 strains were grown in 
duplicate in 5 mL LB overnight, washed twice in M9GF, and diluted 100-fold in fresh M9GF and 
grown at 37 °C. After 4 hours, cultures were induced with 0.5 mM IPTG and moved to 30 °C. 
After 48 hours, supernatants of these cultures were collected and FR900098 concentrations were 
analyzed by LC-MS to find the top producer from each round of screening. E. coli BL21(DE3) 
strains carrying retransformed plasmids showed FR900098 production similar to that of the 
original strains. 
 
 Determining promoter assignments  
 
To determine the promoter assignments for a pathway, four PCR reactions were set up for each of 
the nine genes for a total of 36 PCR reactions. For a single gene, four different forward primers 
(T7-low-for-check, T7-med-for-check, T7-hi-for-check, T7-WT-for-check) were used in separate 
reactions, with each primer having an annealing preference to one of the four promoters. Because 
these primers were gene independent, they could be used to determine the assignments for all nine 
genes depending on the reverse primers used, which were unique for each gene (FrbA-prom-seq-
rev, FrbB-prom-seq-rev, FrbC-prom-seq-rev, FrbD-prom-seq-rev, FrbE-prom-seq-rev, FrbF-
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prom-seq-rev, FrbG-prom-seq-rev, FrbH-prom-seq-rev, and DxrB-prom-seq-rev). The PCR 
reactions were resolved on an agarose gel, and if a clear band was seen for only one of the forward 
primers for a gene, the respective promoter was assigned to that gene. For ambiguous results, 
samples were submitted for sequencing to ACGT, Inc. using the reverse primers stated above. 
 
 FR900098 production cultures 
 
All production cultures were grown in M9GF, except for the optimized production culture which 
was supplemented with 0.8% acetate. Starter cultures were washed twice in fresh media and then 
diluted 100-fold into 5 mL of fresh media in culture tubes. Cultures were grown at 37 °C, induced 
at 4 hours after inoculation with 0.5 mM IPTG, and moved to 30 °C; for optimized conditions, 
induction was done at 10 hours after inoculation. Forty-eight hours induction, cultures were 
collected and analyzed by LC-MS. 
 
 Liquid chromatography-mass spectrometry (LC-MS) analysis  
 
Supernatant from 1 mL of culture was collected after pelleting at 20,000xg for 2 minutes. 
Supernatant was diluted 10-fold into water. For the standard curve, standards of 5, 15, 30, 60, and 
120 mg/L FR900098 in water were made and diluted similarly to the production samples.  LC-MS 
was performed on an Agilent 1100 series LC/MSD XCT plus ion trap mass spectrometer (Agilent, 
Palo Alto, CA). 10 µL of sample was loaded on a Luna 5µ C18(2) 100Å 100x4.6mm 5 micron 
column (Phenomenex, Torrance, CA) with mobile phases H2O+0.1% formate (solvent A) and 
acetonitrile+0.1% formate (solvent B) at a flow rate of 350 µL/min with 100% solvent A for 0.5 
minutes, a gradient of 0 to 100% solvent B over 7 minutes, 100% solvent B for 6 minutes, a 
gradient from 100% to 0% solvent B over 1 minute, and 100% solvent A for 3.5 minutes. Manual 
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MS(3) was set up scanning for a 198 m/z to 138 m/z fragmentation from MS(2) to MS(3) with 
positive polarity. Using an extracted ion chromatogram MSn filter of 138.1±0.3 m/z, the 
FR900098 peak with a retention time of ~7.5 minutes was measured. Interpolation of the 
FR900098 standards was used to measure the concentrations of the experimental samples.  
 
 Finding optimal overhangs for Golden Gate assembly  
 
A Perl script was written that used UNAfold [47] to calculate the Gibbs free energy of all 256 
possible 4-base pair overhangs against themselves. Those having a negative free energy against 
themselves were screened out as well as those that had a free energy greater than -1 kcal/mol (an 
arbitrarily chosen cutoff) when hybridized with their reverse complement, leaving 154 overhangs. 
The Gibbs free energy for binding between each of the remaining overhangs was calculated against 
all other overhangs and their reverse complements.  A set of four overhangs were found, ACAC, 
CCCT, TAGC, and TTCG, that gave strong binding to their own reverse complements but not to 
themselves, the other overhangs, or the reverse complements of the other overhangs (Table 2.7). 
 
 Enriched library simulations  
 
Simulations were performed using MATLAB (Mathworks, Natick, MA). For each simulation, a 
library of 1800 pathways was made where each of nine genes was assigned a promoter strength, 
pi, that matched the strengths of the promoter library of 0.03, 0.15, 0.45, and 1. The output for each 
pathway was then modeled using the equations outlined below, where the theoretical maximum 
output is 1.  The total product output (PT) of each pathway is the cellular output (PC) multiplied by 
a cell mass term (m): 
 𝑃𝑇 = 𝑚𝑃𝐶 (Equation 1) 
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Cellular output is determined by the rate-limiting step of the simulated pathway: 
 𝑃𝐶 = ⁡ min
𝑖=1…8
(𝑘𝑖𝑝𝑖) (Equation 2) 
where k represents the turnover rate for enzyme i. Random values between 1 and 10 were assigned 
for each k (values 10, 2, 3.5, 1, 3, 1.5, 6, and 4 were assigned to enzymes 1 through 8). At least 
one pathway enzyme was assigned a turnover rate of 1 which with the rate-limiting output would 
ensure the maximum output did not exceed 1.  The cell mass (also with a maximal possible value 
of 1) was dependent on the metabolic load caused by the promoter strengths (L), toxicity of an 
intermediate (tI), and toxicity of the product (tP): 
 𝑚 = (1 − 𝐿 − 𝑡𝐼)𝑡𝑃 (Equation 3) 
The metabolic load was calculated by summing the promoter strengths and dividing it by a 
normalization factor (n1, described in more detail below) to ensure that the growth rate will be 
positive: 
 
𝐿 =
1
𝑛1
∑𝑝𝑖
9
𝑖=1
 
 
(Equation 4) 
The toxic intermediate was only present if a rate-limiting step upstream of the intermediate (steps 
1 through 4) was greater than enzymatic step 5. Another normalization factor was used, again to 
ensure a positive growth rate: 
 
𝑡𝐼 = {
0,⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡ min
𝑖=1…4
(𝑘𝑖𝑝𝑖) ≤ 𝑘5𝑝5
1
𝑛2
[ min
𝑖=1…4
(𝑘𝑖𝑝𝑖)−𝑘5𝑝5⁡],⁡⁡⁡⁡⁡⁡⁡⁡ min
𝑖=1…4
(𝑘𝑖𝑝𝑖) > 𝑘5𝑝5
 
 
(Equation 5) 
Product toxicity was determined by the cellular output as well as the expression of the immunity 
enzyme (gene 9): 
 
𝑡𝑃 = {
1 − (𝑃𝐶 − 𝑝9),⁡⁡⁡⁡⁡⁡⁡⁡𝑝9 < 𝑃𝐶
1,⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡𝑝9 ≥ 𝑃𝐶
 
 
(Equation 6) 
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According to equation 3, it is possible for the cell mass to be negative if L + tI > 1; however, this 
is dependent on the turnover values (k) that the enzymes are assigned. For the mock pathway, 
normalization factors of n1 = 12 and n2 =10 were used, giving a maximal value of (L + tI)max = 
0.761. These values were chosen to give the metabolic load greater weight (Lmax = 0.75) in 
determining cell mass as compared to the toxic intermediate (tI,max = 0.091), which is known to 
have low toxicity in the FR900098 pathway. Although these values to an extent are arbitrary, it 
should be remembered that the primary purpose of the model is to show the searching capabilities 
of the enriched library screening strategy and not to elucidate the actual metabolic characteristics 
of the FR900098 pathway. 
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2.5 Figures and tables 
 
 
Figure 2.1  1-Deoxy-D-xylulose 5-phosphate (DOXP) rearrangement inhibition by FR900098.  
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Figure 2.2  Biosynthetic pathway of FR900098. PEP, phosphoenolpyruvate; PnPY, phosphono-
pyruvate; 2-PnMM, 2-phosphonomethylmalate; 3-PnMM, 3-phosphonomethylmalate; 2-OPn, 2-
oxo-4-phophonobutyrate; 2-APn, 2-amino-4-phosphonobutyrate; CMP-5’-3APn, CMP-5’-3-
aminopropylphosphonate; CMP-5’-H3APn, CMP-5’-N-hydroxy-3-aminopropylphosphonate; 
CMP-FR900098, CMP-5’-FR900098. 
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Figure 2.3  Growth inhibition feeding assay.  Feeding assay of various amounts of supernatant 
from all WT T7 promoter strain fed to 120 µL culture of the phosphonate uptake strain WM6242. 
Each point shows average of 48 culture wells (half of 96-well plate), with error bars showing the 
minimum and maximum OD 600 measured for each supernatant volume fed. Although the assay 
is not quantitative, it can show whether the concentration is above a certain threshold. 
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Figure 2.4  Schematic of enriched library construction and screening. A random pathway 
library is constructed of multiple genes (different arrow columns) with a range of expression 
strengths (multiple arrow sizes) (I) and screened (II). The promoter assignments of the top strain 
are identified (III) and enriched in the following library assembly (IV). This leads to strains in the 
new library having promoter assignments biased toward its parent pathway (V). The new library 
is screened (VI) and the enriched library cycle can be repeated. 
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Figure 2.5  Distributions of four promoter strength fragments in biased library assemblies 
with different enrichment ratios. 
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Figure 2.6  Results of pathway enrichment simulations. (A) The percent of simulations ran that 
found the optimal pathway after the initial random round (R1) and nine rounds of enriched library 
screening (E1 through E9) for different ratios of enrichment. (B) All 100 simulations graphed for 
each of the three enrichment ratios over the ten rounds of screening. All outputs were normalized 
to the theoretical top performing pathway. 
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Figure 2.7  Two-round Golden Gate assembly for high-efficiency construction of the 
FR900098 pathway into a single plasmid. The type IIs restriction enzyme for each round of 
assembly is listed. 
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Figure 2.8  Promoter strengths of a chosen library. Originals promoters screened in at least 
quadruplicates, and reconstructed promoters in duplicates except for the High promoter, which 
only had one sample. 
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Figure 2.9  FR900098 production of the top strains from each round of screening. HZ960, 
strain from reference 10; All WT, all WT T7 promoters in nine-gene plasmid; 4pT, top strain from 
random library; 4pTR, top strain from first round of enriched library screening; 4pTRA, top strain 
from second round of enriched library screening. Error bars indicate standard deviations of 
triplicate samples. 
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Figure 2.10  FR900098 production from the top strains from each round of screening under 
optimal conditions. Error bars indicate standard deviations of triplicate samples. 
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Table 2.1  Promoter assignments (Low/Med/High/WT) of the top strains from each round of 
screening. Consensus shows all assignments from the top four producing strains identified from 
the second round of enriched library screening and 4pTR. For example, among these top strains, 
FrbA was found to be expressed by either the medium or high strength promoter. Promoter 
assignment changes from the immediately preceding round are indicated in bold face. 
 
 Gene/Promoter Assignment 
Strain FrbD FrbC FrbA FrbB FrbE FrbH FrbG FrbF DxrB 
4pT Med High Med Low Low Low High Med High 
4pTR Low High High Low Low Low High High High 
4pTRA Low High High Med Low Low High High Low 
Consensus Low High Med/High Low/Med Low Low High High Low/High 
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Table 2.2 Primers used in this work. 
Primer Sequence Use 
NdeI-FrbA-for TGACGCCATATGCGCGACCTGTTACGGGAC 
FrbA 
mutations 
FrbA-G1374T-for 
GTCCCGTCCTGGGTTAAGACCAGTCTGGCGCCGGGCT
CGC 
FrbA-G1374T-rev 
GCGAGCCCGGCGCCAGACTGGTCTTAACCCAGGACGG
GAC 
FrbA-C1725G-for 
GACCCGGACGGCGCCGAGGTGTTCCTCGCGGACCTGT
GGC 
FrbA-C1725G-rev 
GCCACAGGTCCGCGAGGAACACCTCGGCGCCGTCCGG
GTC 
HindIII-FrbA-rev TGACCTAAGCTTTCAGGCCTCGGCGTCGAGCAG 
NdeI-FrbC-for TGACGCCATATGCGCAACGACTTAGTGCTCG 
FrbC 
mutations 
FrbC-C395G-for 
CAAGGACCGGGGCGCGTTCGTGTCGATCAGCGCCGAG
GACATC 
FrbC-C395G-rev 
GATGTCCTCGGCGCTGATCGACACGAACGCGCCCCGG
TCCTTG 
HindIII-FrbC-
C1077G-rev 
TGACCTAAGCTTTCAGGCGGCGGCCTTGTTGTAGATC
TCGACGAGCTGCTCGTGCGACACGGCGCCGCCGATCC
TGATC 
HindIII-FrbC-rev TGACCTAAGCTTTCAGGCGGCGGCCTTGTTGTAG 
NdeI-FrbD-for TGACGCCATATGACCAAGCGAACCATGTTAC 
FrbD 
mutations 
FrbD-G384A-rev 
CTTGGCCGCCGCGAGCTTGGCGGCGAAGCCCTCGATC
GTTTCCTGGTCCTGGGCCCCGTC 
FrbD-G468A-for 
CTTCGCCGCCAAGCTCGCGGCGGCCAAGAAGGCCCAG
CAGACCGACGACTTCGTGGTCGTGGCGCGGATCGAAA
CCTTCATCGCCG 
HindIII-FrbD-rev TGACCTAAGCTTTCAGCGCTGGAGCTCGAAGACC 
NdeI-FrbE-A33T-
for 
TGACGCCATATGCGTAAACACACAGTCACTCTGATCG
CGGGTGACGGCAGCGGCCCG 
FrbE 
mutation 
HindIII-FrbE-rev TGACCTAAGCTTTCATCCGATGTCCCGCAGGCGCTCG 
NdeI-FrbG-C45T-
for 
TGACGCCATATGACGCACTACGCGACCGTCATCTGCG
GCGGTGGCCCCGCGGGTGTCTCCGCGGTGGTG 
FrbG 
mutation 
HindIII-FrbG-rev TGACCTAAGCTTTCAACGCCCATCCTCCGTACGATC 
NdeI-FrbH-for TGACGCCATATGAACGAGAACCGGACCTTCGCCAC 
FrbH 
mutation 
FrbH-G1773T-rev 
GCCCCGCGGGCCGCCGACGATCTCGGCGACCGCGGCG
ACCACCACCTCGTTCTCCGCGCGGCTGCGGCTGGAGA
CACGCAGGTAGGCGTC 
HindIII-FrbH-rev 
TGACCTAAGCTTTCAGCCGTCGGCACGGCCCGCCCCC
TCGGTCGTCGCGGCGCCCCGCGGGCCGCCGACGATC 
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Table 2.2 (cont.) Primers used in this work. 
 
 
Primer Sequence Use 
1A-low-for CGGAAGACTAACACGTCTCAACACGAAATTAATACGACT
CACTACCACCGAATTGTGAGC 
Pathway 
assembly 
1A-med-for 
CGGAAGACTAACACGTCTCAACACGAAATTAATACGACT
CACTAGGTGAGAATTGTGAGC 
1A-hi-for 
CGGAAGACTAACACGTCTCAACACGAAATTAATACGACT
CACTAAGGCGGAATTGTGAGC 
1A-WT-for 
CGCCTAGGAAGACTAACACGTCTCAACACGAAATTAATA
CGACTCACTATAGGGGAATTG 
1B-low-for 
CGGAAGACTACCCTCGAAATTAATACGACTCACTACCAC
CGAATTGTGAGC 
1B-med-for 
CGGAAGACTACCCTCGAAATTAATACGACTCACTAGGTG
AGAATTGTGAGC 
1B-hi-for 
CGGAAGACTACCCTCGAAATTAATACGACTCACTAAGGC
GGAATTGTGAGC 
1B-WT-for 
CGCCTAGGAAGACTACCCTCGAAATTAATACGACTCACT
ATAGGGGAATTG 
1C-low-for 
CGGAAGACTATAGCGAAATTAATACGACTCACTACCACC
GAATTGTGAGC 
1C-med-for 
CGGAAGACTATAGCGAAATTAATACGACTCACTAGGTG
AGAATTGTGAGC 
1C-hi-for 
CGGAAGACTATAGCGAAATTAATACGACTCACTAAGGC
GGAATTGTGAGC 
1C-WT-for 
CGCCTAGGAAGACTATAGCGAAATTAATACGACTCACTA
TAGGGGAATTG 
2A-low-for 
CGGGTCTCAACACGTCTCACCCTCGAAATTAATACGACT
CACTACCACCGAATTGTGAGC 
2A-med-for 
CGGGTCTCAACACGTCTCACCCTCGAAATTAATACGACT
CACTAGGTGAGAATTGTGAGC 
2A-hi-for 
CGGGTCTCAACACGTCTCACCCTCGAAATTAATACGACT
CACTAAGGCGGAATTGTGAGC 
2A-WT-for 
CGCCTAGGTCTCAACACGTCTCACCCTCGAAATTAATAC
GACTCACTATAGGGGAATTG 
2B-low-for 
CGGGTCTCACCCTGCGAAATTAATACGACTCACTACCAC
CGAATTGTGAGC 
2B-med-for 
CGGGTCTCACCCTGCGAAATTAATACGACTCACTAGGTG
AGAATTGTGAGC 
2B-hi-for 
CGGGTCTCACCCTGCGAAATTAATACGACTCACTAAGGC
GGAATTGTGAGC 
2B-WT-for 
CGCCTAGGTCTCACCCTGCGAAATTAATACGACTCACTA
TAGGGGAATTG 
2C-low-for 
CGGGTCTCATAGCGAAATTAATACGACTCACTACCACCG
AATTGTGAGC 
2C-med-for 
CGGGTCTCATAGCGAAATTAATACGACTCACTAGGTGAG
AATTGTGAGC 
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Table 2.2 (cont.) Primers used in this work. 
Primer Sequence Use 
2C-hi-for 
CGGGTCTCATAGCGAAATTAATACGACTCACTAAGGCGG
AATTGTGAGC 
Pathway 
assembly 
2C-WT-for 
CGCCTAGGTCTCATAGCGAAATTAATACGACTCACTATA
GGGGAATTG 
3A-low-for 
CGGGTCTCAACACGTCTCATAGCGAAATTAATACGACTC
ACTACCACCGAATTGTGAGC 
3A-med-for 
CGGGTCTCAACACGTCTCATAGCGAAATTAATACGACTC
ACTAGGTGAGAATTGTGAGC 
3A-hi-for 
CGGGTCTCAACACGTCTCATAGCGAAATTAATACGACTC
ACTAAGGCGGAATTGTGAGC 
3A-WT-for 
CGCCTAGGTCTCAACACGTCTCATAGCGAAATTAATACG
ACTCACTATAGGGGAATTG 
1A-rev 
CTTGAGGAAGACTAAGGGCTCCTTTCAGCAAAAAACCCC
TCAAG 
1B-rev 
CTTGAGGAAGACTAGCTACTCCTTTCAGCAAAAAACCCC
TCAAG 
1C-rev 
CTTGAGGAAGACTACGAACGTCTCAAGGGCTCCTTTCAG
CAAAAAACCCCTCAAG 
2A-rev 
CTTGAGGGTCTCAAGGGCTCCTTTCAGCAAAAAACCCCT
CAAG 
2B-rev 
CTTGAGGGTCTCAGCTACTCCTTTCAGCAAAAAACCCCT
CAAG 
2C-rev 
CTTGAGGGTCTCACGAACGTCTCAGCTACTCCTTTCAGC
AAAAAACCCCTCAAG 
3C-rev 
CTTGAGGGTCTCACGAACGTCTCACGAACTCCTTTCAGC
AAAAAACCCCTCAAG 
BB-I-for 
TGACTCGAAGACTATTCGCAATAAACCGGTAAACCAGCA
ATAGAC 
pFRGG1 
backbone 
BB-I-rev 
CTTGAGGAAGACTAGTGTCGACCGATGCCCTTGAGAGCC
TTCAAC 
BB-I-for 
TGACTCGAAGACTATTCGCAATAAACCGGTAAACCAGCA
ATAGAC 
BB-I-rev 
CTTGAGGAAGACTAGTGTCGACCGATGCCCTTGAGAGCC
TTCAAC 
BB-II/III-for 
TGACTCGGTCTCATTCGCAATAAACCGGTAAACCAGCAA
TAGAC pFRGG2/3 
backbone 
BB-II/III-rev 
CTTGAGGGTCTCAGTGTCGACCGATGCCCTTGAGAGCCT
TCAAC 
GGBB-lacZa-for 
TGACTCGGTCTCACCCTTATGCGACACACAGAGACGTCA
GCCGCTACAGGGCGCGTCCC 
pFRGG-BB 
assembly GGBB-lacZa-rev 
TGACTCGGTCTCACAAGCGAATGAGACGACCGGTGGAA
AGCGGGCAGTGAG 
GGBB-pET-1-for TGACTCGGTCTCACTTGCCAGCGCCCTAGCGCCCGC 
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Table 2.2 (cont.) Primers used in this work. 
Primer Sequence Use 
GGBB-pET-1-rev 
TGACTCGGTCTCATAGCCGCGGTATCATTGCAGC
ACTGG 
pFRGG-BB 
assembly 
GGBB-pET-2-for 
TGACTCGGTCTCAGCTACCACGCTCACCGGCTCC
AGATTTATCAG 
GGBB-pET-2-rev 
TGACTCGGTCTCACGAAAACTCACGTTAAGGGA
TTTTG 
GGBB-pACYC-1-
for 
CTCGGTCTCATTCGTTCCACTGAGCGTCAGACCC
CGTAGAAACGTAACGGCAAAAGCACC 
GGBB-pACYC-1-
rev 
TGACTCGGTCTCAGTGTCACTGGTGAAAAGAAA
AACC 
GGBB-pACYC-2-
for 
TGACTCGGTCTCAACACGGGCAACAGCTGATTG
CC GGBB-pACYC-2-
rev 
TGACTCGGTCTCAAGGGAGAGCGTCGAGATCCC
G T7-WT-for-check CCCGCGAAATTAATACGACTCACTATA 
PCR assay 
for promoter 
assignments 
T7-hi-for-check CCCGCGAAATTAATACGACTCACTAGGTGA 
T7-med-for-check CCCGCGAAATTAATACGACTCACTAAGGC 
T7-low-for-check CCCGCGAAATTAATACGACTCACTACCACC 
FrbA-prom-seq-rev GTTCGTACTCACGGCGCATG 
Sequencing 
for promoter 
assignments 
FrbB-prom-seq-rev ACGAACTCGGAAACCCGGTC 
FrbC-prom-seq-rev TGGCACTGCACGTCGATGTC 
FrbD-prom-seq-rev GAGTTGCGCTTCGGGAAGAC 
FrbE-prom-seq-rev TGATCGGCTTCAGCGAGAAGG 
FrbF-prom-seq-rev GAGAACGTCGGCATGACCAG 
FrbG-prom-seq-rev AGTAGAAGATCGGCGGCAGC 
FrbH-prom-seq-rev TCGGAGGTTGTTGGTCGTCG 
DxrB-prom-seq-rev CCTTGTTCGCCAGGATGAGC 
T7-mut-3N 
CGTAGCATGCCGAAATTAATACGACTCACTANA
NGNGAATTGTGAGCGGATAACAATTC T7 promoter 
library 
generation 
T7-mut-6N 
CGTAGCATGCCGAAATTAATACGACTCACTNNN
NNNGAATTGTGAGCGGATAACAATTC 
XhoI-GFP-rev CACGTACTCGAGTCATTTGTATAGTTCATCCATG 
T7-low-for CGTAGCATGCCGAAATTAATACGACTCACTACC
ACCGAATTGTGAGCGGATAACAATTC Reconstruct 
chosen T7 
promoter 
mutants 
T7-med-for 
CGTAGCATGCCGAAATTAATACGACTCACTAGG
TGAGAATTGTGAGCGGATAACAATTC 
T7-hi-for 
CGTAGCATGCCGAAATTAATACGACTCACTAAG
GCGGAATTGTGAGCGGATAACAATTC 
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Table 2.3  Mutations made in FR900098 biosynthetic genes for Golden Gate compatibility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Mutation 1 RE site Mutation 2 RE site 
frbA 1374G>T BbsI 1735C>G BbsI 
frbC 396C>G Esp3I 1077C>G Esp3I 
frbD 384G>A Esp3I 468G>A BsaI 
frbE 33A>T Esp3I   
frbG 45C>T Esp3I   
frbH 1775G>T BsaI   
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Table 2.4  PCR and OE-PCR for mutations in FR900098 biosynthetic genes. 
 
Gene Fragment Template Forward primer/fragment Reverse primer/ fragment Method 
frbA A1 pET26b-
frbA NdeI.FrbA for FrbA G1374T rev 
PCR 
A2 pET26b-
frbA 
FrbA G1374T for FrbA C1725G rev PCR 
A3 pET26b-
frbA 
FrbA C1725G for HindIII.FrbA rev PCR 
A4 - A1 A2 OE-PCR 
A5 - A2 A3 OE-PCR 
A6 - A4 A5 OE-PCR 
A7 A6 NdeI.FrbA for HindIII.FrbA rev PCR 
frbC 
C1 pET26b-frbC NdeI.FrbC for FrbC C395G rev PCR 
C2 pET26b-frbC FrbC C395G for HindIII.FrbC C1077G 
rev 
PCR 
C3 - C1 C2 OE-PCR 
C4 C3 NdeI.FrbC for HindIII.FrbC rev PCR 
frbD 
D1 pET26b-frbC NdeI.FrbD for FrbD G384A rev PCR 
D2 pET26b-frbC FrbD G468A for HindIII.FrbD rev PCR 
D3 - D1 D2 OE-PCR 
D4 D3 NdeI.FrbD for HindIII.FrbD rev PCR 
frbE E1 pET26b-frbE NdeI.FrbE A33T for HindIII.FrbE rev PCR 
frbG G1 pET26b-
frbG 
NdeI.FrbG C45T for HindIII.FrbG rev PCR 
frbH H1 pET26b-
frbH NdeI.FrbH for 
FrbH G1773T rev PCR 
H2 H1 NdeI.FrbH for HindIII.FrbH rev PCR 
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Table 2.5  PCR reactions for fragments to construct the FR900098 combinatorial pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fragment Template Forward primer Reverse primer 
frbA-lo pFRGG-A 1A low for 1A rev 
frbA-med pFRGG-A 1A med for 1A rev 
frbA-hi pFRGG-A 1A hi for 1A rev 
frbA-WT pFRGG-A 1A WT for 1A rev 
frbB-lo pET26b-frbB 1B low for 1B rev 
frbB-med pET26b-frbB 1B med for 1B rev 
frbB-hi pET26b-frbB 1B hi for 1B rev 
frbB-WT pET26b-frbB 1B WT for 1B rev 
frbC-lo pFRGG-C 2A low for 2A rev 
frbC-med pFRGG-C 2A med for 2A rev 
frbC-hi pFRGG-C 2A hi for 2A rev 
frbC-WT pFRGG-C 2A WT for 2A rev 
frbD-lo pFRGG-D 2B low for 2B rev 
frbD-med pFRGG-D 2B med for 2B rev 
frbD-hi pFRGG-D 2B hi for 2B rev 
frbD-WT pFRGG-D 2B WT for 2B rev 
frbE-lo pFRGG-E 2C low for 2C rev 
frbE-med pFRGG-E 2C med for 2C rev 
frbE-hi pFRGG-E 2C hi for 2C rev 
frbE-WT pFRGG-E 2C WT for 2C rev 
frbF-lo pET26b-frbF 3A low for 2A rev 
frbF-med pET26b-frbF 3A med for 2A rev 
frbF-hi pET26b-frbF 3A hi for 2A rev 
frbF-WT pET26b-frbF 3A WT for 2A rev 
frbG-lo pFRGG-G 1C low for 1C rev 
frbG-med pFRGG-G 1C med for 1C rev 
frbG-hi pFRGG-G 1C hi for 1C rev 
frbG-WT pFRGG-G 1C WT for 1C rev 
frbH-lo pFRGG-H 2B low for 2B rev 
frbH-med pFRGG-H 2B med for 2B rev 
frbH-hi pFRGG-H 2B hi for 2B rev 
frbH-WT pFRGG-H 2B WT for 2B rev 
dxrB-lo pET26b-dxrB 2C low for 3C rev 
dxrB-med pET26b-dxrB 2C med for 3C rev 
dxrB-hi pET26b-dxrB 2C hi for 3C rev 
dxrB-WT pET26b-dxrB 2C WT for 3C rev 
BB-I pACYCDuet-1 BB-I for BB-I rev 
BB-II/III pACYCDuet-1 BB-II/III for BB-II/III rev 
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Table 2.6  PCR reactions for the construction of pFRGG-BB. 
 
Fragment Template Forward primer Reverse primer 
GGBB lacZα lacZα GGBB lacZa for GGBB lacZa rev 
GGBB pET 1 pETDuet-1 GGBB pET 1 for GGBB pET 1 rev 
GGBB pET 2 pETDuet-1 GGBB pET 2 for GGBB pET 2 rev 
GGBB pACYC 1 pACYCDuet-1 GGBB pACYC 1 for GGBB pACYC 1 rev 
GGBB pACYC 2 pACYCDuet-2 GGBB pACYC 2 for GGBB pACYC 2 rev 
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Table 2.7  Gibbs free energy (kcal/mol) between the four chosen overhangs (ACAC, CCCT, 
TAGC, TTCG). Dark green denotes strong binding. Maximum calculation for free energy is 5 
kcal/mol, which has been listed for combinations with no binding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Forward sequences Reverse complements 
  ACAC CCCT TAGC TTCG GTGT AGGG GCTA CGAA 
O
v
er
h
an
g
s ACAC 5 5 5 5 -2.32 5 5 5 
CCCT 5 5 0.61 5 5 -4.05 5 5 
TAGC 5 0.61 0.003 1.859 5 5 -2.762 5 
TTCG 5 5 1.859 1.569 5 5 5 -2.511 
63 
 
2.6 References 
 
1. World Health Organization, World Malaria Report 2013. 2013, Geneva, Switzerland: 
World Health Organization. 
2. Bledsoe, G.H., Malaria primer for clinicians in the United States. Southern Medical 
Journal, 2005. 98(12): p. 1197-1204. 
3. Raghavendra, K., et al., Malaria vector control: from past to future. Parasitology Research, 
2011. 108(4): p. 757-779. 
4. Hempelmann, E., Hemozoin biocrystallization in Plasmodium falciparum and the 
antimalarial activity of crystallization inhibitors. Parasitology Research, 2007. 100(4): p. 
671-676. 
5. Miller, L.H. and X.Z. Su, Artemisinin: Discovery from the Chinese Herbal Garden. Cell, 
2011. 146(6): p. 855-858. 
6. Cumming, J.N., P. Ploypradith, and G.H. Posner, Antimalarial activity of artemisinin 
(qinghaosu) and related trioxanes: mechanism(s) of action. Advances in Pharmacology, 
1997. 37: p. 253-97. 
7. Pates, H. and C. Curtis, Mosquito behavior and vector control. Annual Review of 
Entomology, 2005. 50: p. 53-70. 
8. White, N.J., Antimalarial drug resistance. Journal of Clinical Investigation, 2004. 113(8): 
p. 1084-92. 
9. Noedl, H., et al., Evidence of Artemisinin-Resistant Malaria in Western Cambodia. New 
England Journal of Medicine, 2008. 359(24): p. 2619-2620. 
64 
 
10. Kester, K.E., et al., Efficacy of recombinant circumsporozoite protein vaccine regimens 
against experimental Plasmodium falciparum malaria. Journal of Invectious Diseases, 
2001. 183(4): p. 640-7. 
11. Stoute, J.A., et al., A preliminary evaluation of a recombinant circumsporozoite protein 
vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation 
Group. New England Journal of Medicine, 1997. 336(2): p. 86-91. 
12. Agnandji, S.T., et al., A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. 
New England Journal of Medicine, 2012. 367(24): p. 2284-95. 
13. Seder, R.A., et al., Protection against malaria by intravenous immunization with a 
nonreplicating sporozoite vaccine. Science, 2013. 341(6152): p. 1359-65. 
14. Hoffman, S.L., et al., Development of a metabolically active, non-replicating sporozoite 
vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin, 2010. 6(1): p. 97-106. 
15. Okuhara, M., et al., Studies on new phosphonic acid antibiotics. I. FR-900098, isolation 
and characterization. Journal of Antibiotics, 1980. 33(1): p. 13-7. 
16. Jomaa, H., et al., Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as 
antimalarial drugs. Science, 1999. 285(5433): p. 1573-6. 
17. Rohmer, M., et al., Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps 
leading to isopentenyl diphosphate. Biochemical Journal, 1993. 295 ( Pt 2): p. 517-24. 
18. Foth, B.J. and G.I. McFadden, The apicoplast: a plastid in Plasmodium falciparum and 
other Apicomplexan parasites. International Review of Cytology, 2003. 224: p. 57-110. 
19. Umeda, T., et al. (2011) Molecular basis of fosmidomycin's action on the human malaria 
parasite Plasmodium falciparum. Scientific Reports 1,  DOI: 10.1038/srep00009. 
65 
 
20. Wong, U. and R.J. Cox, The chemical mechanism of D-1-deoxyxylulose-5-phosphate 
reductoisomerase from Escherichia coli. Angewandte Chemie International Edition, 2007. 
46(26): p. 4926-9. 
21. Eliot, A.C., et al., Cloning, expression, and biochemical characterization of Streptomyces 
rubellomurinus genes required for biosynthesis of antimalarial compound FR900098. 
Chemistry & Biology, 2008. 15(8): p. 765-70. 
22. DeSieno, M.A., Microbial synthesis of antimalarial compound FR-900098: pathway 
characterization and engineering, in Chemical and Biomolecular Engineering. 2011, 
University of Illinois at Urbana-Champaign: Urbana. p. 143. 
23. Johannes, T.W., et al., Deciphering the late biosynthetic steps of antimalarial compound 
FR-900098. Chemistry & Biology, 2010. 17(1): p. 57-64. 
24. Fokin, A.A., et al., Synthesis of the antimalarial drug FR900098 utilizing the nitroso-ene 
reaction. Org Lett, 2007. 9(21): p. 4379-82. 
25. Perruchon, J., R. Ortmann, and M. Schlitzer, A novel short and efficient synthetic route to 
the antimalarial agent FR900098 and derivatives. Synthesis-Stuttgart, 2007(22): p. 3553-
3557. 
26. Suresh, S., D. Shyamraj, and M. Larhed, Synthesis of antimalarial compounds 
fosmidomycin and FR900098 through N- or P-alkylation reactions. Tetrahedron, 2013. 
69(3): p. 1183-1188. 
27. Cobb, R.E., et al., Structure-guided design and biosynthesis of a novel FR-900098 
analogue as a potent Plasmodium falciparum 1-deoxy-D-xylulose-5-phosphate 
reductoisomerase (Dxr) inhibitor. Chem Commun (Camb), 2015. 51(13): p. 2526-8. 
66 
 
28. Kim, B., et al., Combinatorial Design of a Highly Efficient Xylose-Utilizing Pathway in 
Saccharomyces cerevisiae for the Production of Cellulosic Biofuels. Applied and 
Environmental Microbiology, 2013. 79(3): p. 931-941. 
29. Du, J., et al., Customized optimization of metabolic pathways by combinatorial 
transcriptional engineering. Nucleic Acids Research, 2012. 40(18). 
30. Nowroozi, F.F., et al., Metabolic pathway optimization using ribosome binding site 
variants and combinatorial gene assembly. Applied Microbiology and Biotechnology, 
2014. 98(4): p. 1567-1581. 
31. Ajikumar, P.K., et al., Isoprenoid Pathway Optimization for Taxol Precursor 
Overproduction in Escherichia coli. Science, 2010. 330(6000): p. 70-74. 
32. Farasat, I., et al., Efficient search, mapping, and optimization of multi-protein genetic 
systems in diverse bacteria. Molecular Systems Biology, 2014. 10(6). 
33. Wu, J.J., et al., Metabolic engineering of Escherichia coli for (2S)-pinocembrin production 
from glucose by a modular metabolic strategy. Metabolic Engineering, 2013. 16: p. 48-55. 
34. Wu, J.J., et al., Multivariate modular metabolic engineering of Escherichia coli to produce 
resveratrol from L-tyrosine. Journal of Biotechnology, 2013. 167(4): p. 404-411. 
35. Latimer, L.N., et al., Employing a combinatorial expression approach to characterize 
xylose utilization in Saccharomyces cerevisiae. Metabolic Engineering, 2014. 25: p. 20-29. 
36. Smanski, M.J., et al., Functional optimization of gene clusters by combinatorial design and 
assembly. Nature Biotechnology, 2014. 32(12): p. 1241-U104. 
37. Wanner, B.L. and W.W. Metcalf, Molecular Genetic-Studies of a 10.9-Kb Operon in 
Escherichia-Coli for Phosphonate Uptake and Biodegradation. FEMS Microbiology 
Letters, 1992. 100(1-3): p. 133-139. 
67 
 
38. Eliot, A.C., et al., Cloning, expression, and biochemical characterization of streptomyces 
rubellomurinus genes required for biosynthesis of antimalarial compound FR900098. 
Chemistry & Biology, 2008. 15(8): p. 765-770. 
39. Engler, C., et al., Golden Gate Shuffling: A One-Pot DNA Shuffling Method Based on Type 
IIs Restriction Enzymes. Plos One, 2009. 4(5). 
40. Gibson, D.G., et al., Enzymatic assembly of DNA molecules up to several hundred 
kilobases. Nature Methods, 2009. 6(5): p. 343-U41. 
41. Shao, Z.Y., H. Zhao, and H.M. Zhao, DNA assembler, an in vivo genetic method for rapid 
construction of biochemical pathways. Nucleic Acids Research, 2009. 37(2). 
42. Seidel, H.M., et al., Phosphonate Biosynthesis - Isolation of the Enzyme Responsible for 
the Formation of a Carbon Phosphorus Bond. Nature, 1988. 335(6189): p. 457-458. 
43. Bowman, E., et al., Catalysis and Thermodynamics of the Phosphoenolpyruvate 
Phosphonopyruvate Rearrangement - Entry into the Phosphonate Class of Naturally-
Occurring Organo-Phosphorus Compounds. Journal of the American Chemical Society, 
1988. 110(16): p. 5575-5576. 
44. Lee, M.E., et al., Expression-level optimization of a multi-enzyme pathway in the absence 
of a high-throughput assay. Nucleic Acids Research, 2013. 41(22): p. 10668-10678. 
45. Johannes, T.W., Directed evolution of phosphite dehydrogenase and engineered 
biosynthesis of FR-900098, in Department of Chemical and Biomolecular Engineering. 
2008, University of Illinois at Urbana-Champaign: Urbana, IL. 
46. Temme, K., et al., Modular control of multiple pathways using engineered orthogonal T7 
polymerases. Nucleic Acids Research, 2012. 40(17): p. 8773-8781. 
68 
 
47. Markham, N.R. and M. Zuker, UNAFold: software for nucleic acid folding and 
hybridization. Cdna Libraries: Methods and Applications, 2008. 453: p. 3-31. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
69 
 
3Chapter 3: Escherichia coli strain engineering for FR900098 production 
3
 
 
3.1 Introduction 
 
 Strain engineering: from precursors to products 
 
Although pathway engineering can be key to enhancing the production of secondary metabolites, 
strain engineering can be equally important. Because secondary metabolites, including natural 
products, rely on basic metabolic building blocks and cofactors for construction, increasing 
relevant precursor pools can improve production of target molecules. Two basic strategies to 
increase precursor pools are 1) to limit pathways that consume upstream precursors by gene 
knockouts and knockdowns, and 2) to increase flux into metabolite pools by overexpressing 
enzymes that will convert other metabolites into the desired building blocks. For FR900098 
production both of these strategies were applied. Once precursor pools are identified, relevant 
pathway enzymes can be chosen for engineering that can raise the target precursor concentrations.  
 
These methods have been used extensively in metabolic engineering with varying success for 
different classes of natural products. For instance, polyketide and flavanone synthesis relies on 
sequential additions of malonyl-CoA and related subunits as molecules are built. By focusing on 
building up the malonyl-CoA pool, Xu et al. created an E. coli strain with two genes knocked out 
(ΔfumC and ΔsucC) and the overexpression of six genes (aceEF, lpdA, pgk, aacA, and gapA) that 
led to a four-fold increase in intracellular malonyl-CoA [1].  Engineering can also be carried out 
for less major precursors, as is the case for the deletion of the gene bioH for simvastatin production 
in E. coli [2]. It was found that the native enzyme BioH in E. coli was hydrolyzing dimethylbutyryl-
S-methyl mercaptoproionate (DMB-S-MMP), a necessary acyl donor in simvastatin synthesis. By 
deleting the gene bioH, a conversion rate that was twice as fast as the parent strain was seen [2]. 
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Isoprenoids are another type of natural products where strain engineering has been used to boost 
production. By using a stoichiometric flux balance analysis, Alper et al. developed a triple 
knockout strain of genes gdhA, aceE, and fdhF that led to a nearly 40% increase in the production 
of the isoprenoid lycopene in E. coli [3]. The enzymes encoded by these are all related to the 
consumption of pyruvate and NADPH, compounds necessary for lycopene production. 
 
This chapter outlines strain engineering performed for the increased production of FR900098, for 
which three precursor pools were identified for targeting. As the entry point for all phosphonate 
biosynthesis, phosphoenolpyruvate (PEP) was chosen as one of the target pools as well as acetyl-
CoA and NADPH.  For each of these metabolites there are examples in the existing literature that 
were used for guidance in engineering E. coli for FR900098 production. 
 
 Gene knockout and knockdown in E. coli 
 
The most efficient method of gene knockout in E. coli was introduced in 2000 by Datsenko and 
Wanner, who developed a simple method that made the procedure fast and straightforward [4]. 
These knockouts are performed by transforming E. coli with an antibiotic resistance marker 
flanked by sequences that are homologous to regions neighboring the gene to be knocked out. 
During DNA replication, a strand of the introduced DNA is incorporated as an Okazaki fragment, 
replacing the deleted gene in one of the daughter cells [5]. For this to be accomplished, it is 
necessary that the strain is expressing the Red β protein from the Lambda bacteriophage. Since 
this method is easily scalable, it has allowed the Mori lab at Keio University to knockout every 
gene in E. coli, creating what is known as the Keio collection [6].   
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Other gene editing methods have been built upon this recombination technology for higher 
efficiency and extended functionality. When the Lambda Red system is incorporated with 
CRISPR-Cas9 technology, point mutation efficiency can be as high as 65% without using any 
selection [7]. By uncovering the mechanism of the recombinase proteins, Mosberg et al. were able 
to significantly improve the recombination efficiency. With recombination rates greater than 30% 
within a cell population, they were able to develop Multiplex Automated Genomic Engineering, 
or MAGE, which performs multiple rounds of automated knockouts and screening to engineer 
strains with multiple mutation sites [8]. Another technology dependent on the Lambda Red 
recombination system is Synthetic Cellular Recorders Integrating Biological Events (SCRIBE), 
which creates genomic mutations upon induction [9].  
 
Although gene knockout has been used extensively in metabolic engineering, it is limited to only 
non-essential genes. Until recently, specific and efficient gene knock down in E. coli was not a 
straightforward task to achieve. Two recent strategies have allowed for the knockdown of genes 
with general ease. Synthetic small regulatory RNAs (sRNA) are short RNAs with a MicC scaffold 
attached to a strand of nucleotides that can complement a transcript of interest. When the 
expression the expression of a synthetic sRNA is induced, it binds to target RNA where the MicC 
scaffold recruits the protein Hfq which assists in blocking translation (Figure 3.1) [10]. Another 
technology for gene knockdown in E. coli is CRISPR interference or CRISPRi [11]. An engineered 
Cas9 is expressed that targets a stretch of DNA based on a guide RNA. Whereas wild-type Cas9 
cleaves the target DNA, dCas9 only binds without cutting the DNA thus blocking transcription. In 
this chapter, a version of sRNA knockdown is used to engineer FR900098 production strains.  
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 Metabolic precursors and cofactors for FR900098 production 
 
The carbon atoms in each molecule of FR900098 are supplied by one molecule of PEP and two 
molecules of acetyl-CoA (Figure 3.2). The PEP is isomerized in the first step of FR900098 
biosynthesis by the enzyme phosphoenolpyruvate mutase (PepM), and its product is then 
acetylated with the first acetyl-CoA molecule to thermodynamically drive the pathway. The second 
acetyl-CoA is incorporated near the end of the pathway with the acetylation of CMP-5’-N-
hydroxy-3-aminopropylphosphonate. The product also requires an amination from an unknown 
source as well as the addition of a hydroxyl group which is coupled with the reduction of O2 to 
water by NADPH. Conjugation with cytidine-5’-triphosphate (CTP) is another molecule that is 
required for FR900098 biosynthesis, with its monophosphate form being cleaved from the 
phosphonate as the final step.  For this study, the pools of metabolites PEP, acetyl-CoA, and 
NADPH were focused on in efforts to increase FR900098 production. 
 
Precursor pools for PEP have been targeted for the production of both aromatic amino acids [12, 
13] and succinate [14] using gene knockouts.  One method of increasing PEP has been eliminating 
dependence on the phosphotransferase system (PTS), which uses PEP to phosphorylate glucose in 
its uptake. By bypassing the PTS, using either genetic methods or by using a different carbon 
source, PEP can be conserved. As detailed in Chapter 2, FR900098 production was found optimal 
when engineered strains were grown on glycerol, which may be in part to the bypassing of the 
PTS. Pyruvate kinases I and II, encoded by pykF and pykA, respectively, are also targets to increase 
PEP availability. These kinases are responsible for the conversion of PEP to pyruvate with the 
phosphate group transferred to make ATP, and pykF was included as a target knockout for 
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FR900098 production. Because pyruvate is the source for the FR900098 precursor acetyl-CoA, 
altering flux between PEP and pyruvate could result in product loss instead of product gain.  
 
Acetyl-CoA is also used as a building block in many pathways including FR900098 biosynthesis. 
As the entry point for the tricarboxylic acid (TCA) cycle, it can be a necessary intermediate to 
some of the cycle’s metabolites and their downstream products, such as glutamate and other amino 
acids from α-ketoglutarate. Several products of interest, such as fatty acids, polyketides, and 
flavonoids, rely on malonyl-CoA, a product of acetyl-CoA carboxylation. Primary knockout 
targets to increase acetyl-CoA and malonyl-CoA pools include adhE (acetaldehyde 
dehydrogenase), ackA (acetate kinase), and pta (phosphotransacetylase), the former gene 
responsible for acetyl-CoA degradation to ethanol and the latter two genes responsible for the 
conversion of acetyl-CoA to acetate [15, 16]. A triple-knockout of these genes in E. coli led to a 
slight increase in acetyl-CoA and over a six-fold increase in malonyl-CoA concentrations [16]. 
Each of these genes was knocked out in the efforts to increase FR900098 production. 
 
Additional targets for knocking out were identified from the literature by finding other metabolites 
that relied on PEP and acetyl-CoA as precursors. The Ingram lab engineered E. coli for the 
production of both acetate and pyruvate, both being closely linked with the precursors of interest 
[17, 18]. For acetate production, beneficial knockouts were seen for ldhA (lactate dehydrogenase) 
and adhE (aldehyde-alcohol dehydrogenase), which prevented carbon loss from central 
metabolism to lactate and ethanol, respectively. Deletion of pflB (formate acetyltransferase), which 
is responsible with aceE (pyruvate dehydrogenase) for pyruvate conversion to acetyl-CoA, 
increased acetate production as well. A less apparent choice of knockouts includes frdBC 
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(fumurate reductase B and C), part of the complex responsible for succinate to fumarate conversion 
in the TCA cycle. This was done to prevent substrate channeled to the fermentation product 
succinate considering low oxygen solubility. The knockout of atpFH of the F1F0-ATP synthase 
was another interesting choice and was done to prevent abundant ATP pools that could be used to 
generate more cell mass instead of target molecules. For pyruvate overproduction, the same strain 
for acetate overproduction was used plus two additional deletions: ackA (acetate kinase) and poxB 
(pyruvate dehydrogenase). Individual knockouts for each of the genes mentioned were tested for 
effects on FR900098 production. 
 
Other studies showed that the overexpression of certain genes had a positive effect on acetyl-CoA 
derived products. Vadali et al. showed that the overexpression of panK (pantothenate kinase), 
responsible for a necessary step in coenzyme A biosynthesis, led to increased production of acetyl-
CoA, which was increased further with the deletion of ackA and pta [19].  The overexpression of 
panK, as well as a feedback resistant mutant, R106A [20], were tested with the top FR900098 
pathway. Another enzyme tested to increase acetyl-CoA pools was acetyl-CoA synthase, encoded 
by the gene acs. The overexpression of this gene led to a 10-fold increase in flavonoids titers in E. 
coli [21].  
 
Redox balancing is an important aspect of all metabolic pathways that require any reduction or 
oxidation reactions. For FR900098, only one reduction reaction is observed, which is carried out 
by NADPH. When glucose or glycerol is used as a carbon source, only NADH is regenerated in 
the glycolytic steps that lead to the production of PEP and acetyl-CoA, which may limit NADPH 
availability. Utilizing other sugar metabolizing pathways, such as the pentose phosphate pathway 
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(PPP) and the Entner-Doudoroff (ED) pathway, is one method of increasing NADPH pools. A 
strain can be forced into the PPP by deleting pgi, the gene encoding glucose 6-phosphate 
isomerase, an early step in glycolysis. This deletion has been implemented in several metabolic 
pathways reliant on NADPH and has showed considerable improvements in product titers [22, 23]. 
Although the PPP produces a relatively high amount of NADPH (6 molecules/glucose) compared 
to NADH in glycolysis (2 molecules/glucose), half of the carbon is lost as CO2. The ED pathway 
is able to produce one molecule each of NADH and NADPH from a single glucose with no carbon 
loss. To decouple the ED pathway in E. coli from native regulation, Ng et al. recently introduced 
the ED pathway from Zymomonas mobilis, observing a 25-fold increase in NADPH availability 
and additional product improvement after further rounds of engineering [24].  For the FR900098 
pathway, the forced PPP pathway was tested to see if NADPH could be a rate-limiting cofactor. 
 
All genes with altered gene expression are diagrammed in Figure 3.3. Genes that were knocked 
out without literature basis are fabH, which helps build fatty acids from acetyl-CoA and malonyl-
CoA, as well as acs.  Knockdown was performed on necessary genes that may improve FR900098 
production upon lowered expression, and include csrA, gltA, and accAD. The regulator csrA, or 
carbon storage regulator A, represses gluconeogenesis and activates glycolysis. By knocking down 
its expression, it may be possible for increased flux to PEP. The genes gltA and accAD were 
targeted in efforts to prevent loss of acetyl-CoA to citrate and malonyl-CoA, respectively. 
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3.2 Results and Discussion 
 
 Non-essential gene knockout for increased FR900098 production 
 
Thirteen single knockouts of non-essential genes (adhE, aceE, acs, atpFH, frdC, ldhA, pflB, pgi, 
poxB, ppc, pta, and pykF) were introduced into E. coli BL21(DE3) by P1 phage transduction from 
the Keio collection [6]. The three genes that failed to be knocked out by transduction, ackA, fabH, 
and frdB, were removed by Labmda Red recombineering [4]. A BL21(DE3) triple knockout 
(ΔackA/adhE/pta) previously constructed for improved malonyl-CoA production knockout was 
also tested [16]. To each strain the top performing pathway plasmid, 4pTRA, was introduced for 
FR900098 biosynthesis. When all the deletions (except Δpgi) were tested in M9GF (M9 + 0.4% 
glycerol + 10 µM FeSO4), none showed a significant increase in FR900098 titers at 24 hours while 
some had very little or no production (Figure 3.4). 
 
The purpose of the pgi knockout was to increase NADPH regeneration by driving glucose through 
the PPP.  Thus, for better comparison, M9 medium with glucose as a carbon source was tested as 
well as M9 with glycerol. As can be seen in Figure 3.5, despite engineering efforts to increase the 
NADPH pool, FR900098 production was significantly diminished in the Δpgi strain. This decrease 
may be partly due to half of the carbon being lost to CO2 in the pentose phosphorous pathway. 
 
 Essential gene knockdown for increased FR900098 production  
 
A knockdown plasmid was developed based on the synthetic sRNA system develop by Na et al. 
[10]. To test the in-house system, sRNAs were designed to knockdown GFP expression in E. coli 
BL21(DE3). GFP was tested under three T7 promoters with different strengths (weak, medium, 
and high – as described in Chapter 2), and its expression as well as transcription of the knockdown 
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system were induced by IPTG.  Knockdown of GFP was seen as early as 3.5 hours, with the 
relative difference in expression even more pronounced at 18 hours (Figure 3.6). 
 
Because the genes accAD, csrA, and gltA are essential, their knockdown has to be timed to allow 
enough cell growth before the synthetic sRNA transcription is induced. Initial tests with early 
knockdown induction at 2 hours showed that the gene knockdown was having a positive effect on 
FR900098 production (Figure 3.7a). However, culturing optimization without the knockdown 
showed that a later induction at 10 hours gave higher titers of product. When this induction time 
was applied to the knockdown strains production was decreased (data not shown). Testing multiple 
induction times with the gltA knockdown strain showed that maximal production was seen with 
induction at 40 minutes post inoculation (Figure 3.7b). Although a five-fold increase in production 
is seen, it was still lower than titers reached in the non-knockdown strain with 10 hour induction. 
It is important to recognize that a difference between the knockdown cultures and other cultures 
tested is that the seed culture for synthetic sRNA system was grown in M9 medium instead of LB 
medium because the rich medium leads to leaky expression of the knockdown RNAs and inhibits 
growth. For this reason direct comparisons cannot be made between the data of the knockdown 
cultures and other experiments. It should be noted that a csrA mutant was previously tested with 
the FR900098 pathway [25]. The earlier reported mutant has a transposon near the 3’ end of the 
gene leaving some activity in the essential enzyme [26]. When the mutant is cultured with the 
FR900098 pathway genes, there was a substantial decrease in production of the FR900098 
compound. 
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 Gene overexpression for increased FR900098 production 
 
The genes acs, panK, and panK-R106A were all overexpressed under the lac promoter on a 
replicating plasmid in BL21(DE3) also expressing the 4pTRA FR900098 pathway. Like the gene 
knockout and knockdown results, none of the overexpression engineering efforts led to an increase 
in FR900098 (Figure 3.8). Previously, the overexpression of genes pps and pck were also tested to 
increase PEP, but those efforts failed as well in improving FR900098 titers [25]. 
 
3.3 Conclusions 
 
Despite the range of efforts to engineer an E. coli strain for higher FR900098 production, none of 
the strategies was successful, which may be due to several reasons. For one, the FR900098 
pathway relies on both PEP and acetyl-CoA for biosynthesis, and balancing the two pools 
appropriately may be necessary for maximum product. Deleting genes that link these two 
intermediates, such as aceE, pflB, poxB, and acs, may disrupt the balance of these pools, leading 
to no increase in FR900098 production. Another possibility is that the FR900098 pathway is still 
rate limiting, so precursor supply engineering by gene knockout and knockdown may have little 
effect on FR900098 production.  
 
Although none of the single knockouts significantly increased titers, there may be combinations 
of the chosen knockouts that could increase FR900098 output. This effort was not realized because 
the strategy was to combine positive single knockouts, which did not materialize. Further, to test 
each double knockouts would result in over 200 different engineered strains. It is possible that 
multiple deletions are necessary before any beneficial effects are seen. For the strain engineered 
for acetate production detailed above, when the genes pflB, frdBC, and ldhA were knocked out, a 
79 
 
slight decrease in acetate was actually seen; it was only after the additional deletion of atpFH was 
there an increase in acetate [18]. However, a triple knockout strain verified to increase malonyl-
CoA levels was tested with the FR900098 pathway, which had a decrease in product titers.  
 
Despite not giving higher titers at later inductions, the knockdown system appears promising given 
the early induction results. By decoupling the knockdown and pathway inductions, it may be 
possible to time the two activations for higher FR900098 output. Also, combinations of 
knockdowns may also improve production. One benefit of using the knockdown system is that 
combinations of targets can be engineered faster than those of knockouts. It is also possible to use 
the synthetic sRNA system to knockdown those genes chosen as knockout targets, making it easier 
to screen multiple target combinations. 
 
3.4 Methods and Materials 
 
 Strains, media, and reagents 
 
All plasmid cloning was performed in E. coli DH5α, and all FR900098 production was done in E. 
coli BL21(DE3). Antibiotics were used at the following concentrations: ampicillin (Amp), 100 
mg/L; chloramphenicol (Cm), 34 mg/L; kanamycin (Kan), 50 mg/L, and streptomycin (Sm), 100 
mg/L. Antibiotics and isopropyl--D-thiogalactoside (IPTG) were purchased from Gold 
Biotechnology (St. Louis, MO). All other reagents were from Sigma-Aldrich (St. Louis, MO). 
PCR primers and oligos were synthesized by Integrated DNA Technologies (Coralville, IA). PCR 
reactions were performed in FailSafe PCR PreMix G (Epicentre Biotechnologies, Madison, WI) 
with either Phusion or Q5 DNA polymerase (New England Biolabs, Ipswich, MA). Restriction 
enzyme Esp3I was from Thermo-Scientific (Pittsburgh, PA), and other restriction enzymes and T4 
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ligase were from New England Biolabs. Plasmids were purified using QIAprep Spin Miniprep Kit 
(QIAGEN, Valencia, CA) and DNA from agarose gels were purified using QIAquick Gel 
Extraction Kit (QIAGEN). Genomic DNA from E. coli BL21(DE3) was extracted using Wizard 
Genomic DNA Purification Kit (Promega, Madison, WI) following the manufacturer’s protocol. 
 
 Gene knockout construction  
 
Genes aceE, acs, adhE, atpF, atpH, frdC, ldhA, pflB, poxB, ppc, pta, and pykF were knocked out 
using P1 phage recombineering. E. coli  BW25113 knockout strains from the Keio collection [6], 
kindly provided by the John Cronan lab at the University of Illinois at Urbana-Champaign, were 
used as a source of the mutations, and genomes were compared between this strain and E. coli 
BL21(DE3) to ensure that other modifications would be unlikely. To 1 mL of LBCG (LB broth 
with 2.5 mM CaCl2 and 0.1% glucose), 5 µL of P1 phage was added. 50 µL of the P1/LBCG 
solution was then added to 0.1 mL of LB-grown donor cells in a disposable culture tube and 
incubated at room temperature for 10 minutes for phage adsorption. To this solution 2.5 mL LBCG 
was added and gently mixed. 2.5 mL of molten LB top agar, cooled to 55 °C, was added and 
poured onto a thick (40 mL) LBCG agar plate and placed in a 37 °C incubator. After 4 hours, plates 
were checked for lysis. If lysis had begun, phages were harvested by adding 5 mL of ice cold Tris-
Phage buffer (10 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 7.2 pH) to each plate, and plates 
were left overnight at 4 °C. Buffer was then collected, and a few drops of chloroform were added, 
mixed gently, and centrifuged for 10 minutes. Buffer containing phage was then transferred to a 
new tube for another round of decontamination by addition of chloroform. For P1 transduction, a 
BL21(DE3) colony was grown for 4 hours at 37 °C in 5 mL LB, and 1 mL of culture was 
centrifuged for 10 minutes and resuspended in 1 mL MC (10 mM MgCl2, 4 mM CaCl2) and stood 
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for 5 minutes and then vortexed. 5 µL phage lysate was added to 0.1 mL LB to which 0.1 mL of 
resuspended cells were added and mixed gently. Cell/phage mixture stood for 20 minutes, then 1 
mL LB with 10 mM ethylene glycol tetraacetic acid (EGTA) was added and vortexed. Cells were 
collected by centrifugation, the supernatant was discarded, and the cells were resuspended in 
another 1 mL of LB+EGTA.  Cells were placed on a 37 °C shaker for 2 hours and then spread on 
LB agar plates with 25 µg/mL kanamycin and incubated at 37 °C for up to 2 days. Colonies were 
then streaked out on LB + 50 µg/mL kanamycin plates, and colony PCR was performed to see if 
the correct deletions were present. Primers used to check for the deletions are named with the 
ending “KO-seq-for” and “KO-seq-rev”. Knockout strain ackA/pta/adhE was previously 
constructed [16]. 
 
Genes ackA, fabH and frdB were knocked out by Lambda Red recombineering using Datesenko 
and Wanner method [4]. Primers used to amplify the kanamycin cassettes are given in Table 3.2 
and were detected by colony PCR using the respective primers in Table 3.1. 
 
 Gene knockdown by synthetic sRNA 
 
A synthetic sRNA backbone, called KD-BB, was assembled by standard Golden Gate procedures 
[27] with enzyme Esp3I using four fragments amplified by PCR using primers in Table 3.3. One 
fragment was of lacZ (primer pair: “KD LacZ for”/”KD LacZ for”) and another two were of the 
pCDF-Duet backbone to remove BsaI and Esp3I cutsites for assembly (primer pairs: “KD Term 
for”/”KD Mid rev” and “KD Mid for”/”KD T7 rev”). A final fragment was of the Hfq recruiting 
hairpin and was amplified using primers “KD Hfq for” and “KD Hfq rev” without any template. 
Targeting sRNA sequences were made by annealing the oligos in Table 3.3 for the respective genes 
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of GFP, gltA, accA, accD, and csrA by cooling 1 µM of each primer from 80 ºC to 12 ºC at 0.1 
ºC/s and mixing the annealed oligos in an equimolar ratio with 50 ng of KD-BB for a Golden Gate 
reaction using enzyme BsaI. 
 
 Gene overexpression  
 
A replicating backbone was prepared using pET26b as a template with primers “OE BB for” and 
”OE BB rev”. Genes acs and panK were amplified using primer pairs “panK for”/”panK rev” and 
“acs for”/”acs rev”, respectively, using E. coli BL21(DE3) genomic DNA as template. For the 
panK R106 mutation, the panK fragment was used as a template with primer pairs “panK for”/ 
“panK R106A rev” and “panK R106A for”/”panK rev” to create a 5’ and a 3’ fragment of the 
gene.   To insert a lac promoter, the acs, panK, and 5’-panK-R106A fragments were amplified 
with the “pLac for” primer and their respective reverse primer. Plasmids were then assembled by 
Golden Gate using BsaI. Each plasmid was then transformed into E. coli BL21(DE3) competent 
cells carrying the 4pTRA plasmid. Strains were grown in a 5 mL LB+Amp+Kan seed culture 
overnight, washed 3x in M9GF, and 50 µL was inoculated into 5 mL M9GF+Amp+Kan for 10 
hours and then induced with 0.5 mM IPTG. Samples then collected at 24 hours for quantification 
by LC-MS.   
 
 Strain culturing and product detection 
 
Knockout strain seed cultures were grown overnight in 5 mL LB+Amp. Before inoculation into 
production cultures, 1 mL of starter cultures were washed 3x in M9GF (M9 + 0.4% glycerol + 10 
µM FeSO4) with 50 µL used to inoculate 5 mL M9GF+Amp for production. Pathway expression 
induced with the addition of 0.5 mM IPTG 10 hours after inoculation. Gene overexpression 
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cultures were grown similarly except with the addition of kanamycin to each culture. Knockdown 
starter cultures were grown in 5 mL M9GF+Amp+Sm overnight with 100 µL inoculated into fresh 
M9GF+Amp+Sm for production. After 2 hours growth (unless otherwise noted) pathway 
expression and synthetic sRNA transcription were induced by the addition of 0.5 mM IPTG. 
Product quantification was carried out as detailed in Chapter 2. 
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3.5 Figures and tables 
 
 
Figure 3.1  Gene knockdown with synthetic sRNAs.  Synthetic small RNA with designed 
variable region (red) binds to mRNA target while MicC secondary structure (green) binds to 
protein Hfq, blocking ribosome binding site (RBS) and preventing translation. 
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Figure 3.2  Biosynthesis of FR900098. Targeted precursor pools for engineering are highlighted 
in gold. PEP, phosphoenolpyruvate; PnPy, phosphonopyruvate; 2-PnMM, 2-
phosphonomethylmalate; 3-PnMM, 3-phosphonomethylmalate; 2-OPn, 2-oxo-4-
phosphonobutyrate; 2-APn, 2-amino-4-phosphonobutyrate; CMP-5′-3APn, CMP-5′-3-
aminopropylphosphonate; CMP-5′-H3APn, CMP-5′-N-hydroxy-3-aminopropylphosphonate; 
CMP-FR900098, CMP-5′-FR900098. Adapted from reference 1. 
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Figure 3.3  Schematic of E. coli strain engineering for FR900098 production.  Genes targeted 
in this study for knockout (red), knockdown (blue), and overexpression (green) are highlighted. 
Dashed line for csrA represents regulation interactions.    
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Figure 3.4  Relative FR900098 production from single gene knockout strains.  Error bars show 
standard deviation for triplicates of each strain.  
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Figure 3.5  FR900098 production for pgi knockout.  The Δpgi knockout was tested on both 
glycerol and glucose as a carbon source to test whether use of the pentose phosphate pathway’s 
regeneration of NADPH affects FR900098 production. 
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Figure 3.6  Testing synthetic sRNA knockdown against GFP expression.  GFP expressed under 
T7 promoters with varying strength were coexpressed with and without the synthetic sRNA 
knockdown system and tested at 3.5 hours and 18 hours. For 3.5 hours, average and standard 
deviations are based on triplicates. 
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Figure 3.7  Synthetic sRNA knockdown on FR900098 production. (A) Testing of knockdown 
of four genes with induction at 2 hours. (B) FR900098 production of WT and gltA knockdown 
with induction time ranging from 0 to 600 minutes. All error bars show standard deviations of 
triplicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
0 200 400 600
FR
9
0
0
0
9
8
 (
m
g/
L)
Induction time (min)
WT
KD-gltA
B 
0
1
2
3
4
5
6
7
All WT accA accD csrA gltA
FR
9
0
0
0
9
8
 (
m
g/
L)
A 
91 
 
 
Figure 3.8  FR900098 production of strains overexpressing genes.  Error bars show standard 
deviations of experimental triplicates. 
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Table 3.1  Primers used for to check knockouts by PCR 
Primer Sequence 
aceE KO seq for CGCATCGCCATCTGGCCTTTATCG 
aceE KO seq rev CAACTTTGTCGCCCACTTTGACCAGG 
ackA KO seq for AGGTATCCTTTAGCAGCCTGAAGGCC 
ackA KO seq rev TGCACGGATCACGCCAAGGC 
acs KO seq for CCCGCTCCCTTATGGGAGAAGG 
acs KO seq rev CAACAGCATGCATAACTGCATGTTCCTC 
adhE KO seq for GCATGAGCAGAAAGCGTCAGGC 
adhE KO seq rev CGCCACCTGGAAGTGACGC 
atpF KO seq for CGACTCGGCGAGCGTTTCTGG 
atpF KO seq rev TCCCGATGATCGCTGTAGGTCTGG 
atpH KO seq for CCCGGCAGGGAGATCATTTCACC 
atpH KO seq rev GCAGATTCTGGACGAAGCGAAAGCTG 
fabH KO seq for GTCGCGATTGAACAGGCAGTGC 
fabH KO seq rev CGGTGCTTTACCGCCCTGC 
frdB KO seq for CATCTCAGGCTCCTTACCAGTACAGG 
frdB KO seq rev CGAGCGTGACGACGTCAACTTCC 
frdC KO seq for CCAATGAAGCTCTGCGCGAACG 
frdC KO seq rev CCACGGTAAGAAGGAGCGTATGGC 
ldhA KO seq for TGCTGTAGCTGTTCTGGCGTAACAGC 
ldhA KO seq rev CCGAGCGTCATCAGCAGCG 
pflB KO seq for ATTGCGGTGTTTCTCCAGATGTGGCC 
pflB KO seq rev TATTGTAATCCGCGACTTCGCATCCCCG 
pgi KO seq for CAACTAAACGCACGTTGGCATCAGAAAGC 
pgi KO seq rev CGGGATCGAGTATACACAACTAAAGCATGCG 
poxB KO seq for GCCTGAGTGCCGGTAGGCAG 
poxB KO seq rev CGTACCGTGATGACCTGCGGC 
ppc KO seq for CCAACCCAGGGCTTTCCAGC 
ppc KO seq rev CGCATCTTATCCGACCTACACCTTTGG 
pta KO seq for CCTGGCTGCACGTTTCGGC 
pta KO seq rev GGAACTACCCAGGTGGCAAGGC 
pykF KO seq for CAGCGTATAATGCGCGCCAATTGAC 
pykF KO seq rev GTTCGCTCAAAGAAGCATCGAACGC 
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Table 3.2  Primers used for Lambda Red Recombination 
Primer Sequence 
ackA KO for 
ACGTTTTTTTAGCCACGTATCAATTATAGGTACTTCCATGGTGTAGGCTG
GAGCTGCTTC 
ackA KO rev 
CTGAGCTGGCGGTGTGAAATCAGGCAGTCAGGCGGCTCGCCATATGAAT
ATCCTCCTTAG 
fabH KO for 
AAGTGACGGTATATAACCGAAAAGTGACTGAGCGTACATGGTGTAGGC
TGGAGCTGCTTC 
fabH KO rev 
TCATGTTTTAATCCTTATCCTAGAAACGAACCAGCGCGGACATATGAAT
ATCCTCCTTAG 
frdB KO for 
GATAAGGCGGAAGCAGCCAATAAGAAGGAGAAGGCGAATGGTGTAGG
CTGGAGCTGCTTC 
frdB KO rev 
AGTCGTCATGTTGCACTCCTTAGCGTGGTTTCAGGGTCGCCATATGAATA
TCCTCCTTAG 
pgi KO for 
CTTCCAAAGTCACAATTCTCAAAATCAGAAGAGTATTGCTAATGGTGTA
GGCTGGAGCTG 
pgi KO rev 
TCCGGCCTACATATCGACGATGATTAACCGCGCCACGCTTTATACATAT
GAATATCCTCC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
Table 3.3  Primers used to construct synthetic sRNA knockdown plasmids 
Primer/oligo Sequence Use 
KD LacZ for ACGTCTCAACTATGAGACCTCAGCCGCTACAGGGCGC 
Assembly 
of KD-BB 
KD LacZ rev ACGTCTCAGAAATGAGACCACCGGTGGAAAGCGGGCAG 
KD Term for ACGTCTCACGAGCTAGCATAACCCCTTGGGGCCTC 
KD Mid rev ACGTCTCAGTGTCACTGGTGAAAAGAAAAACC 
KD Mid for ACGTCTCAACACGGGCAACAGCTGATTGCC 
KD T7 rev ACGTCTCATAGTGAGTCGTATTAATTTCCTAATGCAGG 
KD Hfq for 
ACGTCTCATTTCTGTTGGGCCATTGCATTGCCACTGATTTTC
CAACATATAAAAAGAC 
KD Hfq rev 
ACGTCTCACTCGAGAAAAAAAGCCCGGACGACTGTTCGGG
CTTGTCTTTTTATATGTTGG 
KD GFP for 
CGGTCTCAACTATAGATGAGTAAAGGAGAAGAACTTTTCTT
TCGGAGACCT 
Insertion 
of gene 
target 
sequence 
KD GFP rev 
AGGTCTCCGAAAGAAAAGTTCTTCTCCTTTACTCATCTATA
GTTGAGACCG 
KD gltA for 
CGGTCTCAACTATAGGAGTTTTGCTTTTGTATCAGCCATTTT
CGGAGACCT 
KD gltA rev 
AGGTCTCCGAAAATGGCTGATACAAAAGCAAAACTCCTAT
AGTTGAGACCG 
KD accA rev 
AGGTCTCCGAAAATGAGTCTGAATTTCCTTGATTTTCTATA
GTTGAGACCG 
KD accD for 
CGGTCTCAACTATAGTTTAATTCGTTCAATCCAGCTCATTTT
CGGAGACCT 
KD accD rev 
AGGTCTCCGAAAATGAGCTGGATTGAACGAATTAAACTAT
AGTTGAGACCG 
KD csrA for 
CGGTCTCAACTATAGAACTCGACGAGTCAGAATCAGCATTT
TCGGAGACCT 
KD csrA rev 
AGGTCTCCGAAAATGCTGATTCTGACTCGTCGAGTTCTATA
GTTGAGACCG 
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Table 3.4  Primers used for gene overexpression 
Primer Sequence Use 
OE BB rev AGGTCTCAATCCGGCTGCTAACAAAGC Overexpression 
backbone 
OE BB for 
AGGTCTCAACGAGCCGGAAGCATAAAGTGTAAA
TTTCGCGGGATCGAGATCTC 
panK for 
GAGCGGATAACAATTTCACACAGGAAACTTAAG
ATGAGTATAAAAGAGCAAACGTTAATG 
Gene 
amplification 
panK rev 
AGGTCTCAGGATCTTATTTGCGTAGTCTGACCTC
TTCTAC 
panK R106A rev AGGTCTCACAGCGGCGGTTGTACTTTTCCCC 
panK R106A for AGGTCTCAGCTGTATTGCAGGCGCTATTAAGC 
acs for 
TGTGAGCGGATAACAATTTCACACAGGAAACTT
AAGATGAGCCAAATTCACAAACACACC 
acs rev AGGTCTCAGGATCTTACGATGGCATCGCGATAG 
pLac for 
AGGTCTCATCGTATGTTGTGTGGAATTGTGAGCG
GATAACAATTTCACACAGG 
pLac extension 
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4Chapter 4: Discovery of a novel phosphonate from Streptomyces species NRRL F-525 
4
 
 
4.1 Introduction 
 
Gram-positive soil dwelling bacteria of the phylum Actionmycetes have been, and continue to be, 
a rich source of antibiotics and other natural products. The screening of actinobacteria genomes 
reveals that a single strain, on average, harbors over a dozen biosynthetic gene clusters for natural 
products [1]. The abundance of possible new molecules has ushered in a new era of compound 
discovery termed genome mining.  In this effort, bioinformatics tools are used to screen genomic 
sequences for natural product biosynthetic gene clusters. Once gene clusters are identified, a 
number of homologous and heterologous expression approaches can be used to elicit their 
production [2], with some of these strategies having been discussed in Chapter 1. 
 
In an effort to discover new phosphonic acids, 10,000 Actinomycete genomes were screened for 
the phosphoenolpyruvate mutase (pepM) gene, which encodes the enzyme for the first catalytic 
step in phosphonate biosynthesis [3]. Of the strains screened by PCR, 278 of them contained this 
enzyme for entry into phosphonic acid production. All of these strains were sequenced, allowing 
for further analysis of each gene cluster and revealing potential pathways for natural products of 
other classes. A bioinformatics analysis that groups together similar gene clusters into families [1] 
was used to classify the phosphonic acid gene clusters into 64 distinct groups with 55 of them 
likely producing new compounds.  A production screening was performed on the pepM positive 
strains with only a fraction of the strains generating phosphonates on the tested media (see Figure 
4.1).  
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To discover what phosphonic acids may possibly be produced from some of the nearly 200 “silent” 
strains, a pathway refactoring strategy was implemented. Pathway refactoring entails removing 
biosynthetic pathways from genetic contexts with unknown or complex regulation and into simple 
genetic contexts with little or no regulation.  Such pathway reengineering has been carried out on 
multiple pathways, including the natural products spectinabilin [4] and A-74528 [5] as well as the 
machinery needed for nitrogen fixation [6]. For the work detailed in this chapter and the next, two 
phosphonic acid pathways were refactored using a library of promoters previously characterized 
in Streptomyces lividans [4].  Fourteen phosphonic acid clusters were chosen as candidates for 
refactoring (denoted by dots in Figure 4.1), and after a preliminary refactoring screen, three were 
refactored completely with two producing stable phosphonic acids (red dots, Figure 4.1). This 
chapter will detail the refactoring efforts of the cluster from Streptomyces species NRRL F-525, 
whereas Chapter 5 will focus on the refactoring of the Kibdelosporangium aridum largum NRRL 
B-24462 phosphonic acid cluster. 
 
4.2 Results and Discussion 
 
 Preliminary refactoring screening of pepM positive strains 
 
Of the 199 strains that were positive for the pepM gene but produced no phosphonates in a 
production screening, fourteen strains were originally chosen as candidates for complete 
refactoring (Table 4.1). Ten of these strains came from nine gene cluster families and an additional 
four were singletons.  Of the fourteen strains selected, one was dropped due to heavy 
contamination by a non-actinobacterial strain and another two were unable to be refactored 
because genes could not be cloned from the genomic DNA after multiple attempts. Each of these 
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dropped strains was tested again from fresh cultures revived from frozen stocks but the same 
problems were encountered.  
 
Before going through the efforts of completely refactoring the biosynthetic gene clusters, a 
preliminary refactoring screen was setup by testing the first two genes of each pathway to see if 
phosphonate production could be detected. From each of the eleven strains for which cloning was 
successful, the genes pepM and phosphonopyruvate decarboxylase (pdc) were placed downstream 
of the promoters gadph(KR) and gadph(EL), respectively, which are from our library of promoters 
characterized in S. lividans. Because pepM and pdc lead to the production of the unstable 
intermediate phosphonoacetylaldehyde, the gene phpC from the phosphinothricin tripeptide 
pathway of Streptomyces viridochromogenes [7], which codes for an alcohol dehydrogenase, was 
also cloned into each truncated cluster to lead to the production of the more stable 2-
hydroxylethylphosphonate (2-HEP, Figure 4.2). [4].  One of the strains, Streptomyces species 
NRRL F-6674, had neither pdc or a phosphonopyruvate acetylase, the two known second pathway 
enzymes for phosphonate biosynthesis, so the pdc gene from S. viridochromogenes was used 
instead. From this preliminary screen, only seven of the eleven chosen clusters showed phosphonic 
acid production as detected by 31P-NMR. 
 
After additional examination of the seven remaining clusters, three were chosen for complete 
refactoring. A six-gene cluster from Streptomyces species NRRL S-1813 produced a possible new 
phosphonate, however it was discontinued due to its instability during the purification process. 
The results from the twelve gene cluster from Streptomyces species NRRL F-525 is discussed 
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below, whereas details from the fourteen gene cluster refactoring from Kibdelosporangium aridum 
largum NRRL B-24462 are given in Chapter 5. 
 
 Refactoring of the Streptomyces species NRRL F-525 phosphonic acid cluster 
 
To determine the boundaries of the Streptomyces species NRRL F-525 phosphonic acid cluster 
(referred to as F-525 from hereon), each gene in the neighborhood of the pepM gene was aligned 
with possible homologous proteins using BLAST alignment (blast.ncbi.nlm.nih.gov). For the top 
one-hundred hits for each gene, the number of homologues with higher than 50% and 70% 
sequence identity were counted.  A plot of the results of this analysis is given in Figure 4.3, 
showing a valley between open reading frames (ORFs) 6 through 18 that lack high homology with 
any other protein sequence in the NCBI database. The highest peak is for pepM (ORF 13, green), 
as expected, followed by ORFs 14 and 15 which code for the two subunits of pdc. The possible 
assignments inferred for each F-525 gene based on sequence homology are given in Table 4.2. Of 
special note, there is no confirmed third step of the pathway, which means this cluster would likely 
exhibit some new chemistry. 
 
The fully refactored pathway was constructed using a three-tier assembly. In the first assembly, 
each gene was cloned from genomic DNA and assembled downstream of one of six promoters 
using Golden Gate assembly. This required the removal of Esp3I cutsites from each gene by 
making silent mutations. For the second assembly, four plasmids were constructed via Gibson 
Assembly [8] where each plasmid contained three of the pathway genes. The final fully refactored 
pathway was then constructed by Golden Gate assembly and introduced into Streptomyces lividans 
by conjugation. Because two copies of each promoter were present in the final construct, an 
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apramycin resistance marker was placed in the middle of the refactored pathway, thus allowing 
for selection against recombination of identical promoters. 
 
 Cluster expression and phosphonic acid isolation and characterization  
 
To optimize phosphonate production of the F-525 cluster in Streptomyces lividans, preliminary 
tests were first carried out in liquid and solid ISP2 media collected at 4, 7, and 10 days. A unique 
strong peak was seen at 19.4 ppm with correlated protons seen at 2.6, 4.1, and 4.2 ppm when 
analyzed by 1H-31P heteronuclear multiple bond correlation (HMBC) NMR. It is these peaks that 
were followed throughout the purification process of isolating the target phosphonate. Production 
was optimal in the solid media with equal production seen at 7 and 10 days. Three additional liquid 
media were tested at 10 days: ISP4, ATCC 172, and GUBC. Although there was comparable 
production in ATCC 172, additional off pathway peaks were seen in the media. Thus, for scale up, 
10 L of ISP2 solid cultured for 10 days was used for phosphonate production.  
 
Two challenges complicate the purification of phosphonic acids that usually aren’t faced with other 
natural products. Unlike polyketides, for example, phosphonic acids often lack conjugated bonds, 
which make them have low UV absorbance and less detectible with methods that rely on UV or 
color measurements. Therefore, after each step of purification NMR was used to determine the 
presence of the target phosphonate in each fraction. The other challenge with phosphonic acid 
purification is that the compounds often have high water solubility and cannot be extracted with 
organic solvents, which are commonly used to separate less soluble natural products. To process 
cultures for phosphonate purification one must rely on multiple steps to remove undesired 
compounds from the bulk, which are outlined for the F-525 phosphonate in Figure 4.4.   
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Fortunately, one solvent that works well with phosphonate extraction is methanol, which was used 
to precipitate less hydrophilic material and to extract phosphonates from the spent agar. Once 
methanol soluble material was dried and reconstituted into water, the sample was treated on a non-
polar resin (Amberlite XAD16N) to remove hydrophobic material and then a hydrophilic-
lipophilic-balanced (HLB) resin. This was followed by weak cationic exchange and then 
immobilized metal affinity chromatography (IMAC) with iron, which was able to weakly bind the 
target phosphonate. Positive fractions were then pooled and run in two sizes of size exclusion 
columns, with a final volume of about 2 mL with 100 mg of material. High performance liquid 
chromatography (HPLC) was used to further purify the phosphonate to a level of purity for 
structure elucidation. 
 
After HPLC, the phosphonate positive sample was tested by various methods of NMR, including 
31P, 1H, 1H-31P HMBC, 1H-1H total correlation spectroscopy (TOCSY), 1H-13C HMBC, and 1H-
13C heteronuclear single quantum coherence (HSQC) NMR. The 1H-31P HMBC shows three 
proton groups (1, 1’, and 2’) that correlate with the phosphorous (Figure 4.5). Interestingly, the 
1H-1H  TOCSY NMR shows that these protons are not all in the same spin system (Figure 4.6), 
where protons 1’ and 2’ correlate with each other but not with protons 1. The strong correlation of 
the phosphorous with protons 1 suggest a carbon-phosphorous bond, whereas the weaker 
correlation between the phosphorous and protons 1’ and the downfield shift of the 1’ protons 
suggest a phosphoester bond. The phasing of the 1H-13C HSQC NMR shows that carbons 1 and 1’ 
are methylenes (CH2) and carbon 2’ is either a methanetriyl (CH3) or methane (CH) group (Figure 
4.7). The 1H-13C HMBC NMR shows two additional carbons (2 and 3’) associated with the 
molecule that are likely carboxyl groups due to their high downfield shifts, lack of attached 
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protons, and correlations to protons on neighboring carbons (Figure 4.8).  Mass spectrometry of 
the phosphonate gave a molecular weight of 226.01192 m/z, matching the molecular formula of 
C5H9O7NP (Figure 4.9). From these data a structure was determined of a novel phosphonic acid, 
O-phosphonoacetic acid serine (O-PnAS, Figure 4.10). The new molecule consists of a 
phosphonoacetic acid (PnA) head group attached to the alcohol side chain of serine via a 
phosphoester bond.   
 
 Verification of O-PnAS pathway 
 
The presence of the PnA head suggested that the cluster’s aldehyde dehydrogenase (ORF 12) 
catalyzed its formation from oxidizing phosphonoacetylaldehyde. This was confirmed when PnA 
was produced by S. lividans expressing the F-525 phosphoenolpyruvate mutase, 
phosphonopyruvate decarboxylase, and aldehyde dehydrogenase (Figure 4.11). This is the first 
instance of an aldehyde dehydrogenase responsible for PnA creation in phosphonic acid 
biosynthesis.  
 
One possible route to O-PnAS is the conjugation of PnA to a nucleotide by the cluster’s nucleotidyl 
transferase (ORF 18), from which it is transferred onto the serine’s alcohol by an alcohol 
phosphatidyltransferase (ORF 16, Figure 4.12a).   This process is comparable to the attachment of 
serine to phospholipids by similar enzymes. Two four-gene constructs were made, each containing 
genes for PnA biosynthesis and either the nucleotidyltransferase or phosphatidyltransferase, 
neither of which produced O-PnAS when cultures were analyzed by 31P-NMR (Spectra 1 and 2, 
Figure 4.12b). However, a construct that produced PnA and contained both the 
nucleotidyltransferase and phosphatidyltransferase did produce O-PnAS as hypothesized (Spectra 
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3 and 4, Figure 4.12b). Although no new phosphonic acid peaks were seen in the 31P-NMR 
spectrum of the four-gene construct containing the nucleotidyltransferase, it is possible that the 
nucleotide conjugated intermediate is short-lived. This is similar to the pathway of the phosphonate 
FR900098, where the cleaving of a CMP moiety can occur in the absence of the pathway’s 
nucleotide hydrolase [9]. 
 
 Bioactivity of PnA 
 
O-PnAS and PnA were assayed for bioactivity with a disc diffusion test using a strain of E. coli 
overexpressing transporters with broad phosphonic acid specificity. Although no zone of inhibition 
was seen for O-PnAS, inhibited growth was seen for PnA. The assays were performed on both rich 
(LB) and minimal (M9) media, and PnA showed antibacterial activity not only when the 
transporter expression was induced on both media types, but had similar activity on the rich 
medium without induction (Figure 4.13). This is likely due to its uptake with other molecules in 
the nutrient rich environment. Antibacterial activity was also seen for PnA against S. lividans when 
it was cultured on the rich medium ISP2. A strain of S. lividans integrated with the F-525 
nucleotidyltransferase and phosphotidyltransferase genes was grown on ISP2 supplemented with 
5 mM PnA to see if the partial pathway would produce O-PnAS; however, the strain’s growth was 
severely limited.  PnA is known as a DNA polymerase inhibitor and has been studied as an antiviral 
for Herpes infections [10, 11], but no antibacterial activity has previously been reported for the 
compound. Phosphonoformate, a similar antiviral, was also tested against the phosphonic acid 
susceptible E. coli strain but did not inhibit growth. 
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To better assess the antibacterial capabilities of PnA, the minimum inhibitory concentration (MIC) 
was tested on several control strains used for such assays [12]. Of the six strains tested, the 
strongest activity was seen against Staphylococcus aureus ATCC 29213 with a MIC of 256 µg/mL 
(Figure 4.14). For the other five strains, Acinetobacter baumannii ATCC19606, Pseudomonas 
aeruginosa PAO1, Enterococcus faecalis ATCC 19433, Escherichia coli ATCC 25922, and 
Klebsiella pneumoniae ATCC 27736, the bioactivity was too low to quantify with the 
concentration range tested (Table 4.3). Although the antibiotic capabilities of PnA are quite low 
(usually MICs of 128 µg/mL or lower are reported), additional modifications of PnA may increase 
potency. It is possible that PnA derived phosphonic acids have similar modes of action as PnA but 
have improved cellular penetration or enzyme inhibition.  
 
4.3 Conclusions 
 
With the majority of the 278 identified phosphonic acid pathways being inactive or below 
detection when cultured on multiple test media, a wealth of novel molecules is overlooked. 
Although several methods of pathway activation are available, many of them rely on genetically 
manipulating the native host. Although not discussed here, one such method of manipulation was 
attempted by introducing promoters via CRISPR/Cas technology into the pathways within the 
native hosts. However, the primary bottleneck with this approach was that the strains need to have 
high rates of transformation or conjugation given that the Cas9 enzyme has increased toxicity. 
Conjugation efficiencies were tested in most of the candidate strains, which were too low for 
successful CRISPR manipulation. 
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Several methods also exist in expressing cryptic pathways in other hosts. One of the most versatile 
methods is refactoring since it frees pathway expression from its native regulation. Using a library 
of previously characterized promoters, an uncharacterized phosphonic acid pathway was activated 
and has produced O-phosphonoacetic acid serine, a novel phosphonate with a phosphonoacetic 
acid head attached to serine by a phosphoester bond.  It was also shown that the cluster’s aldehyde 
dehydrogenase was able to catalyze the formation of PnA from phosphonoacetylaldehyde. 
Although an aldehyde dehydrogenase has been shown to be involved in this reaction for the 
degradation of phosphonic acids [9], this is the first instance of it being involved in phosphonate 
biosynthesis. It should be noted, however, that an α-ketoglutarate dependent dioxygenase has been 
shown to carry out a similar reaction in phosphonate biosynthesis, but this transformation occurs 
at a slower rate than another oxidation reaction it catalyzes in the same pathway [10].  
 
Identification of this branch point is helpful in determining other phosphonic acid pathways that 
have PnA as an intermediate. In fact, by identifying contigs that contain both pepM and PnAA 
dehydrogenase, an additional ten clusters were identified that likely have products derived from 
PnA (Table 4.4). Four of these clusters appear to be in the same gene cluster family of the F-525 
cluster and have been uploaded to the NCBI database over the course of a year, evidence of the 
increasing rate at which new pathways are becoming available for study.  Of the other clusters 
with a PnA intermediate, four appear to be related to each other in a separate gene cluster family 
whereas the remaining two are singletons with no protein homology beyond the steps for PnA 
production.  It is also possible, given PnA’s weak antibacterial capabilities, that the bioactivities 
of these PnA derivatives may have enhanced yet related bioactivities in inhibiting bacterial growth. 
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4.4 Materials and methods 
 
 Strains, media, and reagents 
 
All phosphonate candidate strains were provided by the laboratory of Prof. William Metcalf at the 
University of Illinois at Urbana-Champaign. All cloning was performed in E. coli strain BW25141 
[13], conjugation was done using the E. coli strain WM6026 [7], and all phosphonate production 
and testing was done in Streptomyces lividans 66.  All media reagents were from Sigma-Aldrich 
(St. Louis, MO), Fisher Scientific (Pittsburgh, PA), or Becton Dickinson (Franklin Lakes, NJ). 
Media used for culturing are given as follows for 1 L of medium: ISP2 (10 g malt extract, 4 g 
dextrose, 4 g yeast extract); ISP4 (10 g soluble starch, 2 g (NH4)2SO4, 2 g CaCO3, 1 g K2HPO4, 1 
g MgSO4-7H2O, 1 g NaCl, 1 mg FeSO4-7H2O, 1 mg MnCl2-2H2O, 1 mg ZnSO4-7H2O); ATCC 
Medium 172 (1% glucose, 2% soluble starch, 0.5% yeast extract, 0.5% N-Z amine type A, 0.1% 
CaCO3); GUBC (5 g glycerol, 10 g sucrose, 5 g beef extract, 5 g casamino acids, 5 mL Na2HPO4-
KH2PO4 buffer, 2 mL Hunter’s concentrated base [14], 10 mL Balch’s vitamins [15]). Apramycin 
(Apr) was purchased from Gold Biotechnology (St. Louis, MO). PCR reactions were performed 
in FailSafe PCR PreMix G (Epicentre Biotechnologies, Madison, WI) with Q5 DNA polymerase 
(New England Biolabs, Ipswich, MA). Restriction enzyme Esp3I was from Thermo-Scientific 
(Pittsburgh, PA) and all other restriction enzymes, T4 ligase, shrimp alkaline phosphatase (rSAP), 
pUC19 plasmid, and HiFi DNA Assembly Kit (used for Gibson Assembly) were from New 
England Biolabs. All primers ordered from Integrated DNA Technologies (Coralville, Iowa) and 
are listed in Tables 4.5 through 4.11 in section 4.4.7. Promoters backbones used as templates were 
previously constructed in our lab [4].  EZNA Plasmid Mini Kit (Omega Bio-tek, Norcross, GA) 
was used for plasmid purification and Zymoclean Gel DNA Recovery Kit (Zymo Research, Irvine, 
CA) was used for gel extraction of DNA. 
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 Plasmid assembly and cloning of genes for preliminary refactoring screening 
 
Backbone for promoter plasmids was constructed by Golden Gate assembly [16] with restriction 
enzyme Esp3I using fragments amplified by primers listed in Table 4.5 with plasmid pAE4 used 
as template [17]. Promoters gapdhp(CF), gapdhp(EL), gapdhp(KR), gapdhp(TP), rpsLp(AC), 
rpsLp(SG), and rpsLp(XC) were amplified from templates previously constructed in our lab [4] 
using primers listed in Table 4.6. Promoters were inserted into the promoter backbone using 
Golden Gate assembly with restriction enzyme BsaI. Some promoters had mutations introduced to 
make them Golden Gate compatible, and a xylE reporter assay [18] was used to verify the 
expression of all mutated promoters.  
 
All strains listed in Table 4.1 were streaked out on ISP2 agar plates and cultured in a 30 ºC 
incubator. Colonies were inoculated into 2 mL ISP2 in culture tubes at 30 ºC at 250 RPM except 
for Streptomyces species 31A4, which exhibited a shiny, gooey growth uncharacteristic of 
Streptomyces. Despite additional streaking of the strain from its frozen stock followed by serial 
streakings to isolate pure colonies, an isolated colony was unattainable. In addition, a segment of 
DNA from the contamination was cloned and had high homology to nitrogen-fixing Gram-
negative Rhizobium species. For other candidate strains, 1 mL of culture was collected after three 
days growth for genomic DNA purification using Wizard Genomic DNA Purification Kit 
(Promega, Madison, WI). Streptomyces species NRRL S-15 did not grow with liquid culturing so 
genomic DNA was purified from colonies harvested from solid ISP2.  
 
PepM and pdc genes from each strain were cloned out using the respective primers listed in Table 
4.7, except for Streptomyces species NRRL F-6133 and Stretpomyces albus NRRL F-4971 for 
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which genes were unable to be cloned. After a second restreaking from frozen stock the genes 
could not be amplified, even with multiple primers and PCR conditions, leading to the possibility 
that the strains cultured did not match the available genomic data. All plasmids were verified by 
restriction digestion analysis. The genes pdc and phpC were amplified from genomic DNA of 
Streptomyces viridochromogenes using primer pairs “gEL Sv pdc for”/“Sv pdc rev” and “rSG 
phpC for”/“phpC rev”, respectively, and cloned into individual helper plasmids carrying respective 
promoters (gEL and rSG). 
 
 Assembly of refactored pathways 
 
For preliminary refactoring screening, pepM and pdc genes along with their respective promoters 
were amplified from the promoter-gene plasmids described in section 4.4.2 using primers listed in 
Table 4.8. Golden Gate assembly with restriction enzyme Esp3I was used to assemble the 3-gene 
plasmids. 
 
The complete refactoring of the Streptomyces species NRRL F-525 phosphonic acid cluster was 
performed in three subsequent assemblies. First, pathway genes (amplified by primers listed in 
Table 4.9) were individually cloned into the promoter helper plasmids using Golden Gate assembly 
with restriction enzyme Esp3I, and sequences were verified by Sanger sequencing. Second, each 
promoter-gene cassette was amplified by primers given in Table 4.10 and assembled into four 
partial pathway plasmids (PI, PII, PIII, and PIV), each containing three genes (PI: pdc, ORFs 12 
and 18; PII: ORFs 17 and 16, pepM; PIII: ORFs 6, 7, and 9; PIV: ORFs 10, 11, and 8). The 
backbone for three of the second-tier plasmids (PI, PIII, and PIV) were made by amplifying a 
fragment from the plasmid pUC19 with primers “BbsI.Esp3I.pUC19 for”/”BbsI.EcoRVpUC19 
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rev” and circularizing it in a Golden Gate assembly reaction with enzyme BbsI. The backbone for 
PII, which included an Apr marker, included an additional fragment amplified from the pAE4 Apr 
cassette using primers “BbsI.EcoRV.Apr for”/”BbsI.Apr rev” and assembled with the pUC19 
backbone mentioned above in a Golden Gate assembly with BbsI.  Before the second-tier 
assembly, the backbones were digested with EcoRV and dephosphorylated with rSAP. The third 
and final assemble was made by mixing the four partial pathway plasmids in a Golden Gate 
assembly reaction with enzyme Esp3I and the backbone Final-BB. Final-BB was constructed by 
Golden Gate assembly with the primers prefixed with “BB” and their respective templates as listed 
in Table 4.11. The presence of each gene in the final constructs was confirmed both by restriction 
analysis and PCR. For the partial pathway plasmids, each promoter-cassette were individually 
amplified with primers giving complimentary overhangs to neighboring fragments in a Golden 
Gate assembly reaction with Esp3I and were verified by restriction digestion.  Conjugation of all 
plasmids into Streptomyces lividans was performed as previously described [19]. 
 
 Strain culturing and optimization 
 
All culturing was done at 30 ºC, with liquid cultures shaken at 250 RPM with 50 mL of media in 
250 mL baffled flasks with beads. For optimization tests, liquid ISP2, ISP4, ATCC 172, and 
GUBC with 25 mg/L Apr were tested at 10 days. For solid media testing on ISP2, five plates were 
used, which were frozen, thawed, then squeezed and strained through a milk filter, with 50 mL 
being collected for testing. Upon collection, all cultures were centrifuged at 4000 RPM for 10 
minutes on a tabletop centrifuged and the aqueous phase then freeze dried, reconstituted into 1 mL 
of D2O, filtered through a 0.22 µm spin-column filter, and then tested by NMR. 
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 Purification of novel F-525 phosphonic acid 
 
Streptomyces lividans integrated with the completely refactored F-525 cluster was inoculated from 
a single colony into 4 mL ISP2+25 mg/L Apr and grown for three days. Four 50 mL cultures of 
ISP2+25 mg/L Apr were then inoculated from the starter culture and cultured in 250 mL baffled 
flasks with beads.  The larger cultures were then used to cover 10 liters of ISP2+10 mg/L Apr 
plates which were incubated at 30 ºC. After 10 days, plates were frozen at -20 ºC overnight, 
thawed, and then squeezed with cheesecloth with 6 L of extract collected. Culture extract was 
freeze-dried while the spent agar was soaked in methanol, which was collected.  The freeze-dried 
extract was resuspended in 700 mL water and mixed with 2.1 L of methanol, which was then 
centrifuged to remove precipitates. The aqueous phase was pooled with the methanol used to soak 
the spent agar and the combined methanol extracts were dried and reconstituted in about 300 mL 
of water.  The sample was then mixed with 500 g of Amberlite XAD16N resin (Sigma-Aldrich), 
and flow-through and two 500 mL water washes were collected and dried to 150 mL. The sample 
was then treated with Oasis hydrophilic-lipophilic-balanced (HLB) resin (Waters Corporation, 
Milford, MA) with flow-through and two 250 mL water washes collected and dried to 125 mL. 
The sample was then loaded onto 100 g of Chelex 100 resin (Bio-Rad, Hercules, CA) in its ion-
free form, and the flow-through and two 250 mL water washes were collected and dried to 100 
mL. Because the next chromatography can tightly bind phosphonates and lead to unrecoverable 
loss, 50 mL of the sample was reserved. The other 50 mL was applied to Chelex 100 resin charged 
with FeCl3, with the target phosphonate present in a second water wash of 100 mL plus the 50 mL 
fractions eluted with 10 mM, 25 mM, 50 mM, and 100 mM of ammonium bicarbonate. The second 
water wash and the 10 mM NH4HCO3 were pooled and the 50 mM and 100 mM NH4HCO3 
samples were pooled, and each pooling and the 50 mM NH4HC CO3 elution were separately ran 
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on a 2.5 cm x 1.2 m glass column loaded with Sephadex LH-20 (GE Healthcare Life Sciences, 
Pittsburgh, PA) for size exclusion chromatography. The chromatography was driven by gravity 
flow, and fractions were collected every 9 min (approximately 10 mL each) with the target 
phosphonate was seen in fractions 35 to 39. Fractions positive for the phosphonate were pooled 
and ran on a 1.5 cm x 1.7 m column with Sephadex LH-20, with the target compound being eluted 
in fractions 53 to 57 (3 mL per fraction). The positive fractions were pooled, concentrated, and 
then ran with 0.5 mL per injection on a Zorbax SAX 9.4 mm ID x 250 mm column (Agilent, Santa 
Clara, CA) with mobile phases of 0.1 M KH2PO4 at pH 3.0 (buffer A) and water (buffer B). The 
method ran was as follows with linear gradients between each time point.: t=0 min, 100% B; t=15 
min, 100% B; t=45 min, 0% B; t=75 min, 0% B; t=82 min, 100% B; t=90 min, 100% B.  The target 
phosphonate was eluted between 38 and 40 minutes. Collected fractions expected to have the 
phosphonate were pooled and desalted using a 2.5 cm x 1.2 m size exclusion column with 
Sephadex LH-20.   
 
 
 Nuclear Magnetic Resonance (NMR) analysis 
 
NMR spectra were collected using a Varian Unity Inova 600 MHz spectrometer with an 
AutoTuneX probe (Varian, Palo Alto, CA), with 243 MHz used for 31P, 600 MHz for 1H, and 150 
MHz for 13C . All samples ran in D2O (Sigma-Aldrich) and analyzed using MestReNova v. 10.0.2 
software (Mestrelab Research, Santiago de Compostela, Spain). 
 
 Mass spectrometry analysis 
 
Sample was run on a Q-Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer (ThermoFisher 
Scientific, Waltham, MA) with a sheath gas flow rate of 45 psi, auxiliary gas flow rate of 10 psi, 
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sweep gas flow rate of 2 psi, voltage of 2.5 kV, capillary temperature of 250 ºC and auxiliary gas 
heater temperature of 400 ºC. 
 
 Bioassays 
25 µL of E. coli WM6242 [17] grown to OD600=0.6 was used to inoculate 5 mL of LB or M9 with 
0.7% agar which was spread over agar plates of same medium. To induce the expression of the 
phosphonate transporters, 1 mM IPTG was included in the top agar layers before pouring.  Paper 
discs with 20 µL of either 10 mM O-PnAS, 10 mM PnA or 45 mM FR900098 (positive control) 
were placed in the center of the agar plates, which were then incubated at 37 ºC. Zones of inhibition 
were measured after 18 hours (LB) or 24 hours (M9) from top plating. A similar test was carried 
out with 10 mM phosphonoformate but only on M9. 
  
To determine the minimum inhibitory concentration of PnA, the test strains were grown overnight 
at 37 ºC at 220 rpm in 10 mL of either brain heart infusion medium (from Becton Dickinson, used 
to culture Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 19433), nutrient 
broth (from Becton Dickinson, used to culture Klebsiella pneumoniae ATCC 27736 and 
Escherichia coli ATCC 25922), or tyrpticase soy broth (15 g/L tryptone, 5 g/L soytone, 5 g/L 
NaCl; used to culture Pseudomonas aeruginosa PAO1 and Acinetobacter baumannii 
ATCC19606). 100 µL of each overnight culture was used to inoculate 10 mL of Mueller-Hinton 
(MH) medium (Sigma-Aldrich) and cultured for 1 hour at similar conditions. In a 96-well plate, 
10 µL of 5x106 cfu/mL of each strain was then added to 90 µL of MH medium with PnA 
concentrations ranging from 2 to 1024 µg/mL. OD600 of each well was measured and percent cells 
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dead was calculated. Most notable antibiotic activity was seen against S. aureus, for which the 
assay was repeated to generate a more accurate inhibition curve. 
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4.5 Figures and tables 
 
 
Figure 4.1  Phylogeny of pepM sequences from 278 Actinomycetes. Previously discovered 
phosphonic acids highlighted in blue, with recently discovered compounds highlighted in red. Dots 
denote strains with candidate gene clusters for refactoring, with the two fully refactored clusters 
detailed in this chapter and Chapter 5 denoted with red dots. Figure adapted from [3]. 
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Figure 4.2  Reaction scheme for 3-gene preliminary refactoring screening. The first two genes 
for hydroxyethylphosphonate, phosphonoenolpyruvate mutase (PepM) and phosphonopyruvate 
decarboxylase (Pdc) were cloned from each candidate cluster and coupled with the alcohol 
dehydrogenase PhpC from S. viridochromogenes. 
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Figure 4.3  BLAST analysis of Streptomyces specie F-525 phosphonic acid cluster.  Each 
proximal gene to pepM (green, ORF 13) was entered into a BLAST search and the number of 
proteins with sequence identity above 50% (blue bars) and 70% (red bars) were counted, revealing 
a region of low homology that may correspond to the cluster boundaries.  
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Figure 4.4  Steps for purification and volumes of fractions for phosphonate from 
Streptomyces sp. NRRL F-525 cluster. 
 
 
 
 
 
 
 
ISP2 solid culturing
10 L
Liquid extraction
6 L
Drying by lyophilization
700 mL
75% methanol precipitation and drying
300 mL
Amberlite XAD16N resin treatment, water washes, and drying
150 mL 
Hydrolipic-lipophilic-balnced (HLB) resin treatment, water washes, and drying
125 mL
Weak cationic exchange, water washes, and drying
100 mL (50 mL reseved, 50 mL to next step)
Iron-metal affinity chromoatography, H2O and NH5CO3 elutions and drying
25 mL
2.5 cm x 1.2 m size exclusion chromoatography and drying
10 mL
1.5 cm x 1.7 m size exclusion chromatography and drying
2 mL
High-performance liquid chromatography, pooling, and drying
400 µL
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Figure 4.5  1H-31P HMBC NMR of the F-525 phosphonate. 
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Figure 4.6  1H-1H TOCSY NMR of the F-525 phosphonate. 
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Figure 4.7  1H-13C HSQC NMR of the F-525 phosphonate. 
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Figure 4.8  1H-13C HSQC NMR of the F-525 phosphonate. 
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Figure 4.9  Mass spectrometry of the F-525 phosphonic acid. Molecular formula for the 
phosphonate is C5H9O7NP with -1.42184 ppm. 
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No. δC (ppm) δH (ppm) 
1H-13C 
HMBC 
1H-1H  
TOCSY 
1 35.3, CH2 (JPC=121.4 Hz) 2.73, d (JPH=20.9 Hz)   
2 172.7, qC (JPC=6.0 Hz)  1  
1’ 63.1, CH2 (JPC=5.1 Hz) 4.19, 4.12, m 2’, 3’ 2’ 
2’ 54.9, CH (JPC=5.2 Hz) 3.88, m 1’, 3’ 1’ 
3’ 171.2, qC    
 
Figure 4.10  Structure of F-525 phosphonic acid. Table shows chemical shifts (δC and δH), 
coupling constants (J), and correlations from 2D NMR methods (1H-13C HMBC and 1H-1H  
TOCSY) 
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Figure 4.11  Production of phosphonoacetic acid from three gene F-525 construct in 
Streptomyces lividans. Red trace shows production from three gene construct; turquoise trace is 
with addition of phosphonoacetic acid standard. 
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Figure 4.12  Proposed O-PnAS pathway and confirmation. (A) Proposed pathway for O-PnAS 
based on enzymes present in cluster. (B) 31P-NMR spectra validating proposed pathway where O-
PnAS is present only when both the nucleotidyltransferase and phosphotidyltransferase are 
expressed. Spectra 1: 4-gene construct with pepM, PDC, aldehyde dehydrogenase, and 
nucleotidyltransferase; Spectra 2: 4-gene construct with phosphotidyltransferase in place of 
nucleotidyltransferase; Spectra 3: 5-gene construct with both nucelotidyltransferase and 
phosphotidyltransferase; Spectra 4: 5-gene construct spiked with purified O-PnAS enlarging peak 
at 19.4 ppm.  
B 
A 
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Figure 4.13   Disc diffusion assay showing PnA antibiotic capabilities. Performed on LB agar 
plates with phosphonoacetic acid (PnA, 10 mM, 20 µL) and FR900098 (45 mM, 20 µL) on E. coli 
strain WM6242 with phosphonate transporters induced by IPTG. 
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Figure 4.14  Antibacterial activity of phosphonoacetic acid against Staphylococcus aureus 
ATCC 29213. Error bars shown standard error of biological duplicates. 
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Table 4.1  Candidate strains for phosphonic acid cluster refactoring.  Clusters investigated 
in Chapters 4 and 5 are bolded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Status 
Streptomyces species 31A4 Contaminated 
Streptomyces species        
NRRL F-6133 
Failed cloning 
Streptomyces albus           
NRRL F-4971 
Failed cloning 
Lechevalieria species        
NRRL S-836 
No 2-HEP with 3-gene refactoring 
Streptomyces species        
NRRL S-1022 
No 2-HEP with 3-gene refactoring 
Streptomyces pyridomyceticus 
ISP-5024 
No 2-HEP with 3-gene refactoring 
Streptomyces species         
NRRL F-6674 
No 2-HEP with 3-gene refactoring 
Streptomyces rimosus        
NRRL B-2659 
Produced 2-HEP but not chosen for refactoring 
Streptomyces species        
WM1121 
Produced 2-HEP but not chosen for refactoring 
Streptomyces species           
NRRL B-1140 
Produced 2-HEP but not chosen for refactoring 
Streptomyces species           
NRRL S-15 
Produced 2-HEP but not chosen for refactoring 
Streptomyces species         
NRRL S-1813 
Completely refactored but unstable phosphonate 
Streptomyces species           
NRRL F-525 
Completely refactored with stable phosphonate 
Kibdelosporangium aridum 
largum NRRL B-24462 
Completely refactored with stable phosphonate 
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Table 4.2  Possible gene assignments for ORFs in the Streptomyces species NRRL F-525 
phosphonic acid cluster. 
 
ORF 
Non-hypothetical     
top protein hit Source %ID 
Hypothetical 
protein source %ID 
6 
Putative 
ligase/carboxylase 
Streptomyces 
regensis 
48% 
Herbiconiux sp. 
YR403 
65% 
7 
carboxylate--amine 
ligase 
Bacillus subtilis 35% 
Saccharothrix sp. 
NRRL B-16314 
43% 
8 SetB (permease) Pantoea ananatis 29% 
Saccharothrix sp. 
NRRL B-16314 
39% 
9 Amidase 
Streptomyces 
davawensis 
46% 
Stretpomyces 
xylophagus 
84% 
10 
P-Aminobenzoate N-
oxygenase AurF 
Cylindrospermum 
stagnale 
37% 
Herbiconiux sp. 
YR403 
61% 
11 
rRNA adenine 
methyltransferase 
Xanthomonas 
campestris 
50% 
Herbiconiux sp. 
YR403 
61% 
12 
Aldehyde 
dehydrogenase 
Herbiconiux sp. 
YR403 
68%     
13 PepM 
Streptomyces 
bicolor 
62% 
Herbiconiux sp. 
YR403 
75% 
14 
Phosphonopyruvate 
decarboxylase 
Bacillus 
tequilensis 
49% 
Herbiconiux sp. 
YR403 
66% 
15 
Phosphonopyruvate 
decarboxylase 
Streptomyces 
regensis 
50% 
Herbiconiux sp. 
YR403 
63% 
16 
CDP-alcohol 
phosphatidyltransferase 
Solemya velum 
gill symbiont 
44% 
Herbiconiux sp. 
YR403 
79% 
17 Asparagine synthetase 
Herbiconiux sp. 
YR403 
76%     
18 
Nucleotidyl transferase 
family protein 
Clostridium 
argentinense 
38% 
Herbiconiux sp. 
YR403 
67% 
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Table 4.3  MICs of phosphonoacetic acid against various bacterial test strains. 
 
Strain MIC (µg/mL) 
Staphylococcus aureus ATCC 29213 256 
Acinetobacter baumannii ATCC19606 >512 
Pseudomonas aeruginosa PAO1 >512 
Enterococcus faecalis ATCC 19433 >512 
Escherichia coli ATCC 25922 >512 
Klebsiella pneumoniae ATCC 27736 >512 
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Table 4.4    Percent amino acid sequence identity between Streptomyces sp. F-525 phosphonic 
acid cluster proteins and other phosphonic acid biosynthetic clusters with PnAA 
dehydrogenase. Vertical lines separate clusters into possible gene cluster families based on shared 
homology of additional genes. AB, Actinobacteria bacterium OK074; HYR, Herbiconiux sp. 
YR403; XA, Xanthomonas axonopodis strain DSM 3585; CM, Clavibacter michiganensis; SK, 
Streptomyces kanasensis strain ZX01; MMG, Streptomyces sp. MMG1121; KR, Kitasatospora sp. 
Root187; 31A4, Streptomyces sp. 31A4; MBT, Streptomyces sp. MBT76; UAB, Uncultured 
Acidobacteria bacterium (Accession no. AP011710).  
 
F-525 Enzyme AB HYR XA CM SK MMG KR 31A4 MBT UAB 
PepM 94% 74% 41% 68% 58% 61% 59% 61% 47% 53% 
PDC subunit A 90% 66% 41% 56% 50% 54% 54% 54% 50% 37% 
PDC subunit B 92% 59% 38% 59% 52% 51% 52% 51% 38% 44% 
PnAA Dehydrogenase 92% 66% 31% 58% 55% 56% 53% 56% 53% 46% 
Nucleotidyl transferase 86% 56% 39% 43% - - - - - - 
Asparagine synthetase 95% 76% 59% 69% - - - - - - 
N-oxygenase 92% 61% 35% 58% - - - - - - 
Adeneine methyltrasferase 93% 62% 51% - - - - - - - 
Phosphatidyltransferase 91% 69% - - - - - - - - 
Ligase/carboxylase 90% 65% - - - - - - - - 
Carboxylate-amine ligase 86%          
Permease 95%          
Amidase 82%          
Phospholipase 93%          
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Table 4.5  Primers used to construct promoter backbone vector. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Sequence 
Strp GGBB 1 BsaI for 
TCAGCGTCTCAGCATAATTAAGGTCTCAGAGTCCGCGCCGTC
CCGTC 
Strp GGBB 1 rev CGTACGTCTCATGGGGATACCCCACACTACCATC 
Strp GGBB 2 for TCAGCGTCTCACCCATGCGAGAGTAGGG 
Strp GGBB 2 rev CGTACGTCTCACCTTCGTTTCCGAAACAAGCTCGAAG 
Strp GGBB 3 for TCAGCGTCTCTAAGGAGATCACGCGCAACGGCCG 
Strp GGBB 3 rev CGTACGTCTCACAATCGTTTCGCCCCGGGTC 
Strp GGBB 4 for TCAGCGTCTCTATTGGGAAGAAGACCGCTTCAAGC 
Strp GGBB 4 rev CGTACGTCTCACCAACGTTTCTTCGTCGCCTTCG 
Strp GGBB 5 for TCAGCGTCTCATTGGCGCTTCTGTGGGAAGC 
Strp GGBB 5 rev CGTACGTCTCTAGTAGAAACGAAAGTGATTGCGCCTACC 
Strp GGBB 6 for TCAGCGTCTCATACTCCGTTACAAAGCGAGGCTGG 
Strp GGBB 6 BsaI rev 
CGTACGTCTCTATGCCATTGGGTCTCACGCAATCCAGTGCAA
AGCTAGCTTC 
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Table 4.6  Primers used to introduce promoters into promoter backbone vector. 
Primer Sequence 
gCFp GG for ACTGGGTCTCATGCGCACCGGGGCGCCCGTCGTC 
gCFp GG rev AGGTCTCAACTCAGAGACGTCTCATTGCCCTCCTCGGCACGCGC 
gELp GG for ACTGGGTCTCATGCGGCTGCTCCTTCGGTCGGACG 
gELp GG rev 
CCGAGGTCTCAACTCAGAGACGTCTCAGCGTATCCCCTTTCAGATACTCGC
AC 
gKRp GG for ACTGGGTCTCATGCGCACGGGCCGGTGAACCCCG 
gKRp GG rev CCGAGGTCTCAACTCAGAGACGTCTCAGCAATCTCCTCTGCGAGTGGGTG 
gTPp GG For ACTGGGTCTCATGCGTCCGTTCCCGGCGGGGAG 
gTPp GG Rev AGGTCTCAACTCAGAGACGTCTCATTAACTGCTCCTTCGACTGGGTGTGCC 
rACp GG for ACTGGGTCTCATGCGGCGCGGTCACGCCGGCCGG 
rACp GG rev CCGAGGTCTCAACTCAGAGACGTCTCAACGCGCCCTTCGTGGATCC 
rSGp GG for ACTGGGTCTCATGCGAGGGGCGCGCGGCCC 
rSGp GG rev CCGAGGTCTCAACTCAGAGACGTCTCATACTTCTCCGGTTTCTGTGTGCCG 
rXCp GG for ACTGGGTCTCATGCGGCCCTGCAGGCGGAAGTCAG 
rXCp GG rev 
AGGTCTCAACTCAGAGACGTCTCATACGTCACCGTCGTCTTCTCGAGCTCA
CGGAGTCCG 
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Table 4.7  Primers used to clone pepM and pdc from candidate strains. 
Primer Sequence 
gKR S-836 pepM for CACGTCTCATTGCGTGGCACGCATGAGCAAGGCCGCTG 
S-836 pepM rev CACGTCTCAACTCTCACGCTCCCCACTCCTCCCACTCG 
gEL S-836 pdc for CACGTCTCAACGCGTGGGGAGCGTGATCGAGGCGGAGG 
S-836 pdc rev CACGTCTCAACTCTCACCGGTCCACCCCGAGCCCG 
gKR F-525 pepM for CACGTCTCATTGCATGTCACCGGTAAAGTCCCTGCGCGC 
F-525 pepM rev CACGTCTCAACTCTCAACGCTCAACGACATCGGCGTTCCTCC 
gEL F-525 pdc for 1 CACGTCTCAACGCATGACCCAGGTGGCGACGGACGTC 
F-525 pdc rev 1 CACGTCTCAGTGCGGCCGAGACCGGATCCTCGAACG 
F-525 pdc for 2 CACGTCTCAGCACTGGCCTTCGGCTATCGCAGGGC 
F-525 pdc rev 2 CACGTCTCAACTCCTACTTGACCGCGAGAAAGCGGGTGAAGCG 
gKR B-2659 pepM for CACGTCTCATTGCGTGGGCGACACCGGAGGCAGCATC 
B-2659 pepM rev CACGTCTCAACTCTCACGAGGCGTCCCTCCTGGAGG 
gEL B-2659 pdc for CACGTCTCAACGCGTGATCCGGGCCGGGCAGTTCCTC 
B-2659 pdc rev CACGTCTCAACTCTCAGGCCGCCGTGCCGAGGAAG 
gKR S-1813 pepM for 1 CACGTCTCATTGCTTGCGCGCCCTTTTCGACGCCC 
S-1813 pepM rev 1 CACGTCTCACCGTCCTTGAGGATGGTCTCGAAGGTCTGGCTG 
S-1813 pepM for 2 CACGTCTCAACGGCCGTAGCACCGCCGTCG 
S-1813 pepM rev 2 CACGTCTCAACTCTCACGGGGCGTCCCCTCCGGTCAG 
gEL S-1813 pdc for CACGTCTCAACGCTTGCCCCGCACGCTCGATCCGG 
S-1813 pdc rev CACGTCTCAACTCTCACGGGGCGATCGCCTCCTGGAAG 
gKR S-1022 pepM for CACGTCTCATTGCGTGAGCGTCCGCTCCGCGGC 
S-1022 pepM rev CACGTCTCAACTCTCAACGGACCTCCTCCTGACCGGTGAGC 
gEL S-1022 pdc for CACGTCTCAACGCGTGGTGGACCTGCTCCGCGAGCG 
S-1022 pdc rev CACGTCTCAACTCTCACCGGGAGACCGCCTCCATGAACC 
gKR WM1121 pepM for CACGTCTCATTGCATGTCCAAGACCCGCACCCTGCGC 
WM1121 pepM rev CACGTCTCAACTCTCAGCCGAGGGCGGAGTACGTGG 
gEL WM1121 pdc for 1 CACGTCTCAACGCATGCACACGTCCACCGTGGGCTCG 
WM1121 pdc rev 1 CACGTCTCAGATGACTTCGGACACGGAACGGGCCGGATC 
WM1121 pdc for 2 CACGTCTCACATCGACCGCATGGACCAGGAGCAGCG 
WM1121 pdc rev 2 CACGTCTCAGTGGAGAGGATGACGGCGTCCGGGT 
WM1121 pdc for 3 CACGTCTCACCACGTGCGGTTTCACCAGCCGGG 
WM1121 pdc rev 3 CACGTCTCAACTCTCAGGCTGCGGGCGCCGC 
gKR B-1140 pepM for 
CACGTCTCATTGCATGAATGAAACAGTAGGGATCGATCACCAGA
ACGGCG 
B-1140 pepM rev CACGTCTCAACTCTCATCGCTGCGCCGCCCGCTC 
gEL B-1140 pdc for CACGTCTCAACGCATGAGCGCACCCACGGTTCTCGGC 
B-1140 pdc rev CACGTCTCAACTCTCATGCGGAGATCGCCTCCATGAACCGG 
gKR S-15 pepM for CACGTCTCATTGCATGACCACATCATCCGCACGCCTGAGAG 
S-15 pepM rev CACGTCTCAACTCTCATGATTCGAGCGCGTTCCACGTGTCG 
gEL S-15 pdc for 
CACGTCTCAACGCATGATCGAACCGACCTTCTTCTGCGACGAAC
TG 
S-15 pdc rev CACGTCTCAACTCTCAACGGCCATGCGAGCTCCGC 
gKR ISP5024 pepM for CACGTCTCATTGCGTGCGGGAGCTCTTCGCGAGGCC 
ISP5024 pepM rev CACGTCTCAACTCTCACGCGACCTGCCCGGCGAC 
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Table 4.7 (cont.) Primers used to clone pepM and pdc from candidate strains. 
Primer Sequence 
gEL ISP5024 pdc for CACGTCTCAACGCGTGGACGCGGAGGAGGTCGTCGC 
ISP5024 pdc rev CACGTCTCAACTCTCATGCGGTGGCCTCCGCGGAG 
gKR B-24462 pepM for CACGTCTCATTGCATGAACAGCACGACGAGGCTTCGCAAGCTG 
B-24462 pepM rev 
CACGTCTCAACTCTCATTGTTTCTCCAGGTGCAGCCATTTGTCGA
GGTG 
gEL B-24462 pdc for CACGTCTCAACGCATGATCGGTGCGGAGCAGTTCGCCG 
B-24462 pdc rev CACGTCTCAACTCTCAGCTGTCGCCATGTGCGACTGCCAAC 
gKR.G31 pepM for CACGTCTCATTGCATGGGGGTCTACGATGCGCTGACCG 
G31 pepM rev CACGTCTCAACTCCTAGACCTCCGGCCCGCTGCTCG 
gEL Sv pdc for CACGTCTCAACGCATGATCGGCGCGGCCGACCTGG 
Sv pdc rev CACGTCTCAACTCTCATCGTGCGGTCACCCCTCCCGC 
rSG phpC for CACGTCTCAAGTAATGACCGCTGTGTTTCCCGGTGAACTG 
phpC rev 
CACGTCTCAACTCCTATCCGCACGTCTCCTCCATTTCCGATCGTT
CG 
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Table 4.8  Primers used to construct 3-gene plasmids. 
 
Primer Sequence 
BB gKR for ACGTCTCATGCGCACGGGCCGGTGAACCC 
Esp3I gEL for ACGTCTCAGCTGCTCCTTCGGTCGGACGTGC 
Esp3I rSG for ACGTCTCAAGGGGCGCGCGGCCC 
S-836 gEL.pepM rev ACGTCTCACAGCTCACGCTCCCCACTCCTCCCACTCG 
S-836 rSG.pdc rev ACGTCTCACCCTTCACCGGTCCACCCCGAGCCCG 
F-525 gEL.pepM rev ACGTCTCACAGCTCAACGCTCAACGACATCGGCGTTCCTCC 
F-525 rSG.pdc rev ACGTCTCACCCTCTACTTGACCGCGAGAAAGCGGGTGAAGCG 
B-2659 gEL.pepM rev ACGTCTCACAGCTCACGAGGCGTCCCTCCTGGAGG 
B-2659 rSG.pdc rev ACGTCTCACCCTTCAGGCCGCCGTGCCGAGGAAG 
S-1813 gEL.pepM rev ACGTCTCACAGCTCACGGGGCGTCCCCTCCGGTCAG 
S-1813 rSG.pdc rev ACGTCTCACCCTTCACGGGGCGATCGCCTCCTGGAAG 
S-1022 gEL.pepM rev ACGTCTCACAGCTCAACGGACCTCCTCCTGACCGGTGAGC 
S-1022 rSG.pdc rev ACGTCTCACCCTTCACCGGGAGACCGCCTCCATGAACC 
WM1121 gEL.pepM rev ACGTCTCACAGCTCAGCCGAGGGCGGAGTACGTGG 
WM1121 rSG.pdc rev ACGTCTCACCCTTCAGGCTGCGGGCGCCGC 
B-1140 gEL.pepM rev ACGTCTCACAGCTCATCGCTGCGCCGCCCGCTC 
B-1140 rSG.pdc rev ACGTCTCACCCTTCATGCGGAGATCGCCTCCATGAACCGG 
S-15 gEL.pepM rev ACGTCTCACAGCTCATGATTCGAGCGCGTTCCACGTGTCG 
S-15 rSG.pdc rev ACGTCTCACCCTTCAACGGCCATGCGAGCTCCGC 
ISP5024 gEL.pepM rev ACGTCTCACAGCTCACGCGACCTGCCCGGCGAC 
ISP5024 rSG.pdc rev ACGTCTCACCCTTCATGCGGTGGCCTCCGCGGAG 
B-24462 gEL.pepM rev 
ACGTCTCACAGCTCATTGTTTCTCCAGGTGCAGCCATTTGTCGA
GGTG 
B-24462 rSG.pdc rev ACGTCTCACCCTTCAGCTGTCGCCATGTGCGACTGCCAAC 
F-6674 gEL.pepM rev ACGTCTCACAGCCTAGACCTCCGGCCCGCTGCTCG 
Sv rSG.pdc rev ACGTCTCACCCTTCATCGTGCGGTCACCCCTCCCGC 
BB Sv phpC rev GCGTCTCAACTCCTATCCGCACGTCTCCTCCATTTCCGATCGTTC 
BB for ACGTCTCACGCAATCCAGTGCAAAGCTAGCTTCTTC 
BB rev ACGTCTCAGAGTCCGCGCCGTCCCGTCG 
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Table 4.9  Primers used to clone F-525 genes into promoter plasmids. 
 
 
 
 
 
 
 
Primer Sequence 
gEL s4.6 for ACCGTCTCAACGCGTGTGCCTGGTCGAGTCGCCCCG 
s4.6 rev ACCGTCTCAACTCTCAGACGTATTCGGCGCCGCCCTC 
rXC s4.7 for ACCGTCTCACGTAGTGAAGGTACTCGTTCTCAACCGGTTCAAACTCG 
s4.7 rev 1 ACCGTCTCACCAGCTCTTTCTTGCGGGCGGTCTCGTC 
s4.7 for 2 ACCGTCTCACTGGCCGGATTCGCGCACACCGAAG 
s4.7 rev ACCGTCTCAACTCTCATCGGTCGGCCTCTTCCGAGGGTTC 
gKR s4.8 for ACCGTCTCATTGCATGACGGCCCCCACCCCGG 
s4.8 rev 1 ACCGTCTCAGACCACCACTCGGTCCAGGGCGTGGAAG 
s4.8 for 2 ACCGTCTCAGGTCGAGACCGGCGGCGAGAAACTC 
s4.8 rev 2 ACCGTCTCACGACCTCTCGCCTCTTGGCGATCGGG 
s4.8 for 3 ACCGTCTCAGTCGACGTCTTCCTCTGGCCCGTCG 
s4.8 rev ACCGTCTCAACTCTCACGACCGAACACCATATCCATGGCCTGATC 
rCF s4.9 for ACCGTCTCACGTAATGGATATGGTGTTCGGTCGTGATGTCGTTTCTG 
s4.9 rev ACCGTCTCAACTCCTAACCGAGACTGGCGGCGACTTCAGC 
rAC s4.10 for ACCGTCTCAGCGTATGTGCGGTACTGTCGGACTCTTCACGGG 
s4.10 rev 1 ACCGTCTCACGATGGTGAAAAGCAGGTCGATGAAGCCCG 
s4.10 for 2 ACCGTCTCAATCGTGTCGGAAACACTCATCACCGCGTCAC 
s4.10 rev ACCGTCTCAACTCTCAACCGGGCAGCAGGCCGC 
rSG s4.11 for ACCGTCTCAAGTATTGGCCGAGCAGTTGGCGTACTACTCG 
s4.11 rev 
ACCGTCTCAACTCTCAGCGCCTGCGGCCGGTGCCGTACTGGAAGTAGGTC
TCGCTC 
rXC s4.12 for ACCGTCTCACGTAATGTCGTTGAGCGTTGAGATACGGGCCG 
s4.12 rev ACCGTCTCAACTCTCAGCCGACACCGATCGTCGCCG 
rSG s4.16 for ACCGTCTCAAGTAATGACCCAGCAGAACACCCAGGCGAAAC 
s4.16 rev ACCGTCTCAACTCTCATGACCCGATCCCTTGGGCGG 
rAC s4.17 for ACCGTCTCAGCGTATGTGTGGCGTGGCGGGCGTTTTC 
s4.17 rev 1 
ACCGTCTCACAGCGCATCTTGTACTTCACCGGCATCCGGACGAAGGTCTC
GATC 
s4.17 for 2 
ACCGTCTCAGCTGGAACAGCCGCTGGTCCCAGTTCCGGTCCGTGTCCACA
CCCG 
s4.17 rev ACCGTCTCAACTCTCATGCGTCCACCACGTTCTGCAGCC 
rCF s4.18 for ACCGTCTCACGTAATGACGTATCGTCGTGCAATCCTGCTCTGC 
s4.18 rev ACCGTCTCAACTCCTACTCGAACCGTTGCTTCGCGAGCAGATAG 
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Table 4.10  Primers used to construct second-tier refactored plasmids. 
 
Primer Sequence 
GA pUC.gEL-1 for  
GTTAGCTCACTCATTAGGCACCCCAGATCGTCTCACGCTGCTCCTT
CGGTCGGACGTGCG 
GA pUC.gEL-2 for 
TAGCTCACTCATTAGGCACCCCAGATCGTCTCAATCGGCTGCTCC
TTCGGTCGGACGTGC 
GA rXC for GCCCTGCAGGCGGAAGTCAGGTAGAC 
GA gTP for TCCGTTCCCGGCGGGGAGCGG 
GA pUC.rAC-1 for 
GTTAGCTCACTCATTAGGCACCCCAGATCGTCTCAGTAGGCGCGG
TCTCGCCGGCC 
GA pUC.rAC-2 for 
GTTAGCTCACTCATTAGGCACCCCAGATCGTCTCATTAGGCGCGG
TCTCGCCGGCC 
GA rSG for AGGGGCGCGCGGCCC 
GA gKR for CACGGGCCGGTGAACCCCGC 
GA rXC.F-525.pdc rev 
CGTGTCTACCTGACTTCCGCCTGCAGGGCCTACTTGACCGCGAGA
AAGCGGGTGAAGCG 
GA gTP F-525.12 rev 
CCGGGTGTCCCGCTCCCCGCCGGGAACGGATCAGCCGACACCGAT
CGTCGCCG 
GA pUC.F-525.18 rev 
TAAAAATAGGCGTATCACGAGGCGATCGTCTCACTACTCGAACCG
TTGCTTCGCGAGCAG 
GA rSG.F-525.17 rev 
GACGGCCGGCGGCCGGGGCCGCGCGCCCCTTCATGCGTCCACCAC
GTTCTGCAGCC 
GA gKR F-525.16 rev 
CAACATTCATGCGGGGTTCACCGGCCCGTGTCATGACCCGATCCC
TTGGGCGGC 
GA pUC.F-525.pepM 
rev 
CATCACAGTATCGTGATGACATCTAGAGATTCAACGCTCAACGAC
ATCGGCGTTCCTCC 
GA rXC.F-525.6 rev 
CGTGTCTACCTGACTTCCGCCTGCAGGGCTCAGACGTATTCGGCG
CCGCCCTC 
GA gTP F-525.7 rev 
CCGGGTGTCCCGCTCCCCGCCGGGAACGGATCATCGGTCGGCCTC
TTCCGAGGGTTC 
GA pUC.F-525.9 rev 
CTATAAAAATAGGCGTATCACGAGGCGATCGTCTCACTAACCGAG
ACTGGCGGCGACTTC 
GA rSG.F-525.10 rev 
GACGGCCGGCGGCCGGGGCCGCGCGCCCCTTCAACCGGGCAGCA
GGCCGC 
GA gKR.F-525.11 rev 
CAACATTCATGCGGGGTTCACCGGCCCGTGTCAGCGCCTGCGGCC
GGTG 
GA pUC.F-525.8 rev 
ATAAAAATAGGCGTATCACGAGGCGATCGTCTCATCACGACCGA
ACACCATATCCATGGC 
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Table 4.11  Primers used to construct backbones for full pathway refactoring. 
 
Primer Sequence Template 
BbsI.Esp3I.pUC19 for 
CAGAAGACTAATCGAGAGACGGCCTCGTGATACGC
CTATTTTTATAGG pUC19 
BbsI.EcoRV.pUC19 rev 
CAGAAGACTAGATATCTGGGGTGCCTAATGAGTGA
GC 
BbsI.EcoRV.Apr for 
CAGAAGACTATATCGGCCGCCCAACGTCATCTCGTT
CTCC 
pAE4 
BbsI.Apr rev 
CAGAAGACTACGATCTGCTCACGGTAACTGATGCCG
TATTTG 
BB BsaI Cm for 
AGGTCTCATGCGCGCTTGAGACGACGACCGGGTCGA
ATTTGCTTTCGAATTTC 
pACYC-
Duet 
BB BsaI Cm rev 
AGGTCTCAGAGACGGTTACGCACCACCCCGTCAGTA
G 
BB BsaI ACYCori for 
AGGTCTCATCTCTGTGAGGCAAAAGCACCGCCGGAC
ATCAG 
BB BsaI ACYCori rev 
AGGTCTCATCCAATTAATGTAAGTTAGCTCACTCAT
TAGGCACCG 
BB BsaI oriT for AGGTCTCATGGAGCAGATCGATGGCGCGCCGAC 
pAE4 
BB BsaI oriT rev AGGTCTCATACCCCACACTACCATCGGGGGCCATCG 
BB BsaI int for 
AGGTCTCAGGTATCCCCATGCGAGAGTAGGGAACTG
CCAG 
BB BsaI mid int rev AGGTCTCACTTCCCAATCGTTTCGCCCCGGGTCG 
BB BsaI mid int for 
AGGTCTCAGAAGAAGACCGCTTCAAGCGCCTGGGA
C 
BB BsaI int rev 
AGGTCTCACGCAATCCAGTGCAAAGCTAGCTTCTTC
GTCTGTTTC 
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5Chapter 5: Refactoring of the phosphonic acid cluster from Kibdelosporangium aridum 
largum NRRL B-24462 
 
 
5.1 Introduction 
 
For antibacterials to inhibit essential enzymes in a targeted cell, it is first necessary for the molecule 
to cross the cell membrane to be active. Because phosphonic acids are often hydrophobic, such a 
feat cannot be readily done. A number of phosphonates have been developed, both in nature and 
in the lab, that make use of a “Trojan horse” strategy in accessing the inside of antagonist cells. 
Phosphonic acid warheads can be conjugated to small peptides (just one to three amino acids), 
which can be readily taken up by peptide transporters (Figure 5.1). Once inside the cell, peptidases 
can cleave the amino acids from the phosphonic head group which can then inhibit necessary 
enzymatic machinery.  
 
The discovery of phosphonopeptides followed two paths, one through synthetic chemistry and the 
other through natural product isolation. Starting in 1971, a group at the pharmaceutical company 
Roche set out to find inhibitors for bacterial cell wall synthesis, which relies on cross linking of D-
Ala-D-Ala units of cell wall peptidoglycans [1]. Having created over 300 oligopeptides with 
various side chains, one of their most promising molecules was the phosphonopeptide alaphosphin 
(Figure 5.1). When fed to bacterial cultures it was found to be inside cells 100 to 1000-fold in 
excess compared to the peptide concentration in the surrounding medium. Once inside, the 
molecule was cleaved into L-alanine and L-1-aminoethylphosphonate (L-Ala(P)), where the latter 
would then inhibit alanine racemase, which converts the canonical amino acid L-alanine to D-
alanine. The dipeptide structure of the molecule was crucial, for without the attached L-alanine the 
L-Ala(P) would not be taken up [2]. 
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During the period of discovery of alaphosphin, a group in Japan discovered a phosphonopeptide 
called phosphinothricin tripeptide, or also known as bialaphos (Figure 5.1) from cultures of the 
strain Streptomyces hygroscopicus [3].  When the peptide bond is broken between the alanine 
dipeptide and the head group, the released phosphonic warhead is able to inhibit glutamine 
synthase by mimicking the tetrahedral transition state of γ-glutamyl phosphate with ammonia [4]. 
Another group of natural phosphonic acid peptides are rhizocticins, which were discovered in 
Bacillus subtilis cultures in 1949 [5], but their phosphonopeptide structures weren’t realized until 
1988 [6].  Like the phosphonates discussed above, they make use of peptide transporters to access 
cells [7], and their phosphonic head group, L-2-amino-5-phosphono-3-cis-pentenoic acid or APPA, 
is released to target threonine synthase [8]. Plumbemycins, another type of phosphonopeptide from 
Streptomyces plumbeus, also carry APPA as a head group [9].  The most recently discovered 
phosphonates attached to small peptides are argolaphos A and B from Streptomyces monomycini 
NRRL B-24309 [10]. What is interesting about this compound is that both the phosphonate head, 
aminomethylphosphonate, and the attached amino acid, N5-hydroxyarginine, have bioactivities 
[11, 12]. However, it is unclear whether argolaphos bioactivity is due to an uncleaved 
phosphonopeptide or is due to the additive effects of the individual moieties after peptide cleavage.  
 
Dehydrophos is a phosphonopeptide produced by Streptomyces luridus that was first reported in 
1984 by researchers at Eli Lilly [13]. Originally called A53868, its name was changed once its 
structure was conclusively elucidated [14].  Its biosynthetic pathway has been characterized [15], 
and one of its intermediates is L-Ala(P), the bioactive headgroup in alaphosphin discussed above. 
However, in dehydrophos the warhead has further modifications, including the addition of a 
methylester on the phosphorous and a desaturation to give a terminal alkene (Figure 5.2a). Instead 
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of using ATP-dependent peptide ligases to attach amino acids, the dehydrophos pathway differs 
from other phosphonopeptides by relying on tRNAs for peptidyl transfer [15].  Upon entry to the 
cell, the phosphonic head is released from the peptide and undergoes tautomerization and 
hydrolysis to form methyl acetylphosphonate (MAP, Figure 5.2b).  Unlike L-Ala(P), which targets 
alanine racemase, MAP is a pyruvate analog and inhibits pyruvate oxidase and pyruvate 
dehydrogenase. Its methyl ester is crucial for its potency, for it makes the molecule a 125-fold 
stronger inhibitor than acetylphosphonate [16].   
 
While analyzing silent phosphonate clusters for refactoring, a gene cluster from Kibdelo-
sporangium aridum largum NRRL B-24462 was found to have similarities with the dehydrophos 
pathway. In the B-24462 cluster, seven genes had high homology with the first seven enzymes in 
dehydrophos biosynthesis, leading to the possibility that acetylphosphonate (AP) could be a 
common intermediate between the two pathways. In addition, the B-24462 cluster appears to have 
machinery to make a phosphonopeptide. Because a large fraction of the pathway is likely already 
known and the possibility of it having antibacterial activity like many other peptidyl phosphonates, 
the B-24462 cluster was chosen for refactoring and those efforts are highlighted in this chapter. 
 
5.2 Results and Discussion 
 
 Analysis of the B-24462 phosphonic acid cluster 
 
Genes in the neighborhood of the pepM gene in Kibdelosporangium arigum largum NRRL B-
24462 were checked by BLAST search for homologues in an effort to determine boundaries of the 
phosphonic acid cluster (Figure 5.3).  Besides a large gap between ORFs 6 and 7, the assignments 
of ORFs 1 through 6 had high protein sequence identity (75% to 94%) with genes for glycopeptide 
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biosynthesis [17] that were likely not associated with the phosphonate cluster. ORF 24 appeared 
to be a truncated transcriptional regulator, and as a disrupted gene was determined to be the other 
end of the boundary.  For the refactoring of the pathway, ORFs 8 through 21 were chosen. ORFs 
7 and 23, being transcriptional regulators, were not included in the refactoring, and neither was 
ORF 22, because the membrane transporter may not be necessary for production.   
  
ORFs 11 through 17 all had homology to the first seven enzymes of the dehydrophos cluster and 
had similar ordering except that there is no homologue for dhpD, the aminotransferase that 
catalyzes L-Ala(P) formation (Table 5.1). The cluster does have a likely transaminase (ORF 10) 
that may carry out the reaction, or it is quite possible that the amination is carried out by a non-
pathway enzyme, similar to OP-EP’s conversion to pSer(P) in dehydrophos biosynthesis (Figure 
5.2a). Although the B-24462 cluster carries a homologue for the N-terminus of DhpH, it lacks the 
tRNA-transferase domain from the C-terminus of the bifunctional enzyme. However, there are 
homologues for another tRNA-transferase (ORF 20) as well as a ligase (ORF 19) that make it 
likely that the product is a phosphonopeptide.  The B-24462 cluster appears to lack the desaturase 
and O-methyltransferase found in the dehydrophos cluster, but has in addition a putative 
nucleotidyl transferase, acetyltransferase, and peptidases, which may lead to the formation of a 
new head group. 
 
 Refactoring of the B-24462 phosphonic acid cluster 
 
The B-24462 phosphonic acid cluster was refactored in three subsequent assemblies, similar to the 
F-525 cluster described in Chapter 4. First, each gene was amplified by PCR from 
Kibdelosporangium aridum largum NRRL B-24462 genomic DNA and cloned via Golden Gate 
150 
 
assembly [18] into one of seven plasmids containing a promoter characterized in Streptomyces 
lividans [19]. Once each plasmid was verified by sequencing, promoter-gene cassettes were then 
amplified by PCR and assembled by Gibson Assembly [20] into four second-tier constructs of 
three or four genes each. The full pathway plasmid was made by combining the second-tier 
plasmids into a Golden Gate assembly reaction.  
 
Once the plasmid was verified by digestion analysis, it was conjugated into Streptomyces lividans 
66 for expression. Several media were tested for expression, including ISP2 (liquid and solid), 
ISP4 (liquid), ATCC 172 (liquid), and GUBC (liquid). Three unique phosphonate peaks were seen 
at 12.7, 16.85, and 18.6 ppm with 31P-NMR. Like the cluster F-525, best production was seen with 
ISP2 and ATCC 172, but ISP2 was chosen due to the absence of non-pathway peaks. 
 
 Identifying phosphonic acids from B-24462 cluster 
 
S. lividans integrated with the B-24462 phosphonic acid cluster was plated onto ten liters of ISP2 
solid media, and the agar plates were incubated for ten days at 30 ºC. The plates were frozen, 
thawed, and then squeezed with the agar extracts collected. Both agar extracts and spent agar were 
processed with methanol for extraction of phosphonates. Once the methanol was dried and the 
extract was placed back into water, it was treated on non-polar resins for the removal of 
hydrophobic material. For enrichment of phosphonates, the sample was loaded on an IMAC 
column charged with iron. The binding of the phosphonates was much stronger than the competing 
ammonium bicarbonate used to elute the molecules, which resulted in the loss of a considerable 
amount of material. Phosphonates eluted in a final 1 M NH4HCO3 elution and subsequent water 
washes were further purified by size exclusion chromatography, which gave fractions of high 
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enough purity that individual proton peaks could be visualized by 1H nuclear magnetic resonance 
(NMR). 
 
All three unique phosphonates seen by 31P-NMR had protons in the range of 1.1 to 1.3 ppm that 
correlated with the phosphorous according to 1H-31P heteronuclear multiple-bond correlation 
(HMBC) NMR (Figure 5.4). When compared with intermediates within the dehyrdophos pathway, 
only L-Ala(P) and its two next derivatives had protons on the end of their ethyl chains that could 
give these shifts.  By spiking the B-24462 sample with standard L-Ala(P), it was found that the 
phosphonate peak at 12.7 was L-Ala(P) (Figure 5.5)  
 
When the B-24462 sample was run on size exclusion column, the 18.6 ppm target phosphonate 
was seen in a fraction that also contained the small phosphonates 2-aminoethylphosphonate (2-
AEP) and 2-hydroxyethylphosphonate (2-HEP), the latter of which was the most abundant 
molecule. As expected, the protons at 1.15 ppm for this phosphonate gave a doublet of doublet 
similar to spectra for L-Ala(P) (Figure 5.6). Because the size of the unknown phosphonate was of 
similar mass as 2-AEP and 2-HEP and carried a terminal methyl group as observed by the 1H-
NMR spectra, one possible structure for this unknown phosphonate was 1-hydroxyethyl-
phosphonate (1-HEP). By adding standard 1-HEP to the B-24462 sample, the 18.6 ppm peak was 
enhanced, confirming that it is 1-HEP (Figure 5.7) 
 
Although 1-HEP has yet to be observed in nature, it is likely a reduction of acetylphosphonate 
(AP), the compound prior to L-Ala(P) in dehydrophos biosynthesis.  The strongest evidence for 
this is that when the dehydrophos pathway is expressed in S. lividans, the most abundant 
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phosphonate seen is 1-hydroxyethylphosphonate O-methylester (1-HEP O-Me), which is 
hypothesized to be a detoxified and reduced form of MAP [21].   
 
 Knockout study of the B-24462 cluster 
 
Knockouts were made on the seven genes not involved in AP biosynthesis, with only five of the 
strains successfully cultured and tested. Of the five knockout strains tested, the unknown 
phosphonate peak at 16.85 ppm was absent in two of them (Figure 5.8).  The knockout data 
suggests that this unknown phosphonate is related to an intermediate downstream of AP and L-
Ala(P), but it is likely to not be a phosphonopeptide since it elutes in the same fractions as several 
small molecules in size exclusion chromatography (see Figure 5.6). However, considering that the 
presence of the peak is dependent on the cluster’s ligase, the suspected transformation on the head 
group relies on the attachment of an amino acid, much like DhpI and DhpJ require leucine to be 
attached to L-Ala(P) before catalyzing their reactions. It has been shown that when a fosmid 
carrying the dehydrophos pathway in Streptomyces lividans lacks the transporter gene, no 
dehydrophos is seen in the culture but only 1-HEP O-Me [22]. Due to the absence of the B-24462 
phosphonate cluster transporter in the refactored pathway, a phosphonopeptide may be produced 
but is not exported out and therefore degraded, resulting in this smaller unknown phosphonate.  
Considering the small abundance of this phosphonate and its difficultly to separate it from the 
more abundant 2-HEP, its structure could not be characterized.  
 
5.3 Conclusions 
 
With their unique system of entering cells and releasing bioactive warheads, phosphonopeptides 
are a remarkable class of natural products. The phosphonic acid cluster from Kibdelosporangium 
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aridum largum NRRL B-24462 not only contains the machinery for phosphonopeptide synthesis, 
but it shares several biosynthetic enzymes with the known phosphonopeptide dehydrophos.  
Despite their similarities, the clusters are different enough for the B-24462 phosphonate to have a 
novel head group. Refactoring of the B-24462 cluster showed that common intermediates between 
the two pathways could be produced, including L-Ala(P) and AP reduced into 1-HEP. 
  
An unknown phosphonate was also seen in the B-24462 sample, but its structure could not be 
elucidated due to its low abundance and difficulty to separate it from the more prominent 
phosphonate 2-HEP. Although this phosphonate may be novel, it appears to be smaller than a 
phosphonopeptide but may be a broken down product of one. One problem with the refactored 
pathway is that it lacks the membrane transporter from the B-24462 phosphonate cluster. A new 
construct was made that included the transporter, however, no new phosphonic acid peaks were 
seen. 
 
Another problem that should be addressed with both the F-525 and B-24462 cluster is the buildup 
of unwanted intermediates and off-pathway byproducts. Both refactored pathways produce 2-HEP 
and 2-AEP more abundantly than any of the novel phosphonates, channeling off resources that 
could produce more of the phosphonates desired to be investigated. Several strategies could be 
explored to mitigate this flux imbalance, including testing production in different hosts, testing 
various promoters or promoter assignments, or refactoring genes in their native operonic structures 
instead of refactoring each gene individually. Solving this problem would not only help with future 
refactoring of phosphonate clusters but with other natural products as well. 
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5.4 Methods and materials 
 
 Strains, media, and reagents 
 
Strain Kibdelosporangium aridum largum NRRL B-24462 was provided by the laboratory of 
Prof. William Metcalf at the University of Illinois at Urbana-Champaign. All cloning was 
performed in E. coli strain BW25141 [23], conjugation was done using the E. coli strain 
WM6026 [24], and all phosphonate production and testing was done in Streptomyces lividans 66.  
All media reagents were from Sigma-Aldrich (St. Louis, MO), Fisher Scientific (Pittsburgh, PA), 
or Becton Dickinson (Franklin Lakes, NJ). Media used for culturing are given as follows for 1 L 
of medium: ISP2 (10 g malt extract, 4 g dextrose, 4 g yeast extract); ISP4 (10 g soluble starch, 2 
g (NH4)2SO4, 2 g CaCO3, 1 g K2HPO4, 1 g MgSO4-7H2O, 1 g NaCl, 1 mg FeSO4-7H2O, 1 mg 
MnCl2-2H2O, 1 mg ZnSO4-7H2O); ATCC Medium 172 (1% glucose, 2% soluble starch, 0.5% 
yeast extract, 0.5% N-Z amine type A, 0.1% CaCO3); GUBC (5 g glycerol, 10 g sucrose, 5 g 
beef extract, 5 g casamino acids, 5 mL Na2HPO4-KH2PO4 buffer, 2 mL Hunter’s concentrated 
base [25], 10 mL Balch’s vitamins [26]). Apramycin (Apr) was purchased from Gold 
Biotechnology (St. Louis, MO). PCR reactions were performed in FailSafe PCR PreMix G 
(Epicentre Biotechnologies, Madison, WI) with Q5 DNA polymerase (New England Biolabs, 
Ipswich, MA). Restriction enzyme Esp3I was from Thermo-Scientific (Pittsburgh, PA) and all 
other restriction enzymes, T4 ligase, shrimp alkaline phosphatase (rSAP), and HiFi DNA 
Assembly Kit (used for Gibson Assembly) were from New England Biolabs. All primers ordered 
from Integrated DNA Technologies (Coralville, Iowa). EZNA Plamsid Mini Kit (Omega Bio-
tek, Norcross, GA) was used for plasmid purification and Zymoclean Gel DNA Recovery Kit 
(Zymo Research, Irvine, CA) was used for gel extraction of DNA. The construction of all vector 
backbones are discussed in the methods and material section in Chapter 4 of this thesis. 
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 Refactoring of the B-24462 phosphonate gene cluster 
 
Kibdelosporangium aridum largum NRRL B-24462 was streaked out onto ISP2 from a frozen 
stock, from which a colony was used to inoculate 2 mL of ISP2 culture in a culture tube. After 
three days growth at 30 ºC and 250 RPM, 1 mL was removed and genomic DNA was purified 
using a Wizard Genomic DNA Purification Kit (Promega, Madison, WI). Genes for ORFs X to 
Y of the B-24462 phosphonate cluster were amplified using primers listed in Table 5.2, with  
 some primers introducing silent mutations for the removal of Esp3I sites to accommodate   Golden 
Gate assembly. Each gene was then cloned into their respective promoter plasmids by Golden Gate 
assembly with restriction enzyme Esp3I, and plasmids were verified correct by both restriction 
digestion analysis and sequencing.  For the second-tier assembly, each promoter-gene cassette was 
amplified using primers listed in Table 5.3 and additional forward promoter primers in Table 4.8 
in Chapter 4 and then assembled into four constructs, each with three to four genes. Plasmid PI 
contained ORFs 6, 10, and 5; PII, ORFs 1, 2, 7 (pepM), and 3; PIII, ORFs 4, 8, and 9; and PIV, 
ORFs 11, 12, 13, and 14. For the final assembly, the second-tier plasmids were combined with the 
backbone Final-BB (see Section 4.4.3) in a Golden Gate assembly reaction with enzyme Esp3I. 
The plasmid was then conjugated into Streptomyces lividans following procedure as previously 
described [27]. 
 
 Strain culturing and optimization 
 
All culturing was done at 30 ºC, with liquid cultures shaken at 250 RPM with 50 mL of media in 
250 mL baffled flasks with beads. For optimization tests, solid and liquid ISP2+25 mg/mL Apr 
was tested at 4, 7, and 10 days, with maximal production seen at 7 and 10 days on solid medium. 
Liquid ISP4, ATCC 172, and GUBC with 25 mg/L Apr were tested at 10 days. For solid media 
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testing on ISP2, five plates were used, which were frozen, thawed, then squeezed and strained 
through a milk filter, with 50 mL being collected for testing. Upon collection, all cultures were 
centrifuged at 4000 RPM for 10 minutes on a tabletop centrifuged and the aqueous phase then 
freeze dried, reconstituted into 1 mL of D2O, filtered through a 0.22 µm spin-column filter, and 
then tested by NMR. 
 
 Purification of B-24462 phosphonic acids 
 
Streptomyces lividans integrated with the completely refactored B-24462 cluster was inoculated 
from a single colony into 4 mL ISP2+25 mg/L Apr and grown for three days. Four 50 mL cultures 
of ISP2+25 mg/L Apr were then inoculated from the starter culture and cultured in 250 mL baffled 
flasks with beads.  The larger cultures were then used to cover 10 liters of ISP2+10 mg/L Apr 
plates which were incubated at 30 ºC. After 10 days, plates were frozen at -20 ºC overnight, 
thawed, and then squeezed with cheesecloth with 6 L of extract collected. Culture extract was 
freeze dried while the spent agar was soaked in methanol, which was collected.  The freeze dried 
extract was resuspended in 700 mL water and mixed with 2.1 L of methanol, which was then 
centrifuged to remove precipitates. The aqueous phase was pooled with the methanol used to soak 
the spent agar and the combined methanol extracts were dried and reconstituted in about 300 mL 
of water.  The sample was then mixed with 500 g of Amberlite XAD16N resin (Sigma-Aldrich), 
and flow-through and two 500 mL water washes were collected and dried to 150 mL. The sample 
was then treated with Oasis hydrophilic-lipophilic-balanced (HLB) resin (Waters Corporation, 
Milford, MA) with flow-through and two 250 mL water washes collected and dried to 125 mL. 
The sample was then loaded onto 100 g of Chelex 100 resin (Bio-Rad, Hercules, CA) in its ion-
free form, and the flow-through and two 250 mL water washes were collected and dried to 100 
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mL. The sample was then applied to Chelex 100 resin charged with FeCl3. The Chelex 100 was 
washed twice with 100 mL water, followed by 50 mL elutions of 10 mM, 25 mM, 50 mM, 100 
mM, 250 mM, 500 mM, and 1 M NH4HCO3, and two additional 100 mL washes of water. 
Although small amounts of phosphonates eluted out of most fractions, the 1 M NH4HCO3 final 
water washes were the cleanest samples and were carried over for size exclusion chromatography. 
The sample was run on a 1.5 cm x 1.7 m glass column driven by gravity and loaded with Sephadex 
LH-20 (GE Healthcare Life Sciences, Pittsburgh, PA). The 1-HEP fraction eluted around 200 
minutes. 
 
 Nuclear Magnetic Resonance (NMR) analysis 
 
NMR spectra were collected using a Varian Unity Inova 600 MHz spectrometer with an 
AutoTuneX probe (Varian, Palo Alto, CA), with 150 MHz used for 31P and 600 MHz for 1P. All 
samples ran in D2O (Sigma-Aldrich) and analyzed using MestReNova v. 10.0.2 software 
(Mestrelab Research, Santiago de Compostela, Spain). 
 
 Knocking out of B-24462 ORFs 8, 9, 10, 18, and 19 
 
Knockouts of the B-24462 were performed using the method developed by Wanner and Datsenko 
[23]. Primers used to amplify kanamycin casstte from pKD4 are listed in Table 5.4. Removal of 
the kanamycin cassette was performed by a Golden Gate reaction with enzyme Esp3I. 
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5.5 Figures and tables 
 
 
 
Figure 5.1  Examples of phosphonic peptides. The “warheads” released upon peptide cleavage 
are highlighted with dashed boxes. 
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B 
 
 
 
Figure 5.2  Dehydrophos biosynthesis and breakdown. (A) Dehydrophos biosynthesis by the 
ten Dhp pathway enzymes. The transamination from OP-EP to pSer(P) is performed by a protein 
not present in the biosynthetic gene cluster. (B) Breakdown of dehydrophos into the toxic methyl 
acetylphosphonate. Step I: peptidase activity; step II: tautomerization; step III: hydrolysis.   PEP, 
phosphoenol-pyruvate; 2-HEP, 2-hydroxyethylphosphonate; DHEP, 1,2-dihydroxyethyl-
phosphonate; OP-EP, 1-oxo-2-phosphorylethylphosphonate; pSer(p), 1-amino-2-phosphoryl-
ethylphosphonate; AP, acetylphosphonate; L-Ala(P), L-1-aminoethylphosphonate; L-Leu-L-
Ala(P), L-leucine-L-1-aminoethylphosphonate; L-Leu-L-Ala(POMe), L-leucine-L-1-aminoethyl-
phosphonate O-monomethylester; L-Leu-ΔAla(POMe), L-leucine-L-1-aminovinylphosphonate O-
monomethylester. 
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Figure 5.3  BLAST analysis of Kibdelosporangium aridum largum NRRL B-26642 phosphonic 
acid cluster.  Each proximal gene to pepM (green, ORF 14) was entered into a BLAST search and 
the number of proteins with sequence identity above 50% (blue bars) and 70% (red bars) was 
counted. 
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Figure 5.4  1H-31P HMBC NMR of B-24462 phosphonic acids.  Phosphonates with protons in 
the 1.1 to 1.3 ppm range (box) show characteristic shift of methyl group in L-Ala(P). 
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Figure 5.5  31P-NMR of B-24462 sample spiked with standard L-Ala(P).  B-24462 sample (red) 
was spiked with standard L-Ala(P) (turquoise), which increased the phosphorous peak at 12.7 ppm. 
1H-31P HMBC NMR further shows that the two peaks are the same. 
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Figure 5.6  1H-31P HMBC of B-24462 phosphonate sample after size exclusion 
chromatography.  Two unknown phosphonates elute at same time of the small phosphonates 2-
AEP, 2-HEP, and L-Ala(P). A doublet of doublets at 1.2 ppm (blue arrow) is seen for the protons 
of one of the phosphonates at 21 ppm. 
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Figure 5.7  Spiking of standard 1-hydroxyethylphosphonate into B-24462 sample. B-24462 
sample (red) spiked with 1-hydroxyethylphosphonate (turquoise) showed an increase in the peak 
of the unknown phosphonate at 18.4 ppm. 
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Figure 5.8  1H-31P HMBC of B-24462 gene knockouts. ORF knockouts from bottom to top (1 to 
5): ORF 8, ORF 9, ORF 10, ORF 18, and ORF 19. The protons at 1.07 are not present when ORF 
9 (nucleotidyltransferase) and ORF 19 (ligase) are knocked out. 
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Table 5.1  Possible gene assignments for ORFs in the Kibdelosporangium aridum largum 
NRRL B-24462 phosphonic acid cluster. Homologues of genes in the dehydrophos pathway are 
highlighted with protein sequence identities in the second column. 
 
 
 
 
 
 
 
ORF 
DHP 
(%ID) 
Non-hypothetical                
top protein hit Source %ID 
Hypothetical 
protein source %ID 
8  Acetyltransferase 
Kibdelosporangium 
sp. MJ126-NF4 
76%   
9   Nucleotidyltransferase 
Desulfobacca 
acetoxidans 
44% 
Actionplanes 
subtropicus 
54% 
10   Aspartate aminotransferase 
Streptomyces sp. 
TP-A0356 
41% 
Actionplanes 
subtropicus 
51% 
11 
DhpH 
(49%, N- 
terminus) 
Putative amino transferase 
Amycolatopsis 
orientalis 
92%     
12 
DhpG 
(50%) 
Putative alcohol 
dehydrogenase 
Amycolatopsis 
orientalis 
89%     
13 
DhpF 
(48%) 
Phosphonopyruvate 
decarboxylase 
Lechevalieria sp. 
NRRL S-836 
51%     
14 
DhpE 
(56%) 
Phosphoenolpyruvate 
phosphonomutase 
Streptomyces sp. 
WM6372 
56%     
15 
DhbC 
(57%) 
1-hydroxy-2-
phosphorylethylphosphonate 
dehydrogenase (DhpC) 
Streptomyces 
luridus 
57%     
16 
DhpB 
(42%) 
Glycerate kinase  
Sanguibacter 
keddieii 
40% 
Actinoplanes 
subtropicus 
48% 
17 
DhpA 
(49%) 
2-ketoglutarate dependent 
dioxygenase (DhpA) 
Streptomyces 
luridus 
49% 
Actinoplanes 
subtropicus 
55% 
18   Peptidase C39 
Acholeplasma 
laidlawii 
48% 
Saccharaothrix 
espanaensis 
68% 
19   
UDP-N-acetylmuramoyl-
tripeptide--D-alanyl-D-
alanine ligase 
Saccharopolyspora 
spinosa 
59%     
20   
Arginine tRNA protein 
transferase 
Leadbetterella sp. 
JN14-9 
29% 
Pedosphaera 
parvula 
33% 
21   Endopeptidase 
Xanthomonas sp. 
Leaf148 
34% 
Actinobacterium 
Acidi 
39% 
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Table 5.2  Primers used to clone B-24462 genes into promoter plasmids.  
 
 
 
 
 
 
Primer Sequence 
rAC.B-24462.8 for ACCGTCTCAGCGTGTGCGTACAGTACGTGGCGTGCCAACG 
B-24462.8 rev ACCGTCTCAACTCTCAGAGGTACAGCCGATACCCCTGAGCGAG 
rSG.B-24462.9 for ACCGTCTCAAGTAATGGACCGTGAAGTGAGAGTGATCATTCCAGCGG 
B-24462.9 rev ACCGTCTCAACTCCTACGCGAAACTCACCTCGTCGCGTTCGAC 
rKR.B-24462.10 for ACCGTCTCACACTGTGCTGAGTGCGCTTGCTCCCCATTCG 
B-24462.10 rev ACCGTCTCAACTCTCAGCCTGCCAATCTCTCTACGGCACGATCAAG 
gEL.B-24462.11 for ACCGTCTCAACGCGTGAACCTGCGGATTTCCGGACCCACAC 
B-24462.11 rev ACCGTCTCAACTCTCACGACGAGCCTCCCACTCTGGTGAC 
gTP B-24462.12 for 
1 ACCGTCTCATTAAATGACCGATGTGGACGATCAGCGCCG 
B-24462.12 rev 1 ACCGTCTCAGGACGACGCGCTGGCGCGTAGC 
B-24462.12 for 2 ACCGTCTCAGTCCCGCGATCTGGCACGACGTGCG 
B-24462.12 rev 2 ACCGTCTCAACTCTCACAACCGGGACCGCATCAACCCG 
rXC.B-24462.15 for 
ACCGTCTCACGTAATGCGAGTTGATCACCAATCACTGCGTGACTTCA
C 
B-24462.15 rev ACCGTCTCAACTCTCATGGTTCTCTGGCAGGCGGACCAAGC 
rCF.B-24462.16 for ACCGTCTCACGTAATGCGGGTCCTGGTCGCGCCC 
B-24462.16 rev ACCGTCTCAACTCTCAACTCGCATGCGGCACCGATCCG 
rXC B-24462.17 for 
1 ACCGTCTCACGTAATGGATTTTCATCGGCAACGACACAGGTGGTCG 
B-24462.17 rev 1 ACCGTCTCAGGTCTCAAGGCCGGTCATGATCAGGAATCCG 
B-24462.17 for 2 ACCGTCTCAGACCGCCGGGCAGGACGCCTATGAAC 
B-24462.17 rev 2 ACCGTCTCAACTCTCACTTCCCGTCGGTGGTGCGGG 
rAC.B-24462.18 for ACCGTCTCAGCGTATGACATTGCGCCTGCACGAGCAGACTTG 
B-24462.18 rev ACCGTCTCAACTCTCAGCGGAGGATCGCGGTACCGAAGC 
rSGp.B-24462.19 
for ACCGTCTCAAGTAATGATCCCTCTCGATCTCAACGCGATCGCGG 
B-24462.19 rev ACCGTCTCAACTCCTACGGCAGCACGATGTCGTAGTCGCTGTC 
gKRp.B-24462.20 
for 
ACCGTCTCATTGCGTGGTCTTCTCGGAATGCGCCCCGAATTATGAGA
CCCATCTCGCGC 
B-24462.20 rev ACCGTCTCAACTCTCATCGCTCCTCCGTCGAGTCAGCACATCGC 
rKRp.B-24462.21 
for ACCGTCTCACACTGTGACAGAAGTCCCGGGAAGGAGTGCGG 
B-24462.21 rev ACCGTCTCAACTCTCATAATTCGGGGCGCATTCCGAGAAGACCACTC 
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Table 5.3  Primers used for the construction of the second-tier refactored plasmids. 
Primer Sequence 
GA gTP for TCCGTTCCCGGCGGGGAGCG 
GA B-24462.8 rev 
GACGGCCGGCGGCCGGGGCCGCGCGCCCCTTCAGAGGTACAGCCGAT
ACCCCTGAGCG 
GA B-24462.9 rev 
CAACATTCATGCGGGGTTCACCGGCCCGTGCTACGCGAAACTCACCT
CGTCGCGTTC 
GA PII B-24462.10 
rev 
CACAGTATCGTGATGACATCTAGAGATTCAACCTGCCAATCTCTCTAC
GGCACGATCAAG 
GA B-24462.11 rev 
TCGTGTCTACCTGACTTCCGCCTGCAGGGCTCACGACGAGCCTCCCAC
TCTGGTG 
GA PI B-24462.12 
rev 
TAAAAATAGGCGTATCACGAGGCGATCGTCTCACTACAACCGGGACC
GCATCAACCCGAG 
GA B-24462.13 rev 
GTGTCTACCTGACTTCCGCCTGCAGGGCTCAGCTGTCGCCATGTGCGA
CTG 
GA B-24462.14 rev 
CCACCGAGCCCGCACCCAGCCACGCGTGATCATTGTTTCTCCAGGTGC
AGCCATTTGTCG 
GA B-24462.15 rev 
CCCGCCCGAGCCTCCAGCGCCCGCGGCGGGTCATGGTTCTCTGGCAG
GCGGACC 
GA PIII B-
24462.16 rev 
CTATAAAAATAGGCGTATCACGAGGCGATCGTCTCACTAACTCGCAT
GCGGCACCGATCC 
GA B-24462.17 rev 
CCCGCCCGAGCCTCCAGCGCCCGCGGCGGGTCACTTCCCGTCGGTGG
TGCGG 
GA B-24462.18 rev 
GACGGCCGGCGGCCGGGGCCGCGCGCCCCTTCAGCGGAGGATCGCG
GTACCGAAG 
GA B-24462.19 rev 
CAACATTCATGCGGGGTTCACCGGCCCGTGCTACGGCAGCACGATGT
CGTAGTCGCTG 
GA B-24462.20 rev 
ACCACCGAGCCCGCACCCAGCCACGCGTGATCATCGCTCCTCCGTCG
AGTCAGCAC 
GA PIV B-
24462.21 rev  
TAAAAATAGGCGTATCACGAGGCGATCGTCTCATCACTCAAATTCGG
GGCGCATTCCGAG 
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Table 5.4  Primers used to amplify kanamycin cassette for knockout of B-24462 genes. 
 
Primer Sequence 
B-24462.8 for 
KO 
GATCCGAGCCGCGACGACCGAAGATCTGCCTGCCATGAGACGCAAGAT
CCCCTCACGCTG 
B-24462.8 rev 
KO 
GAGGTACAGCCGATACCCCTGAGCGAGCGTTTTGGCTGAGACGCAGAG
CGCTTTTGAAGC 
B-24462.9 for 
KO 
GGACCGTGAAGTGAGAGTGATCATTCCAGCGGCCATGAGACGCAAGAT
CCCCTCACGCTG 
B-24462.9 rev 
KO 
GAAACTCACCTCGTCGCGTTCGACGAGGGCAGTGGCTGAGACGCAGAG
CGCTTTTGAAGC 
B-24462.10 for 
KO 
CGGCCCACCGCGGTCTTTCGACGAGCGATTGGCCATGAGACGCAAGATC
CCCTCACGCTG 
B-24462.10 rev 
KO 
TCTCTCTACGGCACGATCAAGTTGCTCCGCACTGGCTGAGACGCAGAGC
GCTTTTGAAGC 
B-24462.18 for 
KO 
CCAGTTTCGTGCGCTGTCCGTACCGGACCTGGCCATGAGACGCAAGATC
CCCTCACGCTG 
B-24462.18 rev 
KO 
GCGGAGGATCGCGGTACCGAAGCCGTTGAACATGGCTGAGACGCAGAG
CGCTTTTGAAGC 
B-24462.19 for 
KO 
GATCCCTCTCGATCTCAACGCGATCGCGGCCGCCATGAGACGCAAGATC
CCCTCACGCTG 
B-24462.19 rev 
KO 
CAGCACGATGTCGTAGTCGCTGTCATGTCCTGTGGCTGAGACGCAGAGC
GCTTTTGAAGC 
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